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 i 
Abstract: 
 
Exogenous ingestion of alkalising agents, such as sodium bicarbonate (SB), has been 
shown to enhance muscle buffering capacity, thereby delaying the metabolic acidosis 
associated with high-intensity exercise and potentially improving performance. Aim: The 
aim of this research was to examine the effects of acute and chronic SB supplementation 
and a placebo (PLA) on high-intensity intermittent performance, recovery and subsequent 
performance in trained rugby union players. Methods: This aim was achieved through 
the completion of three interconnected studies. Study 1 examined the effects of acute 
versus chronic SB supplementation on high-intensity intermittent performance as 
assessed by 6 x 10s maximal sprint tests on a cycle ergometer. Study 2 investigated 
effects of chronic SB supplementation on a specifically designed field-based, high-
intensity intermittent rugby sevens-specific protocol. Study 3 evaluated the effects of 
acute SB supplementation on an 80-minute high-intensity intermittent 15-a-side rugby-
specific protocol using elite females and sub-elite males. Results: In Study 1, acute SB 
supplementation demonstrated significant elevations in pre-exercise levels for blood 
bicarbonate (StdHCO3
-
), pH and base excess (BE-Ecf) but no significant improvement in 
peak power output (PPO), mean power output (MPO) or total work (TW). Chronic SB 
supplementation exhibited a significant increase in StdHCO3
- 
following Sprint 1. 
However, no significant differences in performance parameters were recorded for either 
acute or chronic SB supplementation when compared to the PLA trial. In Study 2, no 
significant differences in blood or performance related variables were observed between 
chronic SB and PLA supplementation trials. In Study 3, pre-exercise alkalosis was 
induced by acute SB supplementation in both elite females and sub-elite males. However, 
this did not translate into an ergogenic benefit to rugby union-specific performance. 
Vertical jump height and passing accuracy were significantly improved with PLA as 
opposed to SB supplementation in the elite female group. No significant differences in 
performance were observed between trials in the sub-elite male group. Conclusion: The 
major findings of this work suggest that pre-exercise metabolic alkalosis may be induced 
following acute but not chronic SB ingestion. However, results are inconclusive 
regarding the efficacy of acute or chronic SB ingestion to enhance performance in high 
intensity, intermittent performance indicative of the movement patterns and physiological 
demands associated with rugby union. Results also appear to indicate a high degree of 
individual variability, which, in part, may be due to potential gastrointestinal side effects 
of SB ingestion. 
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1.1. Background Information and Justification 
 
The professionalism now associated with the game of rugby union has brought with it a 
more scientific approach to preparation for, and recovery from, competition and training. 
One key area that has developed as a result of the increasing demands placed on players 
is nutrition along with the use of ergogenic aids. Nutritional interventions are widespread 
in sport, with the majority of athletes incorporating some form of nutritional strategy into 
their training to optimise performance. This may range from simple healthy dietary 
choices for the amateur athlete to supplementation with ergogenic aids, such as creatine, 
for elite competitors. Adequate nutrition between bouts of high-intensity exercise is 
essential to optimise performance, recovery and subsequent exercise performance. In 
rugby union, the incentive to obtain even the most marginal advantage over opponents 
has lead to a growing culture of supplement use both among professionals and in the 
amateur game. However, particularly in an amateur rugby union environment, sports 
nutrition information is often delivered by an unqualified source. Information on 
supplement use is often based on anecdotal evidence enforced by collective team 
practices and not on definitive scientific evidence (Burke, 2003). 
 
Sodium bicarbonate (NaHCO3 or SB) is a buffer which occurs naturally in the body. 
Exogenous supplementation with SB prior to exercise has been shown to increase pH 
levels and standard blood bicarbonate (StdHCO3
-
) concentrations, thereby enhancing the 
extracellular buffering capacity (Requena et al., 2005). During high intensity exercise, 
hydrogen ions (H
+
) are formed as a by-product of anaerobic glycolysis (Medbo et al., 
1985). This increase in [H
+
], and consequential decrease in pH, leads to inhibition of 
calcium (Ca2+) release from the sarcoplasmic reticulum (Favero et al., 1995), inhibition 
of the binding of actin and myosin (Fabiato and Fabiato, 1978) and inhibition of 
enzymatic activity involved in energy production (Trivedi et al., 1966). This inhibition of 
cellular processes results in a diminished capacity for muscular force production leading 
to fatigue (Hawley and Reilly, 1997). By creating a state of pre-exercise alkalosis within 
the body, SB is purported to have the capacity to delay acute fatigue caused by exercise-
induced metabolic acidosis (McNaughton, 1992; Jones et al., 1977; Wilkes et al., 1983). 
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SB ingestion has been shown to improve performance in high intensity exercise of 1-7 
minutes duration (McNaughton, 1992; Goldfinch et al., 1988). However, little is known 
regarding the effect of SB on repeated sprint-ability and high intensity intermittent 
activity comparable to the type of movement, duration and intensity necessary in the 
performance of team field sports such as rugby union. Therefore, the aim of this research 
is to investigate the effects of nutritional supplementation with SB on high-intensity 
intermittent sprint performance indicative of the physiological demands of rugby union. 
The research will also aim to examine the effects of SB on recovery from exercise and 
subsequent high-intensity repeat-sprint performance.  
 
 
1.2. Purpose of the Research 
 
In modern sport, there is widespread use of nutritional supplements in team field sports, 
including rugby union. However, there is a dearth of scientific evidence to verify the 
efficacy of all supplement use in promoting performance enhancements, physiological 
recovery after exercise and improvements in subsequent performance. Much of the 
current research in the area of SB supplementation concerns single bout events or 
laboratory based experiments with little emphasis on the response to SB supplementation 
in a team field-based sport-specific setting. In addition, the investigation of the effect of 
SB on recovery from exercise within the literature rarely extends beyond post-exercise 
monitoring of blood parameters, such as StdHCO3
-
, pH, base excess (BE-Ecf) and lactate, 
and seldom expands to examination of subsequent performance. Few studies have 
considered pre-exercise SB ingestion as a potential recovery modality capable of 
enhancing subsequent performance (Siegler et al., 2010). 
 
The purpose of this research, therefore, is to enhance the limited body of knowledge 
concerning SB supplementation in high intensity intermittent exercise indicative of team 
sport performance. In addition, this investigation aims to provide coaches and athletes 
with a fact-based approach to SB supplementation regarding its capacity to improve 
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performance and optimise recovery for enhanced subsequent performance. As part of this 
research, three studies were conducted and are outlined below: 
 
Study 1: The effects of acute versus chronic SB supplementation on high-intensity 
intermittent sprint performance. 
 
Study 2: The effects of chronic SB supplementation on a high-intensity intermittent rugby 
sevens-specific protocol. 
 
Study 3: The effects of acute SB supplementation on an 80-minute high-intensity 
intermittent 15-a-side rugby-specific protocol using elite females and sub-elite males. 
 
 
1.3. Research Aims and Objectives: 
 
To examine the effects of acute and chronic sodium bicarbonate (NaHCO3 or referred to 
as SB when referring to ingestion) supplementation on high-intensity intermittent 
performance, recovery and subsequent performance in rugby union players. 
 
Aims: 
1. To examine the effects of acute versus chronic SB supplementation on a 
controlled laboratory experiment involving high-intensity intermittent sprint 
cycling performance. 
2. To investigate the effects of chronic SB supplementation on a field-based high-
intensity intermittent 7s rugby match-specific protocol. 
3. To analyse the effects of acute SB supplementation on a field-based 80-minute 
high-intensity intermittent 15s rugby match-specific protocol involving elite 
females and sub-elite males. 
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Overall Objectives: 
1. To examine the effects of acute and chronic SB supplementation on group and 
individual performance indices. 
2. To examine the effects of acute and chronic SB supplementation on the various 
biochemical parameters including StdHCO3
-, pH, BE-Ecf and lactate. 
3. To investigate the potential relationship between the aforementioned biochemical 
parameters and performance. 
4. To analyse the impact of acute and chronic SB supplementation on heart rate and 
subjective ratings of perceived exertion, muscle soreness and gastro-intestinal 
discomfort and their potential relationship to performance. 
 
Overall Hypothesis: 
Acute and chronic SB supplementation will significantly enhance high intensity 
intermittent performance, recovery and subsequent performance in both laboratory and 
field-based tests indicative of the movement demands observed in rugby union when 
compared to a placebo (PLA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
1.4. Study One: The Effects of Acute versus Chronic SB Supplementation on High-
Intensity Intermittent Sprint Performance 
 
Aim: 
The aim of this study was to examine the effects of both acute and chronic SB 
supplementation versus PLA on high-intensity intermittent sprint performance in sub-
elite male rugby players. 
 
Hypothesis: 
Acute and chronic SB supplementation will induce sufficient elevations in StdHCO3
-
, pH 
and BE-Ecf to delay fatigue and result in enhanced performance of high intensity 
intermittent sprints on a cycle ergometer when compared to a PLA trial. 
 
 
1.5. Study Two: The Effects of Chronic SB Supplementation on Simulated Rugby 
Sevens Performance 
 
Aim: 
The aim of this study was to examine the effects of chronic five-day supplementation 
with SB on a specifically designed test protocol developed to replicated the specific 
physiological demands associated with a typical rugby sevens match. 
 
Hypothesis: 
Chronic SB supplementation, using a specifically designed loading protocol, will 
stimulate metabolic alkalosis and result in enhanced performance, recovery and 
subsequent performance of high-intensity intermittent performance when compared to a 
PLA trial. 
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1.6. Study Three: The Effects of Acute SB Supplementation on High-Intensity 
Intermittent Performance Using a Simulated 80 minute Rugby-Specific Test 
Protocol in Elite Females and Sub-Elite Male Rugby Players 
 
Aim: 
The aim of this study was to examine the effects of acute SB supplementation versus a 
PLA on high-intensity intermittent performance using a specifically designed test 
protocol developed to simulate typical demands of 80-minute rugby union match. 
 
Hypothesis: 
Acute SB supplementation will cause a significant increase in StdHCO3
-
, pH and BE-Ecf 
and result in enhanced high intensity intermittent performance, recovery during the 10 
minute half time interval and subsequent performance when compared to a PLA trial. 
 
 
1.7. Delimitations  
 
• All tests were administered by the author in order to avoid inter-tester error. 
• Subjects were restricted to male or female rugby union players aged 18-35 years. 
• Male subjects were required to be current club rugby union players of level J2 or 
above. Female subjects were required to be current interprovincial or international 
rugby union players. 
• Subjects were excluded from the study if they were suffering from any 
cardiovascular, pulmonary or metabolic diseases; if they were smokers; or if they 
had any injury or illness that may have affected their performance, as determined 
by the general health questionnaire (Appendix B) completed by each subject prior 
to testing.  
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1.8. Limitations 
 
• Subjects were under specific instruction to maintain their normal diet; not to 
consume any form of performance drinks, ergogenic aids or alcohol and to avoid 
strenuous physical exercise (described as exercise requiring great effort, energy or 
exertion) for the 48 hours prior to each test. However, these criteria may not have 
always been adhered to. 
• Despite the familiarisation protocol, possible learning effects may have affected 
behaviour in the experimental conditions due to the repeated testing involved in 
this research. However, a randomised experimental design was employed to 
negate these effects as much as possible.   
• The limited number of subjects (10 subjects for Study 1 and 2, 20 subjects for 
Study 3) involved in each study may have diminished the statistical power of the 
study and therefore reduced the likelihood of significant findings. 
• Rugby union is a high-impact, collision sport with a high incidence of injury 
resulting in a number of subjects having to withdraw from the study. 
• Arterialised capillary blood samples were used to measure blood gases indicative 
of arterial blood. However, due to field based testing and an inability to accurately 
heat the earlobe to a designated temperature, the sample obtained may have been 
composed of a mixed arterial-venous sample and as a result the PO2 values may 
have been slightly compromised. 
• Measurements for StdHCO3
-
, pH, BE-Ecf, PO2, PCO2 and lactate were obtained 
from the blood and not the muscle. Intracellular measurements may have provided 
more accurate results relevant to the working muscle. However, it was deemed 
that muscle biopsy was impractical in a field based setting.  
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2.1. Introduction 
 
Sports performance is affected by many factors, of which nutrition may be one of the 
most influential (Maughan and Burke, 2011). Adequate nutrition between bouts of high-
intensity exercise is essential to optimise subsequent exercise performance. In order to 
meet the physiological demands of exercise combined with the challenges of modern 
living, there is a trend towards the use of various ergogenic aids by both recreational and 
elite athletes. Sodium bicarbonate (SB) is one such nutritional ergogenic aid that has the 
potential to enhance high-intensity anaerobic exercise performance. However, little is 
known regarding the effect of SB on repeated sprint-ability comparable to the type of 
movement patterns, duration and intensity of exercise necessary in the performance of 
team field sports such as rugby union. The aim of the current research, therefore, is to 
investigate the effects of sodium bicarbonate supplementation on high-intensity, 
intermittent sprint performance, recovery and subsequent repeat sprint performance in 
rugby union players. This review of literature will provide an overview of the research in 
the area of SB supplementation, with a specific focus on its effect on high-intensity 
intermittent exercise, recovery and subsequent exercise performance. The evidence 
surrounding the various mechanisms and supplementation protocols in terms of dosage 
and timing of ingestion of SB will also be presented, as demonstrated in the current 
scientific literature.  
 
 
2.2. Physiological Demands of Rugby Union 
 
Due to the growing culture of supplement use in the sport at present, rugby union was 
chosen as the selected field-based team sport for this research. With the advent of 
professionalism in rugby, a more scientific approach to performance has been adopted. 
Increases in the volume of matches, along with the demands and intensities of those 
games, culminate in escalating physiological stress being placed on elite players. As a 
result, optimal nutrition, both in the preparation for and recovery from exercise, is 
considered as important to performance as the training stimulus itself. The use of various 
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supplements, including SB, among individuals, and in particular in both amateur and elite 
team settings is becoming increasingly prevalent. However, there is a lack of 
comprehensive research to justify this practice (Burke, 2003). 
 
Rugby union is contact, field-based team sport which consists of two 40-minute halves 
separated by a 10-minute half-time period. Fifteen players from each team contest play 
on a field approximately 100m long and 70m wide. The fifteen players on each team are 
divided into eight forwards and seven backs, with each of the fifteen positions possessing 
distinct roles, physical characteristics and physiological attributes. This heterogeneous 
feature of the sport is unique to rugby union in comparison to most other field-based team 
sports. However, from movement analysis, measurement of physiological parameters 
such as heart rate, blood lactate, blood glucose and muscle glycogen, the physiological 
responses to rugby union are typical of many team sports with a range of work intensities, 
durations and recovery periods (Quarrie et al., 1996). 
 
According to match analysis by Nicholas (1997), “rugby is an interval or intermittent 
sport and players must be able to perform a large number of intensive efforts of 5 to 15 
seconds duration with less than 40 seconds recovery between each bout of high intensity 
activity.” Research by Deutsch et al. (1998) purported that rugby players can cover 6km 
during a game. The mean distance that a player will sprint is 15m, and the total distance 
sprinted during competition ranges from 100m (forwards) to 350m (backs). Players run at 
near-maximal pace for an additional total of 370m (forwards) and 550m (backs). 
Although there is a considerable variation in demands relative to each position on the 
field, all rugby players require high levels of strength, speed, power and endurance 
(Gabbett, 2006; Gabbett, 2007; Duthie et al., 2003). As a result, demands are placed on 
both the anaerobic and aerobic systems.  
 
The work to rest ratios of 1:5.7 reported by Cunniffe et al. (2009) were based on GPS 
tracking of just two players (one loose forward and one inside back) during one 
professional Celtic league rugby union match. Time motion analysis of the demands of 
rugby union by McLean et al. (1992) argued the most frequent work to rest ratios 
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observed measured during professional rugby union over five games throughout the 
1989-1990 Five Nations Championship were 1:1-1.9 and 1-1.9:1. Deutsch et al. (1998) 
substantiated this to some extent, identifying a mean work to rest ratio of 1:1.4 and 1-2.7 
for under-19 forwards and backs, respectively. However, the latter two studies were 
conducted using time motion analysis and as a result may not be comparable to the global 
positioning systems (GPS) based work of Cunniffe et al. (2009). It would appear that the 
work to rest ratios performed during rugby union remain disparate depending on the 
method of assessment. Time motion analysis is a valuable tool used to quantify the 
physiological demands of sport. However, due to the dynamic, open nature of rugby 
union, the simplification of movements into categories may prevent accurate comparisons 
with other method such as GPS analysis. 
 
GPS analysis by Cunniffe and colleagues (2009) also indicates that backs travel greater 
distances (7.6% further) during a game than their forward counterparts. However, both 
forward and back position players recorded greater running distances in the second half 
of the game. This would suggest that depletion of energy reserves was not a concern. 
However, the half-time recovery practices undertaken were not outlined in this article. 
Match analysis reported by Deutsch et al. (1998) has shown that the mean distance that 
rugby players sprint is between 10 and 20 metres. Therefore, acceleration speed over 10-
20m will indicate a player’s sprint ability specific to the demands of a typical game. From 
a review of the demands on New Zealand rugby players, it has also been suggested that 
metabolic demands on the players may differ depending on the environment, the level of 
play, the style of referee and the tactical component of the game (Quarrie et al, 1995). 
Given these considerable demands being placed on rugby players, pre-exercise nutrition 
is an evolving area viewed as a key component of performance. 
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2.3. Rugby Sevens 
 
Rugby sevens is a seven-a-side variation of rugby union, played under essentially the 
same laws and on a playing field of the same dimensions as 15s rugby. Rugby sevens 
matches consist of two seven-minute halves with a half-time period of 2 minutes. Sevens 
tournaments typically involve five or six matches and are usually completed over the 
course of one day or a weekend. Sevens rugby is a highly popular version of the game 
worldwide and is now recognised as an Olympic sport making its debut in the 2016 
Summer Olympic Games in Rio de Janeiro, Brazil. Only limited research relating to 
rugby sevens currently exists, with the majority of studies focusing on injury incidence. 
Prior to Olympic inclusion, just one journal article existed relating to the physiological 
demands of rugby sevens (Rienzi et al., 1999). However, the 2009 announcement of 
upcoming Olympic inclusion has prompted three more scientific articles to be published 
analysing the movement patterns, physiological demands and anthropometric profiles of 
rugby sevens players. 
 
Using GPS analysis, Higham et al., (2012) conducted a characterisation and review of the 
movement patterns of 19 international level male rugby sevens players. From comparison 
of this analysis with GPS analysis from an 83 minute 15-a side rugby union game 
(Cunniffe et al., 2009a), rugby sevens was found to be played at a substantially greater 
running intensity. The rugby sevens players covered approximately 45% greater total 
distance per minute at a significantly greater velocity (135% greater distance covered at 
>5m/s). Unsurprisingly, Higham et al., (2012) also observed that in relative terms 
international sevens matches required greater maximum running velocities, greater 
distances covered at high velocity and a greater number of changes in velocity when 
compared to domestic sevens matches. Given the greater relative running loads 
associated with sevens rugby when compared to its 15-a-side rugby counterpart, and with 
international sevens as opposed to domestic sevens, the necessity to maintain 
performance and resist fatigue is seemingly most pronounced in international sevens 
rugby. As a result, this environment may provide the greatest scope for investigation of 
the effects of SB on performance. 
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A combination of GPS analysis and heart rate responses were used to assess running 
demands on seven male domestic sevens players by Suarez-Arrones et al. (2011). It was 
found that that during the course of a 14 minute game, players covered a mean distance 
of 1580±146.3m resulting in a mean running velocity of 6km/h. This is in contrast to a 
15-a-side rugby game, over 80 minutes, which has reported mean distances covered of 
6953m at an mean velocity of 4.2km/h (Cunniffe et al., 2009). Of this mean distance of 
1580m observed for sevens rugby (Suarez-Arrones et al., 2011), standing and walking, 
jogging and cruising comprised 34.8% (549.7±79.1 m), 26.2% (414.8±105.1 m) and 
9.8% (154.6± 53.5 m) respectively. The remainder of the distance was covered by 15.5% 
striding (244.5±80.1 m), 5% high-intensity running (79.5±37.2 m) and 8.7% sprinting 
(137.7±84.9 m). Suarez-Arrones et al. (2011) also found that seven players’ work to rest 
ratio was 1:0.5 and players spent approximately 75% of the 14 minute game at a heart 
rate greater than 80% of their maximal heart rate. 
 
Suarez-Arrones et al., (2011) also investigated the running demands and heart rate 
responses in elite female international sevens players with similar findings. The female 
sevens players also operated at an intensity greater than 80% of their maximal heart rate 
for approximately 75% of a 14 minute game. Female players covered an mean distance of 
1556.2+/-189.3 m per game, which was composed of 29.7% (462.6+/-94.6 m) standing 
and walking, 33.2% (515.9+/-88.6 m) jogging, 11.6% (181+/-61.4 m) cruising, 16.4% 
(255.7+/-88.3 m) striding, 3.7% (57.1+/-40.8 m) high-intensity running, and 5.4% 
(84.0+/-64.8 m) sprinting. The work to rest ratio for female international sevens players 
was 1:0.4, which along with the data revealed for the male players, highlights the 
difference in physiological demands of rugby sevens compared to other rugby codes such 
as 15-a-side rugby where work to rest ratios of 1:1-1.9 (Duthie et al., 2003) and 1: 5.7 
(Cunniffe et al., 2009) have been previously reported. 
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2.4. Fatigue and High Intensity Intermittent Exercise 
 
Fatigue is defined as an inability to maintain a given force or power output (Maughan et 
al., 1997) and is a multifactoral process (Juel and Pilegaard, 1998). Several components 
may contribute to fatigue including substrate availability, metabolic by-products, muscle 
fibre contractile properties and nervous system alterations (McArdle et al,. 2010). High 
intensity intermittent exercise requires a high turnover of skeletal adenosine triphosphate 
(ATP). Given that intramuscular ATP stores are capable of sustaining muscular 
contraction for only a few seconds, ATP must be resynthesised through anaerobic 
glycolysis and phosphocreatine degradation (Hollidge-Horvat et al., 2000). During a 
rugby union game there is a contribution to muscular activity from all three energy 
systems – 1. ATP-PCr system, 2. Anaerobic glycolysis and 3. Oxidative phosphorylation 
(Nicholas, 1997). The relative contributions of each energy system are dependent upon 
both exercise intensity and duration at any given time point within a rugby game. 
Typically, the contribution of the adenosine triphosphate-phosphocreatine (ATP-PCr) 
system may be greater during high intensity, short duration bursts of play. However, 
energy during low intensity periods of the game may be supplied predominantly by the 
oxidative system.  
 
Primarily characterised by short-duration, high intensity efforts interspersed with low 
intensity active recovery and rest periods, rugby union relies heavily on both the ATP-
PCr system and anaerobic glycolysis for energy production (Deutsch et al., 1998). 
Spencer et al. (2005) reported that following 10 second maximal sprint activity, the initial 
source of ATP is predominantly supplied by ATP degradation and glycogenolysis, 
particularly in type II muscle fibres. In addition, it is purported that the depletion of PCr 
within these fibres it is a main contributing factor to fatigue in high-intensity, short 
duration exercise (Spencer et al., 2005). Resting intramuscular ATP stores are usually 
reported to be approximately 20-25mmol/kg dry mass (Gaitanos et al., 1993). During 30 
second sprint exercise, muscle ATP depletion appears restricted to within approximately 
45% of resting levels (Boobis et al., 1982; Cheetham et al., 1986). The fact that muscle 
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ATP levels are mostly maintained during maximal exercise results in significant PCr 
depletion and illustrates the importance of PCr as an energy buffer (Medbo et al., 1999).  
 
It has been reported that following 30 seconds of maximal exercise, resting PCr stores are 
depleted by up to 60-80% (Medbo et al., 1999). PCr depletion during 2.5 seconds of 
electrical stimulation was shown to be only 26% (Hultman and Sjoholm, 1983). As a 
result, sprinting specific to team field sports (2-3 second in duration) is likely to involve 
anaerobic glycolysis along with PCr degradation. The PCr recovery rate is dependent, in 
part, on the kinetic mechanisms of the catalytic enzyme, mitochondrial creatine kinase 
(Malucelli et al., 2011). Low ATP concentration and reduced intramuscular pH following 
high intensity exercise is believed to contribute to fatigue by slowing the rate of PCr 
resynthesis (Spriet et al., 1989). According to Bogdanis et al. (1996), the ability to 
produce high power outputs is directly correlated to the resynthesis of PCr. During team 
sport performance involving typical recovery periods of between 20 and 30 seconds, full 
PCr resynthesis is not possible. Therefore, there is an increasing reliance on anaerobic 
glycolysis and the aerobic energy system (Spencer et al., 2005). Furthermore, creatine 
supplementation has been shown to induce an increased rate of PCr resynthesis and 
therefore, delayed fatigue. This is attributed to a reduction in inorganic phosphate and an 
increased intramuscular pH (Yquel et al., 2002).  
 
Glycolysis is associated with hydrogen ion (H
+
) accumulation which causes both muscle 
and blood pH to decrease (Medbo et al., 1985). This increased acidosis (decreased pH) 
causes a deceleration in glycolysis due to impaired enzyme activity (Trivedi et al., 1966; 
Ui, 1966) and interference with calcium release from the sarcoplasmic reticulum, leading 
to fatigue (Favero et al., 1995; Nakamura and Schwarz 1970). In order to maintain 
homeostasis and potentially delay the onset of fatigue, there must be a balance between 
the formation and removal of H
+
. The ingestion of sodium bicarbonate prior to exercise 
may increase blood buffering capacity and delay the accumulation of H
+
 (Peart et al., 
2012). 
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2.5. Acid-Base Balance 
 
Acid-base balance refers to the state of equilibrium between acidity and alkalinity in the 
blood (Filley, 1971). Hydrogen ions (H
+
) play a central role in maintenance of the acid-
base balance. Acids dissociate in solution, donating H+, whereas bases accept the H+ to 
form hydroxide ions (OH
-
). pH is used as the measure to express the activity of H
+ 
in the 
blood and, therefore, the acid-base balance (Aerenhouts et al., 2011). Due to the 
fractional numbers associated with hydrogen ion concentration (0.00000004 
equivalents/L), pH is defined as minus the decimal logarithm of the hydrogen ion 
concentration [H+] in a solution (Guyton and Hall, 1996): 
 
pH = log(1/[H
+
]) = -log[H
+
] 
pH = -log[0.00000004] 
pH = 7.4 
 
[H
+
] and pH are inversely related, therefore an increased [H
+
] in the blood corresponds to 
a decrease in pH. Conversely, a decreased [H
+
] will equate to an increase in pH. The [H
+
] 
or arterial blood pH must be maintained near to or within the normal range of 7.35-7.45 
pH units. This is the pH at which the chemical reactions in the cells of the body may 
optimally occur. Even minimal deviations from normal arterial blood pH will cause 
marked alterations in enzymatic activity, leading to acceleration or deceleration of 
various chemical reactions and, ultimately, impairing cell function (McArdle, et al., 
2010). As a result, pH plays a key role in the maintenance of homeostasis within the 
body. Below this normal arterial pH range (a pH of <7.35) is considered a state of 
increased acidity in the body, known as acidosis, while an extracellular pH of greater than 
7.35 is indicative of alkalosis. Humans are unable to sustain a pH of below approximately 
6.8 or above approximately 8.0 for more than a few hours. Acidosis and alkalosis may be 
caused by either respiratory or metabolic mechanisms (Muthayya, 2002).  
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The regulation of pH and maintenance of acid-base balance is controlled by the following 
mechanisms: 
1. Buffer systems in body fluid 
2. Respiratory mechanisms 
3. Renal mechanisms 
 
 
2.5.1. Buffering Systems in the Body 
 
Buffers consist of a mixture of a weak acid with its conjugate base or a weak base with its 
conjugate acid. Buffer systems in the body react chemically, within a fraction of a 
second, to changes in the [H
+
] and therefore minimise the change in pH (Martini, 2006). 
Rather than eliminating or introducing H
+
 to the body, buffer systems keep the H
+
 
engaged until the acid-base balance can be restored. The body has a large buffering 
capacity as illustrated by Pitts (1952) following infusion of dilute hydrochloric acid into 
dogs. The authors found that infusion of 14mmol/L of H
+
 caused a decrease in pH from 
7.44 ([H
+
]=36nmols/L) to a pH of 7.14 ([H
+
]=72nmols/L). As a result, an increase of 
only 36nmols/L was observed in the blood, suggesting that the other 13,999,964nmols/L 
infused had been buffered effectively by the body’s buffering systems. In humans, 
approximately 80milliequivalents of hydrogen is ingested or produced by metabolism per 
day. In contrast, the [H
+
] of the body fluids contains only approximately 0.0004 
milliequivalents/L (Guyton and Hall, 1996). This large discrepancy between the quantity 
of acid introduced to the body and the amount that is subsequently visible in the body 
fluids demonstrates the importance and effectiveness of buffering. As a result of these 
buffering systems, the body avoids exposure to the huge changes in [H+] that would 
otherwise occur. The main buffering systems of the blood and other body fluids include 
the phosphate buffering system, the protein buffering system and the bicarbonate 
buffering system (Boning et al., 2007). 
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2.5.1.1. Phosphate Buffering System 
 
The concentration of phosphate in the blood is quite low and as a result, it contributes 
little to the buffering capacity of extracellular fluid. The phosphate buffering system is, 
however, active in intracellular buffering and is by far the most important buffer system 
in the urine. In order to secrete H
+
 in the urine, it must be buffered to maintain the ionic 
gradients. Phosphates allow large amounts of H
+
 to be excreted from the body in urine 
without causing large alterations to urinary pH. The pH of urine may range from 4.5-8.0 
depending on the acid-base status of the extracellular fluid. At the urinary pH of 5.8, 
there is a 10:1 ratio of acid phosphates (H2PO4) to phosphate salts (HPO4). For each 
phosphate ion excreted as acid phosphate, one sodium (Na
+
) ion is released and 
reabsorbed from the kidney back into the body and one H
+
 ion is excreted in urine 
(Muthayya, 2002). This exchange also enables the kidneys to reabsorb bicarbonate 
(HCO3
-
) back into the body with Na
+
 as the two bind to form sodium bicarbonate 
(NaHCO3). As will be discussed in detail later, the kidneys play a key role in the 
regulation of extracellular fluid [H
+
] by altering the rate of excretion of acids or bases 
depending on the acid-base status. 
 
2.5.1.2. Protein Buffering System 
 
Plasma and cell proteins function as buffers through a similar mechanism to the 
bicarbonate buffering system below. Due to the permeability of the cell membrane to H
+
, 
HCO3
-
 and carbon dioxide (CO2), there is a relationship between intracellular and 
extracellular pH, with intracellular pH, which ranges from 6.0-7.4, changing in 
proportion to the pH in the extracellular fluid. As a result, the intracellular proteins may 
also contribute to extracellular buffering. However, with the exception of the rapid 
equilibrium that occurs in red blood cells, the protein buffering system may require 
several hours to achieve a balance with the extracellular fluid due to the slow movement 
of H
+ 
and HCO3
-
 through the cell membranes (Guyton and Hall, 1996). 
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Haemoglobin (Hb) is a globular protein found in the red blood cells which circulate 
throughout the bloodstream. The cytoplasm of the red blood cells also contain large 
amounts of the enzyme carbonic anhydrase, which catalyses the reaction converting CO2 
and H2O to H2CO3 to H
+
 + HCO3
-
 and vice versa. CO2 is capable of rapidly diffusing 
across the red blood cell membrane. As a result, red blood cells have a significant 
influence on the extracellular pH through their absorption of circulating CO2 from the 
plasma and conversion of this CO2 to H2CO3. As the H2CO3 dissociates into H
+
 + HCO3
-
, 
the chloride shift occurs, whereby the intracellular HCO3
- 
ions diffuse into the plasma in 
exchange for extracellular chloride ions. This mass movement exchange does not require 
ATP to take place. The H+ are buffered by the Hb molecules. Of the circulating CO2 in 
the bloodstream, approximately 7% remains dissolved in plasma whereas the remaining 
93%, approximately, diffuses into the red blood cells. Approximately 23% of the CO2 
diffuses into the red blood cells and binds to the exposed amino group (NH2) of the Hb 
molecules to form carbaminohaemoglobin in the following reversible reaction (Martini, 
2006): 
 
CO2 + HbNH2 ↔ HbNHCOOH  
 
The remaining 70% of circulating CO2 is converted to H2CO3, resulting in the exchange 
of HCO3
- for chloride ions and removal of H+ by Hb, as mentioned above.  
 
Hb is a potent buffer of H
+
 and is responsible for the majority of the capacity of the total 
protein buffering system. The Hb buffer system is the only intracellular buffer system 
that can immediately influence the pH of the extracellular fluid. This system helps to 
prevent significant changes in pH when fluctuations in plasma PCO2 (partial pressure of 
arterial dissolved carbon dioxide) are experienced (Martini, 2006). Residues of the amino 
acid, histidine, with an imidazole sidechain that are contained in Hb allow the protein to 
buffer effectively through the following reaction: 
 
H+ + Hb ↔ HHb 
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Deoxygenated Hb is a more effective buffer than oxygenated Hb as it possesses a greater 
affinity to accept protons. The superior capacity for deoxyhaemoglobin to form 
carbamino compounds plays a key role in the Haldane effect. The Haldane effect 
enhances the removal of CO2 from oxygen-consuming tissues and promotes the 
dissociation of CO2 from Hb in the presence of oxygen (Jensen, 2004).  
 
Other proteins in the body have amino and carboxyl groups, both of which may accept or 
donate H
+
, thus contributing to the overall protein buffering system. Proteins are one of 
the most abundant buffers in the body given their high concentrations particularly within 
the cells (Guyton and Hall, 1996). Hb and other circulating proteins are highly effective 
in that they may rapidly minimise the overall pH change by distributing the effects of 
changes in H
+ 
throughout the body. These proteins are then capable of transporting H
+ 
to 
the lungs to be eliminated in the form of CO2 and H2O. However, cellular buffering 
proteins may be confined to a fixed location within the cell and as result function only as 
slow buffers, removing H+ gradually over a period of hours and at increased risk of 
becoming saturated with acid (Hulikova et al., 2012). 
 
2.5.1.3. Bicarbonate Buffering System 
 
The bicarbonate buffering system is the main buffering system in the extracellular fluid 
and is responsible for approximately 80% of extracellular buffering. The bicarbonate 
buffer is considered to be effective due to its high concentration in plasma (~24mmol/L) 
and also because of the tight regulation of two of its components, CO2 and HCO3
-
, by the 
lungs and kidneys respectively (Theis and Barron, 1992). 
 
The bicarbonate buffering system converts hydrochloric acid (a strong acid) to the much 
weaker carbonic acid (H2CO3) by combining with sodium bicarbonate (NaHCO3): 
 
HCl + NaHCO3  → NaCl +  H2CO3 ↔ H
+
 + HCO3
-
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Bicarbonate ions (HCO3
-
) interact with H
+ 
to form carbonic acid (H2CO3), which may 
then be dissociated into CO2 and water (H2O). This reaction is catalysed by the enzyme 
carbonic anhydrase and is reversible: 
 
 
With acidosis caused by an increase in [H
+
], the above reaction is driven to the left and 
ventilation is stimulated to eliminate the excess CO2 produced. Conversely, the 
bicarbonate buffering system may react to a decrease in [H
+
] by inhibiting the ventilatory 
drive in order to retain CO2 (Greenhaff et al., 1987), thus shifting the reaction to the right. 
This CO2 then combines with H2O to form carbonic acid, which dissociates to H
+
 + 
HCO3
-
, thus increasing acidity and normalising pH (McArdle et al., 2010).  
 
The enzyme catalysing this reaction, carbonic anhydrase, is particularly abundant in the 
alveolar walls of the lungs where CO2 is released. This enzyme is also present in the 
cytoplasm of the red blood cells and also the epithelial cells of the renal tubules, where 
CO2 and H2O combined to form H2CO3 (Guyton and Hall, 1996). 
 
The components of the bicarbonate buffering system and therefore, the pH of 
extracellular fluid, are quantifiable using the Henderson-Hasselbalch equation (Harrison, 
1995): 
 
pH = pKa + log ( [HCO3
-
] / [H2CO3] ) 
 
pKa is the negative logarithm of Ka which is the acid dissociation constant i.e. the ease 
with which an acid relinquishes its H
+ 
(Staempfli and Constable, 2003). pKa has a value 
of 6.099 at a temperature of 37C and a plasma pH of 7.4. This value may be altered 
depending on the temperature and [H
+
] but is generally accepted as 6.1: 
 
pH = 6.1 + log ( [HCO3
-] / [0.03 x PCO2] ) 
(0.03 is substituted in as the proportionality constant between dissolved CO2 and PCO2) 
CO2 + H2O                 H2CO3                 H
+
 + HCO3
- 
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pH = 6.1 + log [ 24mmol/L / (0.03 x 40mmHg) ] 
 
pH = 6.1 + log 20/1 
The maintenance of a normal plasma pH within the body, therefore, relies on the 
perpetuation of a ratio of 20:1 between [HCO3
-
] and [CO2] in plasma (Thies and Barron, 
1992). From the Henderson-Hasselbalch equation, it is evident that an increased [HCO3
-
] 
results in a rise in pH, shifting the acid-base balance towards alkalosis (Harrison, 1995). 
In contrast, an increase in PCO2 in extracellular fluid causes a decrease in pH, shifting the 
acid-base balance towards acidosis. [HCO3
-] and PCO2 are regulated by the kidneys and 
lungs respectively (Guyton and Hall, 1996).  
 
2.5.1.4. Isohydric Principle 
 
The isohydric principle states that all buffers in a common solution are in equilibrium 
with each other in terms of [H
+
]. Therefore, a change in the [H
+
] of extracellular fluid 
affects all of the buffer systems due to the fact that H
+ 
are involved in the reactions of 
each of the systems. The buffer systems in fact buffer each other through the movement 
of H
+ 
between them (Guyton and Hall, 1996). 
 
In terms of blood gas analysis, the isohydric principle infers that the concentrations of 
any one acid-base pair may provide a measurement of the overall acid-base balance 
within the body. Given that the components of the bicarbonate buffering system (HCO3
- 
and PCO2) are relatively convenient and accessible to quantify, these are the parameters 
typically utilised to assess overall acid-base balance. Blood gas analysis provides a direct 
measurement of pH and PCO2, from which [HCO3
-
] is subsequently calculated using the 
Henderson-Hasselbalch equation mentioned above. 
 
2.5.1.5. Maintenance of Acid-Base Balance 
 
While the buffering systems provide an effective method of tying up excess H
+
, this only 
serves as a temporary solution to an acid-base imbalance. The body contains a limited 
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reserve of buffer molecules. These molecules will continue to bind to H
+ 
until they 
become saturated, at which point further maintenance of pH may only occur if H
+
 can be 
eliminated from the extracellular fluid or if the buffer molecules are replaced. As a result 
the maintenance of acid-base balance involves the combination of the buffer systems with 
respiratory mechanisms and renal mechanisms. These mechanisms are capable of 
contributing to pH control by secreting or absorbing H
+
, manipulating the excretion of 
acids and bases, and generating replacement buffers (Martini, 2006). 
 
 
2.5.2 Respiratory Mechanisms 
 
The respiratory system is considered the second line of defence, after the buffering 
systems, against acid-base balance disturbances. This system reacts to changes in [H
+
] 
within a few minutes to eliminate CO2 through the lungs. Respiratory compensation 
refers to an alteration in respiratory rate to minimise a change in extracellular pH. The 
respiratory system has a direct effect on the bicarbonate buffering system. An increase in 
the PCO2 of extracellular fluid causes a decrease in pH, whereas a decrease in PCO2 
increases the pH.  
 
Peripheral chemoreceptors, sensitive to the PCO2 of circulating blood, are located in the 
carotid and aortic bodies. The carotid and aortic bodies are stimulated by a decrease in 
pH or PO2 or indirectly by an increase in PCO2. Information from these receptors is 
monitored by the glossopharyngeal and vagus nerves respectively. Central 
chemoreceptors are located on the ventrolateral surface of the medulla oblongata. These 
receptors are sensitive only to the PCO2 and pH of the cerebrospinal fluid (CSF). 
Stimulation of these chemoreceptors leads to an alteration in ventilation. Under normal 
conditions, CO2 levels are the major factor in the regulation of respiratory activity. The 
respiratory centres show little response to arterial PO2 levels until a drop of 
approximately 40% from 100 to 60mmHg is observed. A major decline in arterial PO2 to 
40mmHg induces only a 50-70% increase in respiratory rate, whereas, the respiratory rate 
is doubled in response to just a 10% elevation in arterial PCO2 (Martini, 2006). A rise in 
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PCO2 is detected by the chemoreceptors, stimulating an increase in ventilation (rate and 
depth of respiration). As ventilation increases, more CO2 is eliminated from the 
extracellular fluid, which returns PCO2 levels to normal and also reduces the [H
+
] by 
mass action (Guyton and Hall, 1996). Conversely, a decline in PCO2 levels within the 
blood or CSF causes decreased ventilation leading to an increase in extracellular PCO2 
(Martini, 2006). 
 
Extracellular PCO2 may be influenced by variations in either the respiratory ventilation or 
the rate of intracellular metabolic CO2 production. CO2 is constantly being formed within 
the body through intracellular metabolism. Once formed, CO2 diffuses out from the cells 
into the blood where it is transported to the lungs, diffuses into the alveoli and is expired. 
Extracellular fluid normally contains approximately 1.2mol/L of dissolved CO2, equating 
to a PCO2 of 40mmHg. An increase or decrease in the intracellular metabolic formation 
of CO2 corresponds to proportionate increase or decrease in extracellular PCO2. In 
addition, an increase in the rate of ventilation allows CO2 to be eliminated from the lungs, 
thus decreasing the extracellular PCO2 (Guyton and Hall, 1996).  
 
An increase in [CO2] is associated with corresponding increases in [H2CO3] and [H
+
], 
resulting in a decline in extracellular pH. A two-fold increase in the normal rate of 
alveolar ventilation induces an increase of approximately 0.23 in extracellular pH, which 
would cause an elevation of pH from 7.4 to 7.63. Conversely, an alveolar ventilation rate 
representative of one-quarter of normal reduces the pH by 0.45, which would result in a 
reduction in pH from 7.4 to 6.95. Given the large variations that may occur in the rate of 
alveolar ventilation, the respiratory system plays a major role in pH control and in fact 
operates as a negative feedback regulator of [H+] - an increase in [H+] stimulates 
respiration and an increase in alveolar ventilation in turn decreases [H
+
] (Guyton and 
Hall, 1996). 
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2.5.2.1 Oxyhaemoglobin dissociation curve 
 
 
Under normal conditions, haemoglobin is responsible for transporting approximately 
97% of the oxygen (O2) travelling from the lungs to the tissue. The remaining 3% is 
dissolved in the plasma. Each haemoglobin molecule possesses the capacity to carry four 
O2 molecules at any one time. O2 saturation refers to the ratio between the amount of O2 
bound to haemoglobin and its oxygen-carrying capacity (McArdle et al., 2010). The 
affinity of haemoglobin for O2 is largely dependent on the partial pressure of O2 (PO2) to 
which the haemoglobin is exposed (Guyton and Hall, 1996). For example, in the 
pulmonary capillaries where PO2 is high, O2 binds easily to haemoglobin and may be 
transported to the tissues. Contrastingly, in the tissue capillaries where PO2 is low, O2 is 
released from the haemoglobin. In addition, deoxygenated haemoglobin has an increased 
affinity for CO2 to bind and be transported from the working tissue to the lungs to be 
expired (Haldane effect). 
 
The oxyhaemoglobin dissociation curve, which represents the affinity of haemoglobin to 
bind to O2 molecules, is a sigmoidal curve illustrating the progressive increase in the 
percentage of haemoglobin bound with O2 as the PO2 increases. A normal arterial PO2 of 
approximately 100mmHg equates to approximately 97% O2 saturation. The PO2 of 
normal venous blood is approximately 40mmHg, corresponding to a saturation level of 
approximately 75% (Guyton and Hall, 1996). The oxyhaemoglobin dissociation curve is 
affected by several factors such as pH, temperature, PO2, PCO2 and 2,3-
disphosphoglycerate (2,3-DPG), which is a metabolite of anaerobic glycolysis (Dickson, 
1995). During exercise, the curve may be shifted to the right (low affinity for O2) by a 
decrease in pH, increase in PCO2, increase in temperature, decrease in PO2 and an 
increase in 2,3-DPG (Riggs et al., 1973). The effect of the rightward curve shift during 
exercise encourages O2 to dissociation from haemoglobin at the tissue. Therefore, this 
effect promotes O2 delivery to the working tissue during exercise. In contrast, the curve is 
shifted to the left under the opposite circumstances, whereby H
+
 and CO2 are released 
from haemoglobin, the affinity of haemoglobin for O2 is increased and a decreased 
concentration of O2 is required to saturate haemoglobin with oxygen (Bohr effect).  
 27 
2.5.2.2 Responses of pH, partial pressures and the buffering systems to exercise: 
 
During maximal exericse, O2 diffusing capacity (i.e. the rate at which O2 can diffuse from 
the alveoli to the blood) may be increased by up to three times from resting levels. This is 
reported to be due to the increased blood flow which accompanies exercise. Increased 
blood flow encourages increased perfusion and therefore, a greater surface area over 
which diffusion may occur (Guyton and Hall, 1996). Changes in arterial blood gases as a 
consequence of exercise are normally minimal. There may be a slight rise in arterial PO2 
due to increased ventilation. However, PO2 may eventually decrease at higher work loads. 
During short duration, high intensity exercise involving dominance of anaerobic 
glycolysis, accumulating H
+
 results in an increase in PCO2 (McArdle et al., 2010). 
Respiratory compensation (as mentioned in Section 2.5.2) acts to stimulate ventilation 
and decrease extracellular PCO2, thereby resisting a change in pH (Martini, 2006). 
During moderate exercise, blood pH may remain constant for long durations. However, 
as exercise intensity increases there is an increased reliance on anaerobic glycolysis. The 
resultant accumulation of H
+
 leads to a decrease in pH (Cheetham et al., 1986). 
 
 
2.5.3 Renal Mechanisms 
 
The kidneys play a major role in the regulation of acid-base balance as they function to 
eliminate excess acid or base from the body via the urinary system. The kidneys are 
relatively slow to respond to changes in [H
+
] compared to the buffering systems and 
respiratory system. However, the renal system is an important longer-term contributor to 
acid-base regulation, functioning to maintain the body’s buffer reserve (McArdle et al., 
2010). The kidneys regulate extracellular [H
+
] through secretion of H
+
, reabsorption of 
filtered HCO3
-
 and generation of new HCO3
-
. Renal compensation refers to an alteration 
in the rates of secretion or absorption of H
+ 
and HCO3
-
 by the kidneys in response to 
changes in extracellular pH. In order to maintain acid-base balance the body must 
generate and excrete an equal amount of H+ (Martini, 2006). In alkalosis (decreased 
extracellular [H
+
]), the excess HCO3
-
 ions cannot be reabsorbed and, therefore, the 
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kidneys increase the excretion of HCO3
-
. The removal of HCO3
-
 allows the extracellular 
[H
+
] to return toward homeostasis. In acidosis (increased extracellular [H
+
]), instead of 
excreting HCO3
-
 in the urine, the kidneys reabsorb all the filtered HCO3
-
, generate new 
HCO3
-
 and excrete the excess H
+
 in the urine. The filtered and newly generated HCO3
- 
is 
then returned to the extracellular fluid to function as an available buffer of H+, thus 
reducing the extracellular [H
+
] back towards homeostasis (Guyton and Hall, 1996).  
 
2.5.3.1. Secretion of H
+
 and Reabsorption of HCO3
- 
 
Secretion of H+ and reabsorption of HCO3
- occurs in all segments of the renal tubules 
with the exception of the descending and ascending thin limbs of the loop of Henle. The 
majority (approximately 85%) of the HCO3
- 
reabsorption and H
+ 
secretion takes place in 
the proximal convoluted tubule. Another 10% of the filtered HCO3
-
 is reabsorbed in the 
thick ascending loop of Henle, with the remainder of the absorption occurring in the 
distal convoluted tubule and collecting duct (Guyton and Hall, 1996).  
 
2.5.3.2. Secretion of H
+ 
in the Early Tubular Segments 
 
The mechanism of HCO3
- 
reabsorption also involves secretion of H
+
 from the different 
renal tubular segments. In the early tubular segments, H+ ions are secreted by secondary 
active transport. The epithelial cells of the proximal convoluted tubule, the thick 
ascending loop of Henle and the distal convoluted tubule all secrete H
+
 into the tubular 
fluid by sodium-hydrogen (Na
+
/ H
+
) counter-transport at the membrane of the lumen of 
the tubule (Guyton and Hall, 1996).  
 
The secretion of H
+
 initiates the process of HCO3
- 
reabsorption. HCO3
- 
ions that are 
filtered by the glomerulus cannot be directly reabsorbed as they cannot cross the 
membrane from the lumen into the tubular cells in their existing form. Instead HCO3
-
 
must first bind with H
+
 to form H2CO3, which eventually dissociates into H2O and CO2, 
which can pass readily into the tubular cells from the lumen. CO2 either diffuses from the 
renal interstitial fluid into the tubular cells or is produced by metabolism in the tubular 
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epithelial cells. This CO2 then binds with H2O to form H2CO3, which subsequently 
dissociates into HCO3
-
 and H
+
. The H
+
 ions combine with a carrier protein on the cell 
membrane and are secreted into the lumen of the tubule in exchange for Na
+
 ions that 
also bind to a carrier protein and move into the tubular cells. The Na
+ 
travels into the 
tubular cell from the lumen of the tubule along a concentration gradient established by 
the sodium potassium (Na
+
/K
+
) ATPase pump in the basolateral membrane (membrane 
between the tubular cell and the renal interstitial fluid).  
 
This concentration gradient responsible for transporting Na
+
 into the cell then provides 
the energy required to transfer H+ in the opposite direction from the tubular cell to the 
lumen of the tubule. The bicarbonate ion, formed in the cell from the dissociation of 
H2CO3 then crosses the basolateral membrane from the cell into the renal interstitial fluid 
and the peritubular capillary blood. In summary, the sum of the transport of ions between 
the tubular lumen, tubular cells and renal interstitial fluid result in a HCO3
-
 ion entering 
the blood in exchange for every H+ ion secreted into the tubular lumen (Guyton and Hall, 
1996). 
 
2.5.3.3. Secretion of H
+
 in the Late Distal Tubule and Collecting Duct 
 
In the later sections of the renal tubules, including the late distal convoluted tubule and 
the collecting duct, H
+
 is secreted by primary active transport from the epithelium of the 
tubular cells into the lumen. For every H
+
 that is secreted, a HCO3
-
 ion is reabsorbed and 
a chloride (Cl
-
) ion is passively secreted along with the H
+
. This process occurs in the 
intercalated cells of the late distal convoluted tubule and collecting duct. Similar to the 
proximal tubule H+ secretion previously discussed, dissolved CO2 in the cell binds with 
H2O to form H2CO3. The H2CO3 then dissociates into HCO3
- 
ions, which are reabsorbed 
into the blood and H
+ 
ions, which are secreted into the lumen by a specific protein known 
as a hydrogen-transporting ATPase. The energy necessary for the transport of H
+
 across 
the luminal membrane from the tubular cells into the tubular lumen is derived from the 
breakdown of ATP to adenosine diphosphate (ADP). This active energy-utilising H+ 
pump operating in the distal renal tubules, in contrast to the counter-transport mechanism 
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involved in the proximal tubules is the main difference between the secretion of H
+
 in 
respective segments of the renal tubules (Guyton and Hall, 1996). 
 
2.5.3.4. Renal Buffers 
 
Buffers in the tubular fluid play a key role in the elimination of H
+
 within a normal 
volume of urine. Minimal urine pH is approximately 4.5, equating to a maximum 
excretion of approximately just 0.03milliequivalents/L of free H
+
. As a result, in order to 
excrete the 80milliequivalents/day of non-volatile acid produced by metabolism with H
+ 
remaining in its free form, 2667 litres of urine would be required to be excreted. Large 
amounts of H
+
 (up to 500milliequivalents/day) are capable of being excreted in the urine 
through the combination of H
+
 with buffers in the tubular fluid (Guyton and Hall, 1996). 
These buffers maintain a pH of significant elevation to allow continued secretion of H
+
, 
therefore, preserving acid-base balance. The three major buffer systems involved in 
stabilising the tubular fluid pH include the bicarbonate buffer system, the phosphate 
buffer system and the ammonia buffer system (Martini, 2006).  
 
2.5.3.5. Phosphate Buffer System  
 
As previously discussed, although the phosphate system plays only a minor role in 
extracellular buffering, it is, however, an important tubular buffer. HPO4
2- 
and
 
H2PO4
-
, 
which comprise the phosphate buffer system, are both found in high concentrations in the 
tubular fluid. This is partially due to their poor reabsorption and also the reabsorption of 
H2O from the tubular fluid. In addition, the pKa of the phosphate buffer system is 
approximately 6.8, which is close to the normal pH of urine. As a result, the phosphate 
buffer system is capable of operating close to its most effective pH range within the 
tubular fluid. For the most part, excess H
+
 in the tubular fluid is buffered by HCO3
-
. 
However, once all of the HCO3
-
 has either been reabsorbed or saturated with H
+
, the 
remaining excess H
+
 may bind to other tubular buffers, including HPO4
2-
. HPO4
2- 
and H
+
 
amalgamate with Na+ in the tubular fluid to form NaH2PO4, which can then be excreted as 
a salt. The phosphate buffer system allows a HCO3
-
 ion to be spared from excretion. As a 
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result, the HCO3
-
 ion generated in the tubular cell may be transported into the peritubular 
blood as a new additional HCO3
-
 and not merely as a replacement for the HCO3
- 
excreted 
in the buffering process. However, given that only approximately 30-
40milliequivalents/day of phosphates are available for buffering H
+
, the ammonia buffer 
system regulates the majority of the excess H+ buffering (Guyton and Hall, 1996). 
 
2.5.3.6. Ammonia Buffer System 
 
The ammonia buffer system is composed of ammonia (NH3) and ammonium (NH4
+
). 
Within the proximal convoluted tubule, thick ascending loop of Henle and distal 
convoluted tubule, this system is underpinned by the metabolism of glutamine. The 
breakdown of glutamine produces two NH4
+
 and two HCO3
-
 ions. The NH4
+
 is actively 
secreted, in exchange for a Na
+
, by means of a counter-transport Na
+
/ NH4
+ 
pump. The 
Na
+
 is then reabsorbed along with the HCO3
-
 across the basolateral membrane and into 
the interstitial fluid and then the peritubular blood. Similar to the phosphate buffer 
system, the HCO3
-
 generated through this process is considered new HCO3
-
. The 
ammonia buffer system excretes H
+
 through an alternative mechanism in the collecting 
duct. In this segment of the renal tubules, NH3 diffuses easily into the tubular lumen 
where it combines with H
+
, to form NH4
+
. The tubular cells of the collecting duct are 
highly permeable to NH3 but conversely much less permeable to NH4
+. As a result, the 
NH4
+
, which is composed of the diffused NH3 along with the excess H
+
, is confined to 
the lumen and excreted in the urine. As with the ammonia buffering in the more proximal 
tubules, the collecting ducts also facilitate the generation of new HCO3
-
. Each NH4
+ 
excreted, allows a new HCO3
-
 to be produced and transported to the blood. Under normal 
conditions, the ammonia buffer system is responsible for approximately 50% of the acid 
excreted and 50% of the new HCO3
-
 produced (Guyton and Hall, 1996). 
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2.6. Ergogenic Aids 
 
Ergogenic aids have been used for centuries in a superstitious, ritualistic fashion prior to 
physical exertion with athletes crediting their past performances to particular dietary 
habits. Accounts from ancient times depict athletes and soldiers consuming specific 
animal parts in an attempt to assimilate the physical attributes such as speed and strength 
associated with that animal (Applegate and Grivetti, 1997). In the early 20
th
 Century a 
greater understanding of the biochemistry and physiology of muscular work, fuel use 
during exercise and the specific roles of carbohydrate, fat and protein, gave a degree of 
rationality to the use of ergogenic aids, such as alkaline salts, caffeine, carbohydrate and 
protein (Brown et al., 2006; McArdle et al., 2010). However, the scientific justification of 
the use of nutritional supplements is generally in response to athlete experimentation with 
various substances, volume, form and timing of administration with the aim of 
performance enhancement. Prohibited forms of performance enhancement substances 
including anabolic steroids and blood doping have also been developed for athletes, 
however, ethically and in the interests of health and sportsmanship, these practices should 
not be condoned. 
 
Along with genetic factors and training, many athletes view ergogenic aids as essential 
vehicles to enhance performance (Applegate, 1999). Nutritional supplements are a multi-
billion euro industry worldwide (Burke et al., 2004), form an integral part of the sports 
nutrition strategies of many athletes, from recreational to elite. One such supplement is 
sodium bicarbonate. Much of this athlete support of various supplements is based on 
manufacturers’ assurances of positive outcomes such as weight loss, muscle gain, 
performance enhancement and not on definitive scientific evidence. The absence of 
regulation in the supplement industry facilitates product advertisements with unsupported 
claims about health and performance benefits. Many of these products have been found to 
show poor compliance with regard to labelling laws, presence of contaminants and 
undeclared ingredients (Burke, 2003). 
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2.7. Sodium Bicarbonate and Fatigue 
 
Sodium bicarbonate (SB) is a naturally occurring buffer in the body which has resulted in 
reported performance enhancements when used as an ergogenic aid prior to high intensity 
exercise lasting between 1 and 7 minutes (McNaughton, 1992). The buffer systems of the 
body act to attenuate the accumulation of H
+
 and therefore aid in the regulation of pH. 
The production and removal rates of H
+
 , which both contribute to H
+
 accumulation, are 
influenced by the muscle’s oxidative capacity, muscle fibre type, transport proteins and 
the work-to-rest ratio involved during repeated exercise bouts (Yoshida et al., 1993). SB 
supplementation has been investigated as a potential aid to increase the body’s buffering 
capacity (Hollidge-Horvat et al., 2000).  
 
Research into the area of SB supplementation originated from findings from animal 
studies, demonstrating an increased resistance to fatigue in isolated muscle preparations 
of dogs and frogs and a change in the rate of lactate efflux from the muscle (Hirche et al., 
1975; Mainwood and Worsley-Brown, 1975). By inducing a state of pre-exercise 
alkalosis within the body, the decrease in pH associated with exercise may be delayed. 
Therefore, a greater capacity for contraction of working muscular tissue may be 
facilitated, by means of enhanced muscle glycolytic ATP production (Sutton et al., 1981; 
Bishop et al., 2004). As a result, the ability to limit the changes in pH during high 
intensity exercise may delay fatigue and potentially enhance performance (McNaughton, 
1992). 
 
Research into the acid base balance and its effect on the capacity for work has been 
investigated since the 1930s (Dennig et al., 1931). In this and similar studies at the time, 
the investigators identified that the administration of acid salts caused runners to be more 
acidic and less able to efficiently utilise oxygen. According to Spriet et al., (1986), 
acidosis decreases the muscle’s ability to generate isometric tension and diminishes 
aerobic and anaerobic metabolism. This led to the conclusion that induced alkalosis may 
potentially have the opposite effect. 
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2.8. Sodium Bicarbonate and Sports Performance 
 
In terms of single bout, high intensity, short duration exercise lasting less than 120 
seconds, conflicting results have been reported regarding SB supplementation. 
McNaughton (1992) observed significant performance enhancements with acute SB 
ingestion prior to a 60 second maximal cycle ergometer test. McNaughton (1992) found 
that SB supplementation with 0.3g/kg body mass (BM) resulted in significantly higher 
peak power (1295 +/- 72.8 W) and work completed (41.9 kJ/min) when compared to a 
placebo (PLA) trial.  Similarly, in a study by Goldfinch et al. (1988), it was found that 
ingestion of SB resulted in significantly faster 400 m running times (1.52 seconds) when 
compared to the control. This evidence suggests that SB ingestion facilitates removal of 
excess hydrogen ions from the working muscle, decreasing intracellular pH and delaying 
the onset of fatigue. 
 
Although the majority of the research involving SB supplementation demonstrates 
perturbations in the acid-base balance inducing a state of alkalosis, this condition does 
not always translate into an enhanced performance. Horswill et al., (1988) found no 
significant improvement in the total work performed in a 2 minute cycling sprint with SB 
supplementation. No improvements were recorded, either for work performed or power 
output, following 90 seconds of maximal cycling exercise by untrained males (Marx et 
al., 2002). The lack of significant findings in certain studies may also be as a result of 
factors such as sample size, subject characteristics, SB doses and insufficient durations 
and/or intensities of exercise. 
 
Similar to the findings relating to single bout performances lasting less than 2 minutes, 
research examining repeated bout protocols is also inconclusive. According to the 
findings of a study by Lavender and Bird (1989), SB supplementation resulted in a 
significant improvement in performance of 10 x 10 second cycle sprints with 50 seconds 
recovery between each sprint. In contrast, Gaitanos et al., (1991) found no improvement 
in the performance of 10 x 6 second running sprints with 30 seconds recovery between 
each sprint. 
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To date the majority of studies investigating the effects of SB supplementation on 
exercise performance have involved short repeated bouts of high intensity exercise 
lasting between 60 and 360s. In contrast, numerous studies have investigated the effect of 
SB supplementation on prolonged endurance exercise. In a study investigating the effect 
of 0.2g/kg BM of SB on time to exhaustion at a running velocity corresponding to a 
blood lactate concentration of 4 mmol/L, George and MacLaren (1988) found a 17% 
longer time to exhaustion with SB supplementation when compared to the placebo trial. 
Similarly, McNaughton et al., (1999) reported that, following ingestion of 0.3g/kg BM of 
SB, 10 well-trained cyclists improved their total work by 13 % in a 1 hour maximal cycle 
ergometer test In contrast to these findings, Stephens et al., (2002) found no difference 
between SB and control trials in performance of 30 minutes of continuous cycling at 77% 
VO2max followed by a performance ride (time to complete 469 +/-21 kJ work). 
 
Analysis of SB supplementation in relation to its effect on prolonged intermittent exercise 
is also represented in the research, with only minimal emphasis on team field sports. One 
such study involving a team field sport was undertaken by Bishop and Claudis (2005), in 
which subjects ingested 0.2g/kg BM of SB at 90 and 20 minutes prior to completion of 2 
x 36 minute “halves” of intermittent field hockey-specific activity. Each half consisted of 
2 minute blocks involving a 4 second sprint, 100 seconds at 35% VO2 max, 20 seconds 
passive rest with an additional two repeated sprint bouts of 5 x 2 seconds separated by 35 
seconds at 35 % VO2 max. No significant differences in the total work performed over 
the 72 minutes were observed between the SB and PLA trials. However, an increase in 
work performed in 7 of 18 second half sprints was reported. 
 
In general, studies that have found an increase in exercise performance following SB 
supplementation have been those that have utilised a continuous or intermittent exercise 
protocol that induced a large disturbance in the acid-base balance (McNaughton et al., 
2008). During continuous dynamic exercises, performance enhancements tended to be 
observed in studies whereby the test protocol exhausted the subjects in 1-10 minutes 
(Requena et al., 2005). However, during investigation of the effects of alkaline agents on 
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shorter duration (30-40 seconds) high intensity exercises, conflicting results have been 
reported (Ibanez et al., 1995 and Linderman et al., 1992). 
 
The exact reasons for these conflicting results are unclear but may in part be due to 
inadequate exploitation of the maximum buffering capacity through insufficient duration 
or intensity of exercise, thereby limiting the ergogenic benefits (McNaughton, 1992). In 
addition, there appears to be a highly individual response to SB ingestion, which may be 
partially accounted for by the gastrointestinal side effects associated with SB ingestion. 
Another explanation for the lack of performance enhancement with SB supplementation 
found in some previous studies may be the use of untrained subjects. Elite sprint trained 
athletes tend to produce a greater force capacity leading to a greater systemic acidosis 
when compared with untrained or endurance athletes (Johansen et al., 2003). Therefore 
given the lower intramuscular pH and the high amount of hydrogen ions produced by 
sprinters in competition, it is possible that the effects of SB on trained elite sprinters may 
be more significant than those reported for untrained individuals (Zabala et al., 2008). 
Any potential ergogenic effects that may be produced by pre-exercise metabolic acidosis 
are dependent upon the physiological demands of the activity being sufficient enough to 
result in a performance-inhibiting level of metabolic acidosis (McNaughton et al., 2008).  
 
 
2.9. Sodium Bicarbonate Supplementation Strategies 
 
2.9.1. Timing of Ingestion 
 
There is a large degree of variability across studies in the time elapsed from ingestion to 
the beginning of exercise performance. Although the effects of SB supplementation on 
short-term, high intensity exercise performance have been well-reported, very few studies 
have investigated the optimal loading time prior to exercise. Absorption times in different 
studies vary from 30 minutes (Edge et al., 2006) to 180 minutes (Sutton et al., 1981). The 
majority of the studies involving similar SB ingestion protocols with the first or second 
SB ingestion time at 60 minutes prior to exercise show either decreases or no change in 
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performance times or power output across a range of exercise types including exercise to 
exhaustion and repeated sprint tests (Siegler et al., 2008; Robergs et al., 2005; Matsuura 
et al., 2007; Mero et al., 2004; Aschenbach, et al., 2000). Price et al. (2003) provides an 
exception to this evidence by discovering an increased mean relative power output during 
maximal sprint efforts following ingestion of 0.3g/kg BM of SB at 60 minutes prior to 
exercise. From reviewing the literature, it would appear that SB ingestion commencing 60 
minutes or less prior to exercise may inhibit performance due to gastrointestinal side 
effects arising from such a brief ingestion period.  
 
Various other studies have investigated SB loading at both 120 minutes (Artioli et al., 
2007) and 90 minutes prior to exercise (Bishop et al., 2004) with more positive results 
reported in terms of increased power output and work performed. Analysis of the 
optimum absorption time by Potteiger et al., (1996) found that, for an intake of 0.3g/kg 
BM of SB, 120 minutes was required to reach peak pH and an average of 100-120 
minutes would allow maximum blood bicarbonate concentration to be attained. However, 
Siegler et al. (2012) observed that pre-exercise ingestion time did not influence the 
performance of 10 x 10 second treadmill sprints with 50 second active recovery in 
between each sprint. Subjects ingested 0.3g/kg BM of SB at 60, 120 or 180 minutes prior 
to exercise. No significant differences between the ingestion times were detected in either 
pre-exercise blood buffering capacity or performance across the ten sprints.  
 
2.9.2. Dosage 
 
A study by McNaughton (1992) investigated various doses of SB and their potential 
ergogenic efficacy on anaerobic performance times. Five doses of SB (0.1, 0.2, 0.3, 0.4 
and 0.5g/kg BM), along with a placebo and control, were compared in terms of their 
effect on total work and peak power in an anaerobic 60s cycle ergometer test. In this 
study, although all doses with the exception of 0.1g/kg BM of SB resulted in more work 
completed than the control, the most work was completed in the 0.3g/kg BM of SB trial 
with this dosage also exhibiting the highest level of peak power. Analysis of blood pH 
revealed that a state of alkalosis was achieved after ingestion of all but the 0.1g/kg BM 
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dose. However, in a study by McKenzie et al. (1988), no significant differences in 
performance were found between a sodium bicarbonate dosage of 0.15g/kg BM and 
0.3g/kg BM, suggesting that maximum buffering capacity had been achieved at the lower 
dose and an increased level of alkalosis had no additional benefits. 
 
Based on the current literature it is generally accepted that the optimal SB dosage to 
potentially induce an improvement in performance and also to avoid gastrointestinal 
issues is 0.3g/kg BM (McNaughton, 1992). A SB intake of 0.3g/g BM has generally been 
shown to produce an increase of 4-5mmol/L of bicarbonate concentration and 0.03-0.04 
pH units in venous plasma 2-3 hours after ingestion (Siegler et al., 2012).   
 
2.9.3. Acute versus Chronic Loading 
 
Few studies have examined the effects of chronic SB loading in the days and weeks prior 
to performance, with only three papers currently published outlining the effects of acute 
versus chronic SB supplementation. Douroudos et al., (2006) investigated a five day SB 
loading period with both 0.3 and 0.5g/kgBM/day of SB with no ingestion on the day of 
the 30 second Wingate trial. Significant improvements in relative mean power were 
found for both dosages when compared to the placebo group, with the higher intake of 
0.5g.kgBM/day also shown to be more effective than the moderate intake of 
0.3g/kgBM/day. A study by McNaughton (1999) also observed that 0.5g/kgBM/day of 
SB elicited significantly greater work completed and greater peak power in a 60 second 
cycle ergometer sprint when compared to a control and pre-ingestion group. However, no 
PLA group was involved in this trial. Similarly, a 7-day loading phase of alkalizing 
tablets produced significantly greater upper body power measures in Nordic skiers when 
compared to a placebo group (Heil et al., 2012). 
 
In 2001, McNaughton and Thompson compared the effects of acute and chronic SB 
ingestion. The authors found that chronic ingestion of 0.5g/kg BM of SB over a period of 
six days significantly improved work output for at least two days after cessation of 
ingestion when compared with acute ingestion of 0.5g/kg BM 90 minutes prior to 
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performance of a 90 second maximal cycling test. A study by Edge and colleagues (2006) 
investigated the use of SB supplementation over an eight week training period in which 
subjects supplemented with SB or a placebo prior to each cycle ergometer based interval 
training session. Subjects performed six to twelve 2-minute cycle intervals at 140-170% 
of their lactate threshold three days per week over the course of the eight week period. 
The results of this study reported that both groups demonstrated improvements in muscle 
buffering capacity following the eight week period, suggesting that training intensity may 
be the key component for improvements in muscle buffering capacity. However, the 
group ingesting SB prior to each training session was found to display larger 
improvements in lactate threshold and endurance performance. The authors infer that this 
may be as a result of reduced metabolic acidosis during training and, therefore, the 
development of a greater muscle oxidative capacity. 
 
In contrast to the aforementioned studies regarding chronic SB supplementation, Carr et 
al., (2012) found no improvements in 2000m rowing performance with either acute or 
chronic SB supplementation. Similarly, a study by Joyce et al., (2011) involving elite 
male swimmers observed no improvements in 200m swim performance with either acute 
or chronic SB supplementation with respect to the placebo trial. However, Lindh et al., 
(2008) used an identical acute loading protocol to detect a significant improvement in 
200m swim performance in highly trained males. 
  
Chronic ingestion of SB in the days prior to competition may facilitate improved 
performance while alleviating the potential side affects associated with SB ingestion. The 
use of chronic SB supplementation may also be warranted as part of the training routine 
to augment the training response for endurance performance (Edge et al., 2006). 
Therefore it may be beneficial to examine the potential effects of short or long-term SB 
loading to optimise performance and offset any possible gastro-intestinal issues during 
performance. However the health risks associated with this form of loading require 
further investigation. 
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2.10. Exercise and the recovery process 
 
Recovery is a term referring to the adaptations to physiological stress that occur 
following overload such as training or competition. When recovery is utilized effectively, 
a positive response to exercise is initiated leading to subsequent adaptation to the 
stressors involved (Calder, 1990). Given the volume of competitive games in a rugby 
union season and the need to perform at a consistently high level, recovery plays a key 
role in determining subsequent athletic performance. Athletes aim to push themselves 
harder in training in order to perform to their potential in competition. However, by 
increasing intensity, volume and duration of training without allowing for adequate 
recovery, the risk of excessive fatigue and impaired performance is increased (Hooper 
and Makinnon, 1995). Insufficient recovery will invariably result in maladaptation and 
may lead to detrimental conditions for the athlete, including overreaching, overtraining or 
burnout (Calder, 1990). 
 
Physiological adaptations to exercise come about by progressively overloading the body 
systems, mainly the cardiovascular, respiratory, neuromuscular and the endocrine 
systems. Adaptation to training is accelerated when fatigue associated with the overload 
is minimized and the body is returned to homeostasis as soon as possible. Fatigue can be 
muscular, neural, psychological and metabolic depending on the intensity, duration and 
volume of the training stimulus (Kellman, 2002). This accelerated adaptation to training 
is illustrated in Figure 2.1. When the appropriate recovery for the training stimulus is 
undertaken, both the response to the exercise stress and recovery are accelerated. 
Therefore the body is returned to homeostasis more rapidly and the body can perform to 
maximal capacity in subsequent exercise sessions. 
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Figure 2.1: Accelerated recovery 
 
Stress occurs when demands exceed the body’s capacity to deal with those demands. 
Physiological stress is necessary to stimulate the body’s processes to progress and 
become more efficient. Selye (1936) suggested that under normal conditions, the body 
can utilise its homeostatic mechanisms to dissipate stressors. However, excessive 
amounts of stress without appropriate recovery may lead to symptoms associated with 
overreaching, overtraining and burnout (Murphree, 2004). 
 
Selye (1936) conceptualised the physiological processes that occur when the body is 
exposed to stress with the General Adaptation Syndrome (GAS). A stressor, which can 
range from food deprivation to excessive muscular exercise, if of sufficient intensity and 
duration, can produce various physiological changes as the body attempts to adapt. Selye 
developed the GAS following a study on rats and their responses to noxious agents such 
as excessive muscular exercise. Selye observed symptoms independent of the type of 
stressor applied and rather in response to the damage incurred. The rats developed a triad 
of symptoms resulting from exposure to the stressors including enlargement of the 
adrenal cortex, atrophy of the thymus, spleen and lymph nodes and deep bleeding ulcers 
in the lining of the stomach and duodenum.  
 
The symptoms contributed to an adaptation syndrome, which was observed to progress in 
three main stages. The initial stage, known as the Alarm Stage, occurs when the body has 
first been exposed to the stress, thereby activating the autonomic nervous system and 
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preparing the body for a “fight or flight” response. The hypothalamus stimulates the 
pituitary gland to release adrenocorticotropic hormone (ACTH) into the blood stream. 
This signal prompts the adrenal cortex above the kidneys to produce corticoid hormones. 
These corticoids are then distributed throughout the body and used to defend against a 
stressing agent at various stages. This internal stress-processing mechanism is known as 
the hypothalamus-pituitary-adrenal system. Provided the organism survives this first 
stage, a resistance is built in the second stage of the adaptation syndrome - the stage of 
resistance. However, if the stressor is applied for a continued period of time, the body 
eventually enters the third stage - the stage of exhaustion (Sacco, 2005). The syndrome 
seems to represent a generalized attempt by the organism to adapt itself and so is termed 
the “General Adaptation Syndrome” (Selye, 1946). 
 
Cannon (1932) proposed that organisms are open systems which can be influenced by 
their environment. These organisms require some autonomic adjustments to regulate their 
internal environment to maintain a stable, constant condition or equilibrium. Homeostasis 
refers to the dynamic equilibrium adjustments controlled by interrelated self-regulatory 
mechanisms. These mechanisms may include negative feedback, which attempts to 
reverse any change in the internal environmental, such as core temperature, to maintain 
homeostasis (Sukkar, et al, 1994). 
 
It has been documented that performance enhancement comes about by intentionally 
repeating stimuli to induce recovery-adaptation while avoiding overreaching-overtraining 
(Stone and Stone, 2003). Overtraining can be described as a chronic state of insufficient 
recovery. Overtraining occurs when the volume and intensity of an athlete's training 
exceeds their recovery capacity. Overtraining can result in persistent muscle soreness, 
fatigue, elevated resting heart rate, depression, loss of motivation and appetite, increased 
incidence of infection or injury and/or weight loss. Short term overtraining is described as 
overreaching and is usually exhibited after several days of intense training and results in 
muscular fatigue. According to Shephard (2005), possible mechanisms for overtraining 
may include muscles being subjected to micro-trauma faster than the body can heal itself, 
depletion of amino acids faster than they can be replenished, elevated levels of cortisol 
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(the "stress" hormone) for long periods and dominance throughout the body of catabolism 
over anabolism. 
 
Smith (2000) associates overtraining syndrome (OTS) with excessive training without 
appropriate recovery, which yields a decrement in performance. In a study concerning the 
role of cytokines in OTS, Smith proposes that high volume or intensity training, with 
insufficient recovery, will result in musculoskeletal trauma. Circulating monocytes are 
then activated by injury-related cytokines, which are signalling compounds that 
communicate between cells, to produce proinflammatories (IL-1beta, IL-6, TNF-alpha) 
resulting in systemic inflammation. Elevated circulating cytokines communicate with the 
central nervous system (CNS) and a set of physiological changes ensues. The liver 
adjusts to up-regulate gluconeogenesis, synthesize acute phase proteins and increase 
catabolism. Immune function is also impaired in the body’s response to stress without 
adequate recovery. A review by Dantzer and Kelley (2007) reported that the release of 
proinflammatory cytokines following injury, act in the brain to induce symptoms 
consistent with overtraining syndrome including loss of appetite, fatigue, sleepiness, 
aching joints and withdrawal from social activities. Overtraining syndrome is considered 
as the third stage (stage of exhaustion) of Selye’s general adaptation syndrome and 
therefore, the objective is recovery rather than adaptation. 
 
The evidence presented thus far emphasises the importance of the recovery process in 
physically demanding team field sports, such as rugby union. Recovery time periods 
between matches may vary from days, in 15-a-side rugby, to minutes in rugby sevens. 
However, active recovery periods within games must also be exploited in order to 
optimise performance. Limited research currently exists regarding the potential of SB 
ingestion to impact on the recovery process. This will be discussed in more detail in 
Section 2.12.  
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2.11. Lactate Removal During Recovery 
 
Lactic acid, which dissociates into lactate and H
+
, is a compound converted from pyruvic 
acid, a product of anaerobic glycolysis (the production of energy from glycogen when 
limited oxygen is present). Lactic acid formation occurs at all times, even at rest but it is 
produced in such low levels that it is readily removed from the body (Martini, 2006). 
However, as exercise intensifies, more H
+
 are present (as a result of glycolysis) than can 
be oxidized. To maintain energy metabolism, the H
+ 
must be accepted by a chemical 
other than oxygen, such as pyruvic acid. Pyruvic acid temporarily accepts a pair of 
hydrogens and this reduction of pyruvic acid forms lactic acid (McArdle et al., 2010). 
Lactate is a derivative of lactic acid in salt form, and is a term often used interchangeably 
with lactic acid. Lactic acid, however, can release a H
+ 
 and the remaining compound, 
which is negatively charged, joins with a positively charged ion, such as N
+
 or K
+
, to 
form a salt known as lactate (Kravitz, 2005).  
 
With high intensity, anaerobic exercise, there is a greater flow of excess hydrogen ions to 
pyruvic acid, less oxygen is available, and therefore, lactic acid increases rapidly. Lactic 
acid production proceeds to increase linearly with respect to exercise and eventually, a 
point is reached where clearance of lactic acid is outweighed by the rate of lactic acid 
production. As a result an overall increase in lactic acid and free H+  is observed. This rise 
in H
+ 
exceeds the body’s buffering capability resulting in decreased pH levels and 
therefore, greater acidity in the circulating blood. The accumulation of H
+ 
 stimulates pain 
receptors giving rise to the burning sensation experienced by athletes at maximal 
capacity. During recovery, when more oxygen is present, the excess H
+ 
 used to form 
lactic acid can be oxidized and the pyruvic acid molecule is reformed. Lactate 
dehydrogenase is the enzyme which facilitates this reaction (McArdle et al. 2010). 
According to Baldari et al., (2004), lactate removal was significantly more efficient with 
30 minutes of active recovery than with 30 minutes passive recovery. However, it would 
appear that, while moderate intensity active recovery results in an increased rate of lactate 
removal, high intensity active recovery results in less efficient lactate removal. In a study 
by Belcastro and Bonen (1975), after a 6 minute cycle ergometer test at 89% VO2max it 
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was found that lactate removal rates were faster at self-regulated recoveries than during 
recovery at rest and exercise at 61.8% and 80.8% VO2max. Lactate removal was not 
significantly different for self-regulated recovery and recovery at 29.7 and 45.3% VO2max.  
Additionally, in a study by Kuotedakis and Sharp (1985) concerning lactate removal 
during recovery after strenuous exercise, it was observed that 40% of the maximal rowing 
speed was appropriate for lactate removal. 
 
For short bursts of intense activity, the body relies mainly on anaerobic rather than 
aerobic metabolism. This allows the body to take advantage of the resources that are 
located within the muscle (e.g. adenosine triphosphate (ATP), creatine phosphate and 
muscle glycogen) and also avoids the time lag associated with the delivery of oxygen 
(Bennet and Licht, 1972). The use of the anaerobic system for longer durations of 
exercise appears to be limited by the accumulation by-products such as H
+
. Lactic acid 
accumulation has often been implicated in muscle fatigue (Fletcher and Hopkins, 1907). 
According to Putnam (1979), fatigue produces a marked increase in lactic acid 
production. However, the mechanism by which lactic acid could be responsible for 
fatigue is unknown and highly disputed.  
 
The accumulation of H
+ 
results in a decreased pH below the normal 7.4 and leads to 
metabolic acidosis. According to Martin et al. (1998), metabolic acidosis has been shown 
to have a major role in inducing muscular fatigue during short, high intensity exercise. 
Several potential mechanisms have been proposed to explain the link between metabolic 
acidosis and the predisposition to muscular fatigue. These mechanisms may include 
decreases in pH associated with lactic acid accumulation, causing inhibition of the 
enzymes lactate dehydrogenase and phosphofructokinase, thereby decelerating 
glycolysis; Ca
2+
 can be prevented from binding to troponin; and H
+
 can stimulate pain 
receptors (Martin et al., 1998). Despite the reputation of lactate as a limiting factor in 
exercise, more recent research however (Pederson et al., 2004; (Brooks, 2007, Brooks, 
2010, Gladden, 2008), has purported that lactate actually has protective effects during 
muscle fatigue providing improved conditions for muscular contractions. 
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2.12. Sodium Bicarbonate and Recovery 
 
Few studies have examined the effect of SB supplementation specifically on recovery 
from high intensity exercise and subsequent high intensity performance. Bishop et al. 
(2004) observed performance enhancement in repeated bouts of 5 x 6 second sprint 
cycling, separated by a 24 second recovery period, following induced alkalosis through 
SB supplementation. Similarly, exogenous ingestion of SB prior to 10 x 10 seconds of 
maximal cycling with 50 seconds recovery between each bout was found to elicit 
significantly greater peak power and total work (Lavender and Bird, 1989). Verbitsky et 
al. (1997) also reported positive results with SB supplementation in terms of recovery. 
The increased capacity of the quadriceps femoris muscle to generate torque with SB 
supplementation following high intensity cycle ergometer performance demonstrated a 
reduction in muscle fatigue and enhanced recovery. Siegler et al. (2010) found that a 
combination of SB supplementation and active recovery improved performance in 
repeated 30s bouts of maximal exercise separated by 3 minutes when compared with a 
combination of PLA and passive recovery; PLA and active recovery; and SB and passive 
recovery. This study appears to be unique in that the researchers examined the effects of 
the combination of SB supplementation with different recovery modalities (passive and 
active recovery) on recovery from exercise and subsequent performance. 
 
In contrast to these findings, Aschenbach et al., (2000) found no improvement with SB 
supplementation in performance of eight maximal 15 second upper body sprints with a 20 
second recovery period between sprints. Zabana et al. (2011) reported that, although SB 
ingestion had resulted in significant alterations in acid-base balance, no improvements 
were found in the performance of three consecutive Wingate tests separated by 15 
minutes recovery. Similarly, SB supplementation prior to high-intensity intermittent 
running was shown to induce metabolic alkalosis but did not impact on performance or 
subsequent performance (Price and Simons, 2010).  
 
This finding of induced metabolic alkalosis is indicative of the majority of the research 
regarding SB supplementation. However, as is demonstrated by the aforementioned 
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studies, this does not always translate into an improved performance, recovery or 
subsequent performance. Robergs et al., (2005) provides a rationale for the potential 
benefit of pre-exercise SB supplementation concerning recovery and subsequent 
performance. This study examined the kinetics of acid-base recovery over a 60 minute 
recovery period in response to pre-exercise alkalosis and acidosis in high intensity 
cycling performance. It was noted that recovery of pH to baseline levels may take over 45 
minutes. In addition, recovery of blood lactate concentrations may take longer than 60 
minutes. Although performance was not influenced by SB supplementation, the elevated 
HCO3
-
 observed both prior to exercise and in the recovery period, demonstrated that 
induced alkalosis attenuated metabolic acidosis and enhanced pH recovery when 
compared with acidotic and PLA conditions (Robergs et al., 2005). Further research is 
necessary to determine the effect of different rates of pH and lactate recovery on 
subsequent exercise and the role that SB ingestion may play in this process through a pre-
exercise elevation of pH. 
 
 
2.13. Beta-Alanine 
 
Beta-alanine is a non-proteinogenic amino acid, which is also a rate-limiting pre-cursor to 
carnosine. Carnosine is an important intramuscular buffer, constituting 10-20% of the 
total buffering capacity in type I and type II fibres. The resultant enhanced buffering 
capacity associated with increased muscle carnosine has been linked to significant 
improvements in high intensity exercise performance capacity (Sale et al., 2010). In 
addition, according to Suzuki et al. (2004), an eight week high intensity sprint training 
programme has been shown to almost double the carnosine content in vastus lateralis. 
Suzuki et al. (2002) also found a significant relationship between carnosine concentration 
in human skeletal muscle and high intensity exercise performance in the form of a 30 
second Wingate test. In further support of the this relationship between carnosine 
concentration and high intensity exercise performance, a trend towards higher carnosine 
concentrations has been reported in athletes such as sprinters (Parkhouse et al., 1985) and 
bodybuilders (Tallon et al., 2005). 
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Ingestion of beta-alanine has been shown to increase muscle carnosine, decrease fatigue 
and increase total muscular work done (Derave et al., 2007; Artioli et al., 2010). With the 
exception of carnosine, the concentrations of the other physiochemical buffers are 
constrained by their involvement in the other reactions. After a 10 week strategy, Hill et 
al., (2007) reported a muscle carnosine increase of 58% and 80% after 4 and 10 weeks of 
beta-alanine supplementation respectively. This resulted in an increase of 13% in total 
work completed. Harris et al., (2006) have also demonstrated that carnosine in skeletal 
muscle may be increased by up to 60% with 2-4 weeks ingestion of beta-alanine. 
 
Administration of large doses of beta-alanine, however, has demonstrated taurine 
depletion (Dawson et al., 2002 and Tallon et al., 2005). Beta-alanine ingested in a 
solution or in gelatine capsules can cause paraesthesia in doses above 10mg/kg body 
weight (Harris et al., 2006). Harris et al. (2006) investigated various different doses of 
beta-alanine supplementation and found that 10mg/kg body mass,, which corresponded to 
a mean  beta-alanine level of 800mg,  was the maximum tolerated single dose capable of  
minimising side affects but still eliciting a response in serum-beta-alanine concentration. 
Return to baseline values occurred three hours after capsule ingestion. As a result, it is 
possible to increase the daily dose without experiencing side affects provided a minimum 
period of 3 hours is maintained between single doses. 
 
Recent research has demonstrated that 6.4 g/day of beta-alanine can significantly increase 
skeletal muscle concentrations (Kendrick et al., 2008). Sale et al. (2012) reported that 
beta-alanine supplementation resulted in an increase of approximately 9 seconds 
endurance time in an isometric contraction at 45% of maximum voluntary contraction 
force until fatigue. The intensity of 45% maximum voluntary contraction corresponds to 
the work level resulting in the greatest increase in lactate and pyruvate concentration in 
the muscle (Ahlborg et al., 1972), and therefore, potentially also the greatest decline in 
intramuscular pH.  
 
A more recent study by Bellinger et al., (2012) examined the effects of a combination of 
beta-alanine and SB on 4 minute cycling time trial performance. In contrast to the above 
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findings, the trained cyclists exhibited no significant enhancements in performance with 
the combination of beta-alanine and SB. No significant improvements in performance 
were detected with beta-alanine supplementation alone. However, acute SB 
supplementation alone displayed significantly improved four-minute cycling time trial 
performance. In a similar study, Sale et al., (2011) also combined beta-alanine with SB 
prior to performance of high intensity cycling. A dosage of 6.4g/kg/day beta-alanine was 
shown to improve performance in a cycle to exhaustion at 110% power maximum. 
However, despite a 4% increase in total time to exhaustion with the added 
supplementation of SB, no significant enhancements in performance were observed. 
Although the effects of beta-alanine on performance appears to be generally positive, 
further research is necessary to examine different exercise intensities and durations, 
recovery and subsequent exercise performance. 
 
 
2.14 Summary 
 
Based on a review of the existing literature regarding the ergogenic potential of SB, 
several observations can be made. Firstly, the response to ingestion of SB can have a high 
degree of individual variability. This variability may be accredited to the individual’s 
physical conditioning and tolerance of the particular buffer. McNaughton et al. (2008) 
suggest that approximately 10% of individuals do not tolerate buffering substances well.  
Another common trend that is observed in studies utilising buffers is that following 
ingestion, subjects display higher levels of pH, bicarbonate (HCO3
-
) and lactate in 
exercising blood than subjects that have ingested a placebo. However, this does not 
necessarily translate into an enhanced performance.  
 
Future research may investigate the efficacy of SB in the following areas: short and long 
term chronic loading of SB; comparison and possible effects of the combination of SB 
with additional supplements such as beta-alanine, sodium citrate and caffeine; varying 
doses and ingestion times relevant to different types, intensities and durations of exercise; 
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improvement of performances of team field sport athletes; and the potential of SB to act 
as a recovery modality. 
 
Several studies have examined the effect of SB on recovery of the blood to normal levels 
following exercise or performance (Pruscino et al., 2008). However, there is limited 
definitive scientific research investigating the effect of SB on recovery from exercise and 
its effect on subsequent performance. In addition, the findings of many studies relating to 
exercise performance are conflicting and contradictory (Peart et al., 2012; Carr et al., 
2011). This may be attributed to the high degree of individual variability associated with 
SB ingestion (Siegler et al., 2010).  This research aims to investigate the efficacy of SB 
ingestion to induce alkalosis and its potential effects on high-intensity intermittent 
exercise, recovery from exercise and subsequent performance. This aim will be achieved 
through the implementation of three related studies. These studies will be outlined in 
detail in the following three chapters. 
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Chapter 3 
 
Study One: The Effects of Acute versus Chronic 
Sodium Bicarbonate Supplementation on High-
Intensity Intermittent Performance  
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3.1. Introduction 
 
The aim of this study was to examine the effects of both acute and chronic SB 
supplementation versus PLA on high-intensity intermittent sprint performance in sub-
elite male rugby players. The hypothesis tested stated that acute and chronic SB 
supplementation would induce sufficient elevations in StdHCO3
-
, pH and BE-Ecf to delay 
fatigue and result in enhanced performance of high intensity intermittent sprints on a 
cycle ergometer when compared to a PLA trial. Given the limited research currently 
available regarding both chronic SB supplementation and also the effect of SB 
supplementation of repeated bouts of high intensity exercise, the following chapter will 
discuss the methodology and results associated with the controlled laboratory-based test 
protocol employed. 
 
 
3.2. Methods 
 
3.2.1. Subjects 
 
Ten healthy active males, aged between 18-35 years were recruited through 
correspondence with rugby clubs throughout Leinster to participate in the study. Subjects 
consisted of trained club rugby players currently playing at a Junior 2 level or above and 
with no less than 5 years playing experience. Subjects were instructed to maintain their 
normal dietary intake, avoid strenuous exercise and abstain from alcohol in the 48 hours 
immediately prior to all trials.  Prior to participation in the study, each subject provided 
written informed consent (Informed Consent Form, Appendix A1) and completed medical 
screening forms (General Health Questionnaire, Appendix B). Subjects were excluded 
from the study if they exhibited any contra-indicators to high intensity exercise or if they 
used supplements or drugs that may have interfered with the results. The study was 
approved by the Dublin City University’s (DCU) Research Ethics Committee. 
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3.2.2. Anthropometric Measurements 
 
Baseline anthropometric measurements were recorded prior to commencement of any 
physiological testing. Body mass (kg) was assessed barefoot and in minimal clothing 
using a portable digital scales and stadiometer (Seca, Germany). Data was reported to the 
nearest 0.1 kg. Standing height (cm) was measured to the nearest 0.1 cm using the same 
device. Body mass index (kg/m
2
) was calculated by dividing each individual’s body mass 
(kg) by the square of their height (cm).  
 
 
3.2.3. Overview of Experimental Design 
 
The study took place in the Human Performance Laboratories (HPL) in Dublin City 
University (DCU). 10 competitive rugby players were recruited to take part in this study. 
Each subject was required to report for a habituation trial. Following this, each subject 
completed four trials on separate days, with no less than seven days between PLA and SB 
trials to allow a sufficient wash-out period following supplementation. The four 
supplemented trials were carried out using a double-blind, randomised cross-over design: 
1. Acute placebo trial 
2. Chronic placebo trial 
3. Acute sodium bicarbonate trial 
4. Chronic sodium bicarbonate trial 
 
The habituation trial enabled subjects to become familiar with the performance test (see 
Section 3.2.5 below) and control for any potential learning effects within the 
supplemented trials. Within this habituation, subjects were given a verbal explanation of 
the test prior to three sub-maximal practice efforts. Subjects were then instructed to 
complete the full repeat-sprint performance test at maximum effort. Subjects were 
deemed to be habituated to the protocol as no further increments in performance were 
observed in the latter sprints of the performance test. During the habituation visit, 
subjects were provided with precise, verbal and written instructions on the appropriate 
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procedure for supplementation over the 5 day period as well as being given the 
opportunity to ask questions.  
 
Subjects were also provided with five daily individualised measures of either sodium 
bicarbonate (SB) or placebo (PLA) based on body mass. Each daily dose of either 
0.3g/kg SB or 0.02g/kg PLA (maltodextrin) was contained in identical gelatine capsules 
(matched for capsule number), which ensured the subjects remained blinded and, 
therefore, unbiased. Subjects were advised to remain hydrated and to adhere to their 
normal diet throughout the 5 days of chronic supplementation. In addition, participants 
were instructed to replicate the same diet and hydration pattern for the 48 hour period 
before each trial. This included a 3 hour fasting period prior to each performance trial. 
Alcohol, caffeine and strenuous exercise were not permitted in the 48 hours prior to the 
performance test. 
 
 
3.2.4. Supplementation Protocol 
 
Subjects were required to fast for 3 hours prior to each performance test for both acute 
and chronic protocols.  
 
i) Acute Supplementation 
Acute supplementation consisted of ingesting either SB (0.3g/kg BM) or PLA split 
into three equal doses taken at 90, 60 and 30 minutes prior to the performance test. 
Each dose of 0.1g/kg BM of SB (0.3g/kg BM in total) or PLA was consumed with 
200mls water taken with each of the three doses every 30 minutes prior to the 
performance test.  
 
ii) Chronic Supplementation  
Chronic supplementation involved a five day loading period with SB or PLA. 
Following acute supplementation on Day 1, each subsequent day of the chronic 
loading period involved supplementation with 0.3g/kg BM split into three doses taken 
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at 9am, 12pm and 3pm each day. On Day 6, subjects ingested no supplement and 
carried out the performance test (see Figure 3.1). Previous studies have shown that 
the 5 day loading period followed by no supplementation on the day of the 
performance test may induce pre-exercise alkalosis sufficiently while also allowing 
time for any gastrointestinal discomfort that may affect performance to be alleviated 
(McNaughton et al., 1999).  
 
 
 
Figure 3.1: Schematic of acute and chronic supplementation protocols 
 
 
3.2.5. Performance Test 
 
The performance test selected for this study was a high-intensity, intermittent, controlled 
laboratory-based sprint test on a ‘Monark 824E’ cycle ergometer (Monark Exercise, 
Varberg, Sweden). The cycle ergometer (see Illustration 3.1) recorded various forms of 
power output and was automatically calibrated by the patented self-regulating braking 
system. Absolute peak power output (PPO) and mean power output (MPO) were 
recorded for all sprints. PPO and MPO were also expressed relative to body mass 
(relative PPO and relative MPO). Total work was calculated as a product of the sum of 
the MPO for each sprint and the duration of the sprint (10s). Fatigue index was also 
calculated for each sprint as the PPO minus the minimum power output, expressed as a 
percentage of the PPO (Price et al., 2003). 
 
Day 1 Day 2 Day 3 Day 4 Day 5 
Acute Trial Chronic Trial 
Day 6 
Day 1: 
Supplement with 
PLA or 0.3g/kg 
SB split in three 
doses taken at 
90, 60 and 
30mins before  
acute trial. 
Day 2:  
Supplement with 
PLA or 0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm. 
Day 3:  
Supplement with 
PLA or 0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm. 
Day 4:  
Supplement with 
PLA or 0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm. 
Day 5:  
Supplement with 
PLA or 0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm. 
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Illustration 3.1: Monark 824E Cycle Ergometer 
 
Prior to each performance test, subjects performed a standardised pre-test warm-up, 
cycling for 5 minutes producing a power output of 120W against a resistance of 2 kg for 
each subject. Following the warm-up, subjects were required to perform 6 x 10 second 
maximal sprints (Wingate tests) at a resistance set at 7.5% BM for each subject. Each 
sprint was followed by a 50 second active recovery period in which subjects cycled 
against the resistance of the flywheel only at a cadence of 50 revolutions per minute 
(rpm) for the initial 45 seconds of the 50 second recovery period. A 5 second countdown 
was then provided before each sprint in which the subjects were required to maintain a 
cadence of 90 rpm. Following the 5 second countdown, the cradle loaded with 7.5% BM 
for each individual subject was dropped and the 10 second sprint commenced (see Table 
3.1). 
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Table 3.1: Wingate Protocol 
Stage Duration (s) Resistance and Cadence 
Countdown to sprint 5 Flywheel resistance only, 
cadence of 90rpm. 
Sprint 10 7.5% BM resistance, 
maximal cadence. 
Recovery period 45 Flywheel resistance only, 
cadence of 50rpm. 
 
To avoid any pacing, subjects were instructed to exert themselves maximally during the 
test prior to each trial and reminded between sprints. Strong verbal encouragement was 
provided to each subject during all sprints. Optimal seat height, determined by a knee 
angle of between 25 and 35 degrees at the bottom of the pedal stroke, was adjusted for 
each subject during the habituation trial. The same seat height was used in all subsequent 
trials. Subjects were instructed to remain in the seated position throughout the entire test. 
Adjustable toe clips were used to tightly secure the subjects’ feet. 
 
 
3.2.6. Blood Lactate Analysis 
 
Earlobe blood samples for blood lactate analysis were taken from the ear prior to 
ingestion (baseline), immediately before the warm up after all supplementation (pre-test) 
and in the 50-second recovery period immediately after the first, third and sixth sprints of 
the intermittent sprint test. Blood lactate measurements were obtained by drawing 1ml of 
blood from the earlobe. To ensure an accurate reading was recorded, the sample site 
(earlobe) was cleaned with an alcohol wipe prior to blood being drawn. The skin was 
then dried to avoid haemolysis and the earlobe was pricked with a lancing device. Gentle 
pressure was applied to the earlobe to obtain a blood sample. This first sample of blood 
was wiped away with gauze to make certain that perspiration did not contaminate the 
blood sample for lactate analysis. Pressure was applied to the earlobe once more to obtain 
a second sample of blood. At this point, a lactate test strip was inserted (without the 
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reaction area being touched) into the blood lactate analyser (Lactate Pro
TM
, Quesnel, 
Canada). The blood from the earlobe was then touched with the tip of the lactate test strip 
and the blood lactate analyser produced a lactate reading within 60 seconds (see 
Illustration 3.2). The blood lactate analyser was calibrated with the calibration strip prior 
to each testing session and all lancing devices and lactate strips were disposed of safely 
upon completion of the lactate analysis. 
 
 
Illustration 3.2: Lactate Pro Blood Lactate Analyser 
 
Each lactate test strip contains two reagents in the reaction layer – lactate oxidase (1.92 
units) and potassium ferricyanide (0.096 mg). When the blood touched to the tip of the 
lactate test strip reaches the reaction layer of the strip, lactate in the blood sample reacts 
with lactate oxidase (LOD). Simultaneously, potassium ferricyanide (oxidised form) 
located in the reaction layer, produces potassium ferrocyanide (reduced form). Potassium 
ferrocyanide is produced relative to the concentration of lactate in the blood sample. The 
build up of potassium ferrocyanide is then oxidised back to potassium ferricyanide and 
with this reaction an electrical current is produced and converted into the lactate 
concentration of the blood sample and displayed on the lactate analyser screen. The blood 
lactate analyser (Lactate Pro
TM
, Quesnel, Canada) performs with a measuring range of 
0.8 - 23.3 mmol/L. In terms of precision, the coefficients of variation for blood samples 
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containing normal and abnormal levels of lactate are 3.2% (± 0.07 mmol/L) and 2.6% (± 
0.3 mmol/L), respectively, according to the Lactate Pro
TM
 manufacturer specifications.  
 
 
3.2.7. Blood Gas Analysis 
 
Blood gas analysis was used to measure arterialised capillary blood pH, standard 
bicarbonate (StdHCO3
-
), base excess (BE-Ecf), partial pressure of carbon dioxide in 
blood (PCO2) and partial pressure of oxygen in blood (PO2). Blood gas analysis, using a 
capillary earlobe sample, was carried out at identical time points to blood lactate analysis 
– baseline (prior to ingestion), pre-test, and immediately after Sprint 1, 3 and 6. Prior to 
baseline and pre-test samples, a topical vasodilator cream was applied to the earlobe for a 
period of 5 minutes in order to arterialise the capillary sample. Prior to puncturing the 
skin, this vasodilator cream was removed with gauze and the sample site was cleaned 
with alcohol to avoid contamination of the sample. At all other blood sampling time 
points, given the necessity to obtain an immediate sample, manual massage of the earlobe 
was used to ensure maximum vasodilation.  
 
Using a similar sampling technique as outlined for blood lactate analysis in Section 3.2.6, 
the earlobe was cleaned with alcohol, dried and then pierced with a sterile, disposable 
lancet. The first drop of blood was removed and then 100µL capillary tubes were used to 
collect 90 µL capillary blood samples for blood gas analysis. The capillary tubes were 
held horizontally to the earlobe and collected the blood sample by capillary action. The 
blood samples were analysed immediately to avoid aeration of the sample using the 
‘ABL77 Blood Gas Analyser’ (Radiometer Medical, Denmark). Upon collection of the 
capillary sample, a capillary sample adapter was attached to the inlet probe on the blood 
gas analyser (see Illustration 3.3). The capillary tube containing the blood sample was 
then inserted into the sample adapter and the capillary blood sample was aspirated into 
the blood gas analyser for analysis. The blood gas analyser had an integrated calibration 
system, which was activated before and after every use. The portable blood gas analyser, 
which had been validated against a number of clinical laboratory analysers (Prichard et 
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al., 2006; Stevenson et al., 2004), was also routinely assessed by external quality 
controls. 
 
 
Illustration 3.3: ABL77 Blood Gas Analyser 
 
 
3.2.8. Heart Rate 
 
Heart rate was measured throughout each test and recorded at similar intervals to the 
blood samples - baseline, pre-warm up and immediately after Sprint 1, 3 and 6. Heart rate 
was recorded using a wireless Polar heart rate monitor (Polar Vantage NV™ Polar, Port 
Washington, NY).  
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3.2.9. Subjective Ratings 
 
3.2.9.1 Muscle Soreness 
 
A level on the muscle soreness scale (Appendix C) was selected by each subject at 
identical time points to the blood sampling (baseline, pre-warm up and following Sprint 
1, 3 and 6). The muscle soreness scale was a simple 11 point scale ranging from 0-10, 
which was used to allow subjects to rate their muscle soreness levels at different points 
before and after each aspect of the testing. The muscle soreness scale is adapted from the 
differential descriptor scale (DDS) from Gracely et al., (1978), which involved a soreness 
rating based on both sensory and affective descriptors. 
 
3.2.9.2 Rating of Gastro-Intestinal (GI) Discomfort 
 
Subjects rated GI discomfort on a scale of 0-5 at baseline, pre-warm up and immediately 
following Sprint 1, 3 and 6. 
 
 
3.2.10. Statistical Analysis 
 
SPSS for Windows v.16.0 (SPSS, USA) was used to conduct the statistical analysis. 
Normality of data distribution was tested using the Shapiro Wilks test. As the same 
subjects were used for each of the four treatments, an analysis of variance (ANOVA) 
with repeated measures was carried out. ANOVA with repeated measures was used to 
determine any statistical significance between supplementation groups at each time point. 
Mauchly’s Test of Sphericity was used to validate the ANOVA. If Mauchly’s test was 
significant, the Greenhouse-Geisser correction was utilised. An ANOVA establishes the 
levels of significance between the groups at different intervals. A probability of 0.05 was 
used to ascertain significance. After obtaining a significant ANOVA result, post hoc 
Bonferroni testing was used to determine which means were different from each other 
and the location of any significant findings.  
 62 
3.3 Results 
 
3.3.1. Subject Characteristics 
The descriptive and anthropometric data for the ten subjects are presented in Table 3.2. 
 
Table 3.2: Descriptive and Anthropometric Data 
Variable (n=10) Mean (± SD) 
Body mass (kg) 86.1 ± 9.7 
Height (cm) 183.8 ± 5.9  
Body mass index (kg/m2) 25.5 ± 2.6  
Age (yrs) 28 ± 5  
 
 
3.3.2. Standard Bicarbonate (StdHCO3
-
)  
 
As illustrated in Figure 3.2, StdHCO3
-
 levels StdHCO3
-
 were significantly greater with 
acute SB supplementation for all time points post-ingestion when compared to all other 
supplementation protocols (p=0.0005). The acute SB supplementation protocol elicited a 
mean peak concentration of 30.8 ± 1.1 mmol/L following the ingestion protocol 
compared to 24.5 ± 1.2 mmol/L for the acute PLA supplementation protocol. Chronic SB 
supplementation also showed significantly greater StdHCO3
-
 following Sprint 1 when 
compared to the acute PLA supplementation protocol (p=0.016). 
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Figure 3.2: Standard bicarbonate (StdHCO3
-
) levels across time points for each 
supplementation protocol (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
3.3.3. Blood pH 
 
Following ingestion, blood pH was found to be significantly higher at all time points for 
acute SB supplementation when compared to all other supplementation protocols 
(p<0.05). Peak mean pH was recorded immediately prior to the performance test, with 
acute SB ingestion registering a significantly elevated pH of 7.45 ± 0.02 in comparison to 
chronic SB (7.39 ± 0.02; p=0.0005), acute PLA (7.39 ± 0.03; p=0.001) and chronic PLA 
(7.40 ± 0.02; p=0.0005) supplementation protocols. Chronic SB supplementation was not 
found to exhibit a significantly higher pH at any time point (see Figure 3.3) when 
evaluated against the other three supplementation protocols (p>0.450). 
 
** 
** 
** 
** 
 * 
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Figure 3.3: pH levels across the time points for each supplementation protocol 
(n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
3.3.4. Base Excess in Extracellular Fluid (BE-Ecf)  
 
As is evident in Figure 3.4, no significant differences were detected between the four 
supplementation protocols for baseline levels of BE-Ecf (p=1.000). Following 
supplementation and immediately prior to the repeat sprint cycle test, acute SB 
supplementation demonstrated a significantly higher BE-Ecf (7.93 ± 1.54 mmol/L) when 
compared with chronic SB (2.16 ± 1.53 mmol/L; p=0.0005), acute PLA (0.50 ± 1.56 
mmol/L; p=0.0005) and chronic PLA (1.66 ± 1.61 mmol/L; p=0.0005) supplementation 
protocols. Acute SB supplementation also elicited a significantly higher BE-Ecf response 
following Sprint 1 (4.23 ± 1.96 mmol/L) relative to acute PLA ingestion (-2.23 ± 0.77 
mmol/L; p=0.008) and also chronic PLA ingestion (-1.50 ± 2.13 mmol/L; p=0.021). 
* 
 * 
 * 
* 
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Although the relationship was not found to be significant, chronic SB supplementation 
did exhibit a trend towards inducing a higher BE-Ecf when compared with acute PLA 
supplementation (p=0.083). Following Sprint 3 (the halfway point of the repeat sprint 
cycle test), and also Sprint 6 (the final sprint), acute SB supplementation displayed 
significantly higher BE-Ecf values than all other supplementation protocols (p<0.001). 
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Figure 3.4: BE-Ecf across time points for each supplementation protocol (n=10, 
values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
3.3.5. Blood Lactate Analysis 
 
Baseline lactate levels were identified as lying within the normal ranges prior to 
supplementation for all subjects (0.8-1.8 mmol/L) with no significant differences between 
the groups (p = 1.000). Following acute SB supplementation, blood lactate concentrations 
** ** 
** 
** 
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(see Figure 3.5) were found to be significantly greater than the other supplementation 
protocols after the final sprint only. Following the sixth and final sprint, acute SB 
ingestion resulted in a mean blood lactate concentration of 13.71 ± 1.92 mmol/L, which 
was significantly greater than acute PLA (11.76 ± 1.53 mmol/L; p=0.008), chronic PLA 
(11.56 ± 2.1 mmol/L; p=0.029) and chronic SB ingestion (11.76 ± 2.07 mmol/L; 
p=0.016) supplementation protocols. 
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Figure 3.5: Comparison of lactate concentrations for each supplementation protocol 
(n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
3.3.6. Partial Pressure of Carbon Dioxide (PCO2) 
 
As illustrated in Figure 3.6, significant differences between supplementation protocols 
were found for mean PCO2 at two separate time points. Following Sprint 3, acute SB 
ingestion produced a significantly higher PCO2 when compared to acute PLA (6.04 ± 
** 
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0.53 vs. 5.56 ± 0.58 kPa respectively; p=0.044). In addition at this time point (Sprint 3), 
although not reaching statistical significance, a trend towards significance was identified 
between acute SB and chronic PLA ingestion (p=0.087). Following Sprint 6, however, 
the difference between acute SB and chronic PLA ingestion was found to be significant 
with acute SB supplementation exhibiting an elevated PCO2 (5.44 ± 0.54 vs. 5.01 ± 0.71 
kPa; p=0.014). 
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Figure 3.6: PCO2 (kPa) across time points for each supplementation protocol (n=10, 
values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
3.3.7. Partial Pressure of Oxygen (PO2) 
 
No significant differences between supplementation protocols were observed at any time 
point for PO2 (see Figure 3.7). Baseline PO2 values were identified as 11.03 ± 0.69, 
 * 
* 
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11.22 ± 0.91, 11.63 ± 0.70 and 11.80 ± 1.08 kPa for acute SB, chronic SB, acute PLA 
and chronic PLA supplementation, respectively (p>0.114). Post-test PO2 values were 
recorded as 12.25 ± 0.80, 12.55 ± 1.31, 13.14 ± 0.87 and 12.70 ± 6.1 kPa for acute SB, 
chronic SB, acute PLA and chronic PLA supplementation, respectively (p>0.100).  
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Figure 3.7: PO2 (kPa) across time points for each supplementation protocol (n=10, 
values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
3.3.8. Overview of Performance Outcome 
 
Despite the significantly elevated pH, StdHCO3
-
, blood lactate, BE-Ecf and PCO2 levels 
observed at certain time points with SB supplementation, no significant differences in 
performance were demonstrated between subjects across the four conditions.  
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3.3.9. Peak Power Output (PPO) 
 
Following analysis of absolute mean peak power output (PPO) for all subjects across all 
six sprints, no significant differences (see Figure 3.8) were found among the four 
supplementation protocols (p=1.000). The highest mean PPO within each 
supplementation protocol was recorded during Sprint 1, resulting in a PPO of 1028.3 ± 
161.4 W, 1027.5 ± 219.4 W, 1032.0 ± 201.8 W and 1016.9 ± 208.3 W for acute SB, 
chronic SB, acute PLA and chronic PLA respectively (p=1.000). A similar relationship 
was identified for relative PPO, which also exhibited no significant differences between 
supplementation protocols at any time point (p=1.000). Absolute and relative PPO across 
each of the six sprint trials for all supplementation conditions was also analysed. No 
significant differences were found between the supplementation protocols for any of the 
sprints from Sprint 1 through to Sprint 6 (p>0.05). 
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Figure 3.8: Absolute peak power output across all six sprints for each 
supplementation protocol (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
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3.3.10. Mean Power Output (MPO) 
 
Mean power output (MPO) was analysed for each sprint using each of the experimental 
supplementation protocols with no significant differences observed between protocols in 
any of the sprints (see Figure 3.9). The greatest MPO for each supplementation protocol 
was observed during Sprint 1, at which point MPO values of 886.8 ± 135.3 W, 894.4 ± 
159.2 W, 891.4 ± 160.4 W and 882.5 ± 162.5 W were recorded for acute SB, chronic SB, 
acute PLA and chronic PLA respectively (p=1.000). Similarly, relative MPO exhibited no 
significant differences between supplementation protocols (p>0.05). Mean power outputs 
for each individual sprint from Sprint 1 through to Sprint 6 were also investigated. 
Similar to PPO, no significant differences were detected between the supplementation 
protocols (p>0.05).  
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Figure 3.9: Absolute mean power output across all six sprints for each 
supplementation protocol (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
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3.3.11. Total Work 
 
No significant differences in total work performed over the six sprints were identified 
between supplementation protocols (p=1.000). Total work was calculated as 47.2 ± 6.4 
kJ, 48.2 ± 6.7 kJ, 47.6 ± 7.5 and 47.7 ± 8.7 kJ for acute SB, chronic SB, acute PLA and 
chronic PLA ingestion protocols, respectively. 
 
 
3.3.12. Fatigue Index 
 
No significant differences between supplementation protocols were found for fatigue 
index over the six sprints (p=1.000). Fatigue index was calculated as 27.2 ± 6.5 %, 27.9 ± 
6.5 %, 27.4 ± 6.7 % and 27.5 ± 5.4% for acute SB, chronic SB, acute PLA and chronic 
PLA, respectively. 
 
 
3.3.13. Individual Subject Performance Data Analysis 
 
3.3.13.1. Individual PPO 
 
Individual PPO with each supplementation protocol were also analysed across the six 
sprints in each trial. Figure 3.10 represents the absolute PPO (W) for each subject for 
each supplementation trial. In terms of individual peak power, 20% of the subject group 
(n=2) experienced an improvement in performance with either acute or chronic SB 
supplementation; 70% of subjects (n=7) exhibited no change in PPO across the four 
trials; with the remaining 10% of the cohort (n=1) demonstrating a negative performance 
effect with acute SB supplementation. Three individual case studies displaying 
differences between the trials are presented below. 
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Figure 3.10: Absolute peak power output (W) for each subject using each 
supplementation protocol (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
Across the mean of the six sprints, Subject 8 in Figure 3.10 was found to exhibit greater 
absolute PPO in the acute SB supplementation trial (1016.5 ± 25.3W) than in the chronic 
SB supplementation trial (953.9 ± 21.2W). The superior absolute PPO associated with the 
acute SB supplementation trial also transferred to a significantly greater relative PPO 
(11.05 ± 0.27 W/kg vs. 10.26 ± 0.23 W/kg, respectively) for this subject when compared 
with chronic ingestion of SB. Although absolute and relative PPO were lower with 
chronic SB supplementation, Subject 8 also experienced a lower power drop in this 
chronic SB trial when compared to both the acute PLA and chronic PLA trials (141.7 ± 
34.8 W vs. 283.8 ± 37.1 W and 233.8 ± 27.4 W, respectively). 
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Subject 3, illustrated in Figure 3.10, demonstrated differences between trials for both 
absolute and relative PPO. Acute supplementation with SB generated a greater absolute 
and relative PPO (783.5 ± 22.5 W and 11.52 ± 0.33 W/kg) when compared with both the 
acute PLA (677 ± 32.1 W and 9.96 ± 0.47 W/kg) and chronic PLA (620 ± 21.5 W and 
9.12 ± 0.32 W/kg) trials. Subject 3 also displayed greater absolute and relative PPO with 
chronic SB supplementation (760.9 ± 30.7 W and 11.19 ± 0.45 W/kg) in relation to the 
chronic PLA trial only (620 ± 21.5 W and 9.12 ± 0.32 W/kg) over the six sprints. A 
difference in power drop for this subject was also observed, with the acute and chronic 
PLA trials exhibiting lower power drop values (140.8 ± 29.7 W and 154.2 ± 33.7 W, 
respectively) than the acute and chronic SB supplementation protocols (230.1 ± 21.5 W 
and 236.8 ± 32.7 W, respectively).  
 
In contrast to Subject 8 and Subject 3, Subject 7 generated a lower mean PPO with acute 
SB ingestion when compared to acute PLA supplementation (1115.5 ± 156.9 W vs. 
1169.3 ± 136.4 W, respectively).  
 
 
3.3.13.2. Individual MPO 
 
In terms of individual MPO (see Figure 3.11), 10% of subjects (n=1) experienced a 
performance enhancement with both acute and chronic SB supplementation when 
compared with the PLA trials; 50% of subjects (n=5) showed no change in performance 
following supplementation; and 40% of the subject group (n=4) exhibited a negative 
effect on performance following either acute or chronic SB ingestion. The five subjects 
displaying a change in performance with SB supplementation are presented as case 
studies below. 
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Figure 3.11: Absolute mean power output for each subject using each 
supplementation protocol (n=10, values denote mean ± SD) 
 
 
Subject 3 demonstrated differences between all four trials, with acute SB supplementation 
eliciting the highest MPO (679.6 ± 10.7 W). MPO with acute SB supplementation was 
found to be greater than that reported for chronic SB supplementation (679.6 ± 10.7 W 
vs. 656.5 ± 16.8 W), which, in turn, was greater than the MPO for acute PLA 
supplementation (656.5 ± 16.8 W vs. 613.4 ± 19 W). MPO following acute PLA 
supplementation was greater than MPO performance with chronic PLA supplementation 
(613.4 ± 19 W vs. 546.4 ± 8.2 W).  
 
In contrast to Subject 3, Subject 10 displayed a lower MPO for acute SB supplementation 
when compared with acute PLA ingestion (933.8 ± 72.3 W vs. 977.7 ± 88 W). Similarly, 
Subject 5 exhibited a MPO with acute SB ingestion that was lower than chronic SB, acute 
PLA and chronic PLA ingestion (649.4 ± 102.3 W vs. 729.4 ± 105.3 W, 732.5 ± 64.5 W 
and 717.4 ± 77.2 W, respectively). Subject 6 displayed a lower MPO with chronic SB 
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supplementation when compared with the acute and chronic PLA supplementation 
protocols (736.8 ± 25.9 W vs. 761.3 ± 26.4 W and 761.5 ± 20.3 W, respectively). In 
addition, Subject 7 demonstrated a lower MPO with acute SB supplementation when 
compared with chronic SB supplementation (892.7 ± 129.4 W vs. 915.6 ± 132 W, 
respectively). 
 
 
3.3.14. Gastro-Intestinal (GI) Ratings 
 
The greatest incidence of GI side effects was recorded with the acute SB supplementation 
protocol. However, this was not found to be statistically different when compared to all 
other supplementation protocols. To assess the potential effect of GI discomfort 
experienced by subjects on performance during the trials, a linear regression analysis was 
conducted. The relationship between GI side effects and repeat-sprint cycle performance 
was low and non-significant (r=0.537, r2=0.289, p=0.109). 
 
 
3.3.15. Heart Rate 
 
No significant differences in heart rate responses were identified between the 
supplementation protocols at any time point (p>0.05). 
 
 
3.3.16. Ratings of Muscle Soreness 
 
No significant differences in perceived muscle soreness ratings were detected between 
the four supplementation protocols at any time point throughout the test (see Figure 
3.12). The highest muscle soreness ratings were reported immediately following Sprint 6 
(post-test). At this point acute SB, chronic SB, acute PLA and chronic PLA resulted in 
muscle soreness ratings of 4.6 ± 2.8, 4.4 ± 2.6, 4.4 ± 3.0 and 3.6 ± 2.5 on a scale of 0-10, 
respectively (p>0.05). 
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Figure 3.12: Mean muscle soreness ratings using each supplementation protocol 
(n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, repeated measures 
ACOVA with Bonferroni post hoc test) 
 
 
3.3.17. Summary 
 
Acute SB supplementation resulted in significantly elevated blood pH, StdHCO3
-
 and 
BE-Ecf at all time points following ingestion when compared to the other 
supplementation protocols (p<0.05). Chronic SB supplementation also showed 
significantly greater StdHCO3
-
 following Sprint 1 only, when compared to the acute PLA 
supplementation protocol (p=0.016). In addition, chronic SB supplementation exhibited a 
non-significant trend towards inducing a higher BE-Ecf when compared with acute PLA 
supplementation (p=0.083). 
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Acute SB supplementation also demonstrated significantly greater post-exercise blood 
lactate concentrations following Sprint 6, when compared with all other supplementation 
protocols (p<0.029). Significantly elevated PCO2 values were also observed with acute 
SB supplementation following Sprint 3 when compared to acute PLA (p=0.044) and 
following Sprint 6 when compared to chronic PLA supplementation (p=0.014). No 
significant differences in PO2 were detected between the four supplementation protocols 
at any time point throughout the test. 
 
Despite the changes in acid-base balance elicited by SB supplementation, no significant 
differences in group performance (absolute and relative PPO, absolute and relative MPO, 
total work, fatigue index) were observed between the supplementation protocols. Also, no 
significant differences in heart rate, muscle soreness or GI ratings were reported between 
the four trials. Analysis of the relationship between GI ratings and performance adjudged 
the effect of GI discomfort on performance to be minimal and non-significant (r=0.537, 
r2=0.289, p=0.109). In addition, as outlined in a number of individual case studies in 
Section 3.3.13, it is evident that the performance response to SB supplementation has a 
high degree of inter-individual variability. The results of the current study, along with 
proposed rationales and possible implications, will be discussed in further detail in the 
following section (Section 3.4). 
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3.4 Discussion 
 
3.4.1. Introduction 
 
The purpose of this study was to evaluate the effects of acute and chronic SB 
supplementation on high-intensity intermittent sprint performance in sub-elite male rugby 
union players. The major finding of the present study indicated that neither acute nor 
chronic SB supplementation had a significant ergogenic effect on high intensity 
intermittent performance. Due to the inconclusive and contradictory findings of the 
current literature regarding the effect of SB supplementation on performance, this finding 
may be both supported and opposed. Similar to the current study, Joyce et al., (2012) 
observed no improvement in mean 200m swim time (mm:ss.00) with acute or chronic 
loading of SB (acute SB 1:59.57 ± 0:06.21, chronic SB 1:58.53 ± 0:05.64 and PLA 
1:59.02 ± 0:05.82 mm:ss.00; p>0.05). Conversely, McNaughton et al. (1999) reported a 
significant ergogenic benefit, in terms of total work completed, with chronic SB 
supplementation during 60 seconds of high intensity cycling (chronic SB 24.1 ± 0.9 vs. 
control 21.1 ± 0.9 MJ; p<0.05). The ambiguity surrounding chronic SB ingestion may be 
explained by the small number of studies conducted to date. A thorough review of the 
current literature revealed that only eight studies have examined the effects of chronic SB 
supplementation on exercise performance. Of these eight papers, six relate to anaerobic 
single bout efforts (Carr et al., 2012; Driller et al., 2012; Douroudos et al., 2006; Joyce et 
al., 2012; McNaughton and Thompson, 2001; McNaughton et al., 1999) with the 
remaining two relating to endurance performance indicators (Edge et al., 2006; Heil et 
al., 2012). As a result, the current study is the first to consider the use of chronic SB 
supplementation as an ergogenic aid in the performance of repeated bouts of high 
intensity exercise. 
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3.4.2. Efficacy of SB Ingestion in Inducing Metabolic Alkalosis 
 
The efficacy of the acute SB supplementation protocol in inducing metabolic alkalosis 
was demonstrated through the significant elevation of standard blood bicarbonate 
concentration StdHCO3
- and blood pH. As outlined in the results section, acute SB 
supplementation maintained a significantly greater StdHCO3
-
 and blood pH at all time 
points when compared to all other supplementation protocols. Acute SB supplementation 
corresponded to a significant increase of 5.9mmol/L in mean StdHCO3
-
 (from 24.9 ± 
1.3mmol/L at baseline to 30.8 ± 1.1mmol/L pre-test) and a significant increase of 0.06 in 
pH (from 7.39 ± 0.02 at baseline to 7.45 ± 0.019 pre-test) following ingestion and 
immediately prior to the performance test (p<0.01). These differences are of a similar 
magnitude to the 5.4mmol/L increase in StdHCO3
-
 recorded in Bishop et al. (2004). 
However, in contrast to the present study, the increase in StdHCO3
-
 observed in Bishop et 
al. (2004) corresponded to significant improvements in total work and peak power output. 
A meta-analysis by Matson and Tran (1998), also involving a dose of 0.3g/kg, found a 
mean overall increase of 5.3mmol/L consistent with the findings of the current study. 
Furthermore, the increase in StdHCO3
-
 of 5.9mmol/L in the current study was slightly 
higher than the overall difference between SB and PLA of 3.9 ± 0.9mmol/L reported 
following a meta-analysis of thirty-eight studies (Carr et al. 2011). Carr et al. (2011) also 
reported a mean overall increase in pH of 0.069 (± 0.018) with acute SB supplementation 
when compared with PLA. This meta-analysis found a moderate overall enhancement of 
performance by 1.7% (± 2.0%) for protocols involving acute SB ingestion of 0.3g/kg BW 
prior to a single bout 1-minute sprint. Therefore, the pre-exercise alkalosis induced by SB 
ingestion in this study was representative of the magnitude of alkalosis that has resulted 
in performance enhancements in previous studies. However, in contrast to these studies, 
no improvements in performance were observed in the current study. 
 
In terms of chronic SB ingestion, although mean StdHCO3
-
 was significantly greater than 
acute PLA at one time point (following Sprint 1), pre-exercise alkalosis was not found to 
be significantly elevated nor significantly different from the PLA supplementation 
protocols. In a recent study by Driller et al. (2012) involving chronic SB 
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supplementation, similar results for acid base balance variables for chronic SB 
supplementation were presented including a non-significant difference in blood 
StdHCO3
-
 and blood pH post-ingestion, along with no difference in peak blood lactate 
concentration when compared to placebo. However, significant enhancements in 
performance were found with both acute and chronic SB supplementation in the 4-minute 
cycling test. Driller et al., (2012) purported that the enhanced mean power output 
observed with chronic SB supplementation in spite of a lack of pre-exercise alkalosis 
may suggest an alternative ergogenic mechanism. However, the state of induced alkalosis 
appears to be a key predictor of the magnitude of effect on performance. In the most 
recent meta-analysis of studies relating to sodium bicarbonate use for athletic 
performance, Peart et al., (2012) identified a significant overall relationship between 
performance enhancement and the degree of induced alkalosis (r=0.45, p=0.02). As was 
demonstrated by McNaughton et al., (1999) and Douroudos et al., (2006), a higher 
chronic dose of 0.5g/kg body mass, in contrast to the 0.3g/kg body mass, each day may 
be necessary to significantly increase blood StdHCO3
- and blood pH. 
 
 
3.4.3. Effects of Metabolic Alkalosis on Performance 
 
As shown in Section 3.3 of this thesis, although acute SB supplementation was shown to 
induce significant metabolic alkalosis, as assessed by significantly elevated standard 
blood bicarbonate concentration blood StdHCO3
-
, pH and BE-Ecf, this did not impact on 
the performance outcome. This finding is corroborated by Cameron et al. (2010) who 
concluded that acute SB supplementation induced an increase in pre-exercise StdHCO3
-
 
(30.33 ± 1.25 vs. 24.03 ± 0.34 mmol/L; p<0.001), extracellular pH (7.47 ± 0.01 vs. 7.39 
± 0.01; p<0.001) and also diminished the exercise-induced acidosis (7.25 ± 0.02 vs. 7.19 
± 0.02) recorded immediately following the performance test. However, no significant 
effect on high intensity intermittent field sport-specific activity was observed. Similarly, 
Gaitanos et al. (1991) found that despite a significantly greater muscle buffering capacity 
associated with acute SB supplementation, power output was unaffected in performance 
of 10 x 6 second maximal treadmill sprints with 30 second recovery periods. These 
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findings are also consistent with those of Kozak-Collins et al. (1994) who reported no 
performance enhancements with acute SB ingestion despite significant pre-exercise 
alkalosis in repeated 1-minute cycling bouts to exhaustion with 1 minute recovery 
between each bout. 
 
Conversely, Bishop et al. (2004) found that significant elevations in resting blood 
StdHCO3
-
 (30.0 ± 3.0 vs. 23.6 ± 1.1 mmol/L) and pH (7.50 ± 0.04 vs. 7.42 ± 0.02) 
recorded with acute SB ingestion coincided with significant increases in total work (acute 
SB 16.5 ± 3.1 vs. control 15.7 ± 3.0  kJ; p<0.05) and power output in sprints 3, 4 and 5 of 
a 5 x 6 second maximal repeat sprint test with 24 seconds recovery on a cycle ergometer 
(p<0.05). Similarly, results from research by Costill et al. (1984) and Siegler et al. (2010) 
also adjudged acute SB supplementation to elicit a positive influence on repeated bouts of 
high intensity performance on a cycle ergometer. However, in both of these studies the 
duration of sprint length and rest period was not indicative of the physiological demands 
of many team field sports. The study by Costill et al. (1984) examined the effects of SB 
ingestion on 5 x 1 minute cycling bouts at 100% VO2max with 30 seconds recovery 
between each bout (work to rest ratio of 2:1). The fifth bout was performed to exhaustion 
and time to exhaustion was measured as the performance variable. This study is 
renowned for reporting a significant 42% increase in time to exhaustion for SB versus 
PLA during the fifth cycling bout (160.8 ±19.1 vs. 113 ±12.4; p<0.01). Siegler et al. 
(2010) employed a work to rest ratio of 1:6, which is in accordance with the typical mean 
work to rest ratios of 1:5.7 (back) and 1:5.8 (forward) reported for 15-a-side rugby union 
by Cunniffe et al. (2009). However, the performance test utilised by Siegler et al. (2010) 
involved 3 x 30 second Wingate tests on a cycle ergometer each separated by 3 minute 
rest periods, which represented a more extended sprint and rest duration than that 
experienced within the demands of rugby union. 
 
A study by Nicholas (1997) made reference to rugby union as an intermittent sport in 
which players were required to perform a large number of high intensity bouts of between 
5 to 15 seconds duration. For the purposes of the current study, in an attempt to comply 
with the previously reported work to rest ratios and typical match-play sprint durations 
 82 
(Cunniffe et al. 2009; Nicholas, 1997), a cycle ergometer test consisting of 6 x 10 second 
maximal bouts with 50 seconds recovery between each bout was undertaken. This 
protocol was designed to replicate the high-intensity intermittent efforts indicative of 
rugby union in the controlled setting of the laboratory. Extracellular pH, StdHCO3
-
, BE-
Ecf and blood lactate concentrations were recorded and monitored throughout testing in 
order to provide potential justification for any performance variable differences observed 
between the experimental supplementation protocols.  
 
Given that no performance variable differences were observed between treatments, the 
physiological demands of the performance test cannot be excluded as a possible 
explanation for the conflicting results. The exercise mode (cycling) and sprint duration 
combined with recovery duration involved in the test protocol undertaken in the current 
study may not have induced significant intramuscular pH changes. As previously 
mentioned, Bishop et al. (2004) reported an ergogenic benefit with acute SB 
supplementation in 5 x 6 second cycling bouts performance every 30 seconds. 
Performance enhancements were also found by Siegler et al. (2012) during 3 x 30 second 
Wingates with 3 minutes recovery between efforts. Potentially the use of a shorter 
recovery period between high intensity bouts or, alternatively, longer duration sprints 
may induce the intramuscular pH changes necessary for SB supplementation to elicit a 
more positive ergogenic response. Further research is necessary in this area including the 
possible sampling of muscle biopsy to analyse the intramuscular environment. However, 
the results of this study would suggest that SB supplementation does not have the 
capacity to improve performance indicative of the physiological demands of rugby union. 
 
According to Roberts et al. (2008), fatigue during rugby competition may be anticipated 
through the quantity of high intensity activities performed. Roberts et al. (2008) also 
noted that repeated bouts of high intensity sprinting are most likely to influence match-
play and determine the match outcome. Therefore, the ability to delay the onset of fatigue 
contributes considerably to the maintenance of high intensity sprint performance 
throughout a match and, ultimately, the outcome of a rugby union match. Previous 
studies have reported enhanced performance of single bout high-intensity short duration 
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cycling following chronic SB ingestion (McNaughton et al., 1999; McNaughton and 
Thompson, 2001; Douroudos et al., 2006). The major difference between this study and 
previous studies demonstrating an ergogenic effect of chronic SB ingestion is the 
repeated bout nature of the performance test. As mentioned, to knowledge this is the first 
study to examine the effects of chronic SB supplementation on repeated bouts of high 
intensity short duration exercise.  
 
McNaughton et al. (1999) examined the effects of 0.5g/kg body mass per day of SB 
(0.2g/kg higher than the current study) for a period of five days on a single bout maximal 
60 second sprint on a cycle ergometer. In a similar study by McNaughton and Thompson 
(2001), a 6 day loading period was employed involving chronic SB ingestion of 0.5g/kg 
body mass per day. From the resultant blood pH, StdHCO3
-
 and BE-Ecf, McNaughton 
and colleagues (1999) purported that this loading protocol allowed the extra bicarbonate 
to be stored within the body, thus enhancing the buffer reserve. Both studies reported a 
significant performance enhancement in single bout high intensity short duration cycling 
performance. The latter study (McNaughton and Thompson, 2001) also attributed chronic 
SB loading with a sustained performance enhancement in a second trial performed 24 
hours after the initial trial without any further ingestion of SB. However, no acid-base 
variables were reported pertaining to this second trial. Therefore, inferences regarding 
sustained alkalosis cannot be supported. In both of the aforementioned studies, the acid-
base variables increased significantly above baseline levels in the initial 24 hours after 
ingestion. The initial elevation in pH, StdHCO3
-
 and BE-Ecf recorded was maintained for 
the remaining four (McNaughton et al., 1999) or five days (McNaughton and Thompson, 
2001), respectively, of the loading period but did not exhibit any further increases despite 
continued daily supplementation. This would suggest that a chronic loading period of less 
than 5 days may have been sufficient to obtain the same response.  
 
Joyce et al. (2012) also observed a significant degree of pre-exercise alkalosis but no 
significant alteration in 200m swimming performance with chronic SB loading when 
compared to PLA. Joyce et al. (2012) established that a chronic SB loading dose of 
0.3g/kg body mass per day for 4 days was sufficient to stimulate similar significant 
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increases in pH and StdHCO3
-
 as those previously induced by a higher daily dosage 
(McNaughton et al., 1999; McNaughton and Thompson, 2001). However, similar to the 
current study, no performance enhancement was observed. 
 
In the present study, a SB dose of 0.3g/kg body mass per day was administered for five 
consecutive days prior to performance of 6 x 10 second Wingate’s on a cycle ergometer 
with 50 seconds recovery between each sprint. However, as is shown in the results, acid-
base variables, measured immediately before the performance test, had returned to pre-
ingestion values for chronic SB supplementation. This finding suggests that the body may 
have compensated for the daily SB ingestion-induced perturbations in acid-base balance 
through manipulation of the acid-base status of the urine (Guthrie, 1983) or PCO2 
(Greenhaff et al., 1987). Within the current study, blood gas analysis was not carried out 
during the 5 day loading phase of the chronic supplementation protocol. However, 
significantly elevated PCO2 values were observed with acute SB supplementation 
following Sprint 3 when compared to acute PLA (p=0.044) and following Sprint 6 when 
compared to chronic PLA supplementation (p=0.014). Future research may benefit from 
daily analysis of blood and urine samples throughout the chronic loading period. 
 
 
3.4.4. Effects of Metabolic Alkalosis on Post-Exercise Lactate Concentration 
 
Acute SB ingestion has been associated with significantly greater post-exercise blood 
lactate concentrations when compared with a placebo (Bishop et al., 2004; Lindh et al., 
2008; Gao et al., 1988). The additional ingested HCO3
-
 circulating in the extracellular 
fluid promotes a greater efflux of lactate/H+, through the lactate/ H+ co-transporter (Juel, 
1998), as demonstrated by the widely reported significant elevation of post-exercise 
blood lactate following SB supplementation (Siegler et al., 2008). In this regard, the 
current study is consistent with the majority of the literature in terms of post-exercise 
blood lactate concentration. Following the final bout of the high intensity performance 
test, acute SB ingestion resulted in a mean blood lactate of 13.71mmol/L ± 1.92, which 
was significantly greater than acute PLA, chronic PLA and chronic SB ingestion, which 
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resulted in blood lactate values of 11.76 ± 1.53, 11.56 ± 2.1 and 11.76 ± 2.07mmol/L 
respectively. Elevated post-exercise blood lactate concentrations associated with acute 
SB ingestion tend to accompany enhancements in performance (Requena et al., 2005; 
Bishop et al., 2004; Sutton et al., 1981). Edge et al. (2006) purported that a greater lactate 
accumulation may occur due to an enhanced buffering capacity as a result of SB 
ingestion. The enhanced buffering of the excess H
+ 
allows anaerobic glycolysis to 
continue, thereby providing energy for a prolonged period and attenuating fatigue (Edge 
et al., 2006). However, despite significantly elevated post-exercise blood lactate 
concentration with acute SB ingestion, no performance enhancements were observed. 
 
 
3.4.5. Gastro-Intestinal Discomfort 
 
In the present study, no statistically significant differences were observed for ratings of 
gastro-intestinal discomfort between acute SB, chronic SB or PLA ingestion protocols. 
This contradicts previous findings (Requena et al., 2005), which describe increased GI 
disturbances with acute SB ingestion. This may be attributed to the staggered loading 
protocol utilised in the current study, involving ingestion of 0.1g/lg BM at 90, 60 and 30 
minutes prior to the performance test. A study by Cameron et al. (2010) used a similar 
ingestion protocol of 0.3 g/kg BM taken in one dose 90 minutes prior to the performance 
test. This research found that the severity of GI discomfort was significantly greater with 
acute SB supplementation when compared to the PLA trial. In the current study, an 
identical dose of 0.3g/kg BM was distributed into three doses and ingested at 90, 60 and 
30 minutes prior to performance in an attempt to maximise blood StdHCO3
-
 while 
minimising GI discomfort. The objective of this protocol was achieved, as is evident 
from the significant elevation in pre-exercise StdHCO3
-
 and the lack of a significant 
difference in GI ratings between the four supplementation protocols. However, no 
improvements in performance were observed in spite of the similar GI ratings reported 
for each supplementation protocol. 
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3.4.6. Summary 
 
Consistent with the findings within the literature, analysis of both acute and chronic SB 
ingestion within the current study appears to be inconclusive. In a review by Peart et al. 
(2012) forty research articles were analysed involving 395 participants (348 males, 47 
females), fifteen of the forty studies (38%) found an ergogenic benefit. Although 
metabolic alkalosis was induced with acute SB ingestion within the present study, 
identified by increases in blood StdHCO3
-
, pH and BE-Ecf, no ergogenic benefit was 
observed. Overall effect size has been shown to be higher in untrained individuals as 
opposed to trained individuals (Peart et al., 2012). Trained individuals appear to have a 
higher muscle buffering capacity and, therefore, SB loading may have a diminished 
impact on highly trained athletes (Robinson and Verity, 1987). Given that the subjects 
involved in the current research were trained athletes, this may provide a partial 
explanation for the insignificant findings in relation to performance.  
 
More positive ergogenic results have also been found in single bout as opposed to 
repeated bout performance, possibly due to the inability of the buffering system to 
recover sufficiently in the rest periods associated with repeated bout performance (Peart 
et al., 2012). This may indicate that the high intensity intermittent exercise protocol 
involved in the current study may not be enhanced by SB ingestion. Furthermore, in a 
review by Matson and Tran (1993), thirty-five investigations formed the basis for a meta-
analysis. Within this review, it was identified that the nineteen studies showing positive 
ergogenic effects following ingestion in comparison to the sixteen other studies showing 
no effect. Price and Simons (2010) cited individual variability as an explanation for a 
lack of significant group performance enhancements in high intensity intermittent 
treadmill running despite significant shifts in the acid-base balance with SB ingestion. 
This may also apply to the current study given the large degree of individual performance 
variation in response to SB ingestion. Nonetheless, the current study shows no evidence 
to support the use of either of these specific acute or chronic SB supplementation 
protocols to enhance performance within this particular high intensity, intermittent 
cycling test. Although acute SB supplementation did induce significant elevations in 
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blood parameters as predicted, the overall hypothesis stating that acute and chronic SB 
supplementation would enhance performance was disproved. 
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Chapter 4 
 
Study Two: The Effects of Chronic Sodium 
Bicarbonate Supplementation on Simulated 
Rugby Sevens Performance 
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4.1. Introduction 
 
The aim of this study was to examine the effects of chronic five-day supplementation 
with SB on a specifically designed test protocol developed to replicated the specific 
physiological demands associated with a typical rugby sevens match. The hypothesis 
devised stated that chronic SB supplementation, using a specifically designed loading 
protocol, would stimulate metabolic alkalosis and result in enhanced performance, 
recovery and subsequent performance of high-intensity intermittent performance when 
compared to a PLA trial. Having previously analysed the effect of both acute and chronic 
SB supplementation on a laboratory-based test in Study 1 (Chapter 3), Study 2 aimed to 
focus on chronic SB supplementation with respect to a field-based sport-specific rugby 
sevens test protocol. The previous study (Study 1) had identified the potential for the use 
of chronic SB supplementation through a significantly elevated StdHCO3
-
 value at one 
time point. In addition, by focusing on five days of chronic SB supplementation alone, as 
opposed to the acute trial involved on Day 1 of Study 1, it was believed that this 
experiment may add to the limited current literature investigating chronic SB 
supplementation. The research protocol and results are outlined and discussed throughout 
this chapter (Chapter 4). 
 
 
4.2. Methods 
 
4.2.1. Subjects 
 
10 healthy male subjects, aged between 18-35 years volunteered to participate in the 
study. Subjects consisted of trained club rugby players of Junior 2 level or above and 
were recruited from University and Leinster rugby clubs. Playing experience of each 
player was no less than 5 years. Subjects were excluded from the study if they were 
suffering from any cardiovascular, pulmonary or metabolic diseases; if they were 
smokers; or if they had any injury or illness that may have affected their performance, as 
determined by a general health questionnaire (see Appendix B) completed by each subject 
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prior to testing. All experimental procedures were approved by the Dublin City 
University Research Ethics Committee. 
 
4.2.2. Screening 
 
During the first visit to DCU, written informed consent (see Appendix A2) was obtained 
from all subjects after explanation of the experimental procedure, possible risks and 
proposed benefits of participating in the study. A general health questionnaire, outlining 
the subjects’ medical eligibility to participate in the study was also completed. Baseline 
anthropometric measurements including height (m), body mass (kg), resting heart rate 
(bpm) and body mass index (kg/m
2
) were also assessed. 
 
4.2.3. Overview of Experimental Design 
 
The study took place in the Exercise Physiology Research Hall (EPRH) in Dublin City 
University (DCU). The present investigation took place during the latter phase of the 
competitive season, with trials being performed no less than 2 days after the previous 
match in order to standardise pre-test conditions as much as possible. During this phase 
of the season, players were participating in four training sessions per week (including 
skill, tactical and physical sessions) with a competitive match at the weekend. In addition 
to a habituation session on a separate day, each subject successfully participated in two 
experimental trials which differed only in terms of the supplement ingested in the 
preceding 5 days (sodium bicarbonate - SB versus placebo - PLA). The purpose of the 
habituation visit was to familiarise the subjects with the exercise patterns of the 
specifically developed field based performance test (see Section 4.2.5), designed to 
replicate the demands of rugby union. This initial visit also functioned to control for any 
performance enhancements in subsequent trials as a result of potential learning effects by 
ensuring that performances had begun to plateau by the end of the habituation session. 
Within the habituation session, subjects were given a verbal and physical demonstration 
before 3 sub-maximal practice sets of the full performance test. Subjects then completed 
the full performance test at maximum effort. The two subsequent performance trials were 
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performed in a randomised order using a double-blind, cross-over design and there was 
no less than a seven-day washout period separating the performance test of one trial and 
supplementation for the subsequent trial.  
 
4.2.4. Supplementation Protocol 
 
Prior to the first main trial, participants were instructed to maintain their normal their 
physical activity, diet and hydration pattern for the 48 hour period before the trial and 
were directed to replicate this before the second trial. The two experimental trials 
involved supplementation with either SB or PLA. Following on from Study 1, a 5 day 
chronic loading supplementation protocol with SB and PLA (see Figure 4.1 below) was 
the selected loading protocol as opposed to acute ingestion 90 minutes prior to exercise. 
Chronic SB supplementation for five days prior to performance with no supplementation 
on the day of performance has been shown to potentially minimise the gastro-intestinal 
side effects associated with SB ingestion. Chronic SB supplementation has shown similar 
peak power outputs, mean power outputs and total work performed when compared to 
acute SB supplementation. However, decreased pre-performance gastrointestinal 
disturbances were exhibited with chronic SB supplementation when compared to acute 
SB supplementation (McNaughton and Thompson, 2001).  
Day 1 Day 2 Day 3 Day 4 Day 5
Performance 
Trial
Day 6
Day 2: 
Supplement 
with PLA or 
0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm.
Day 3: 
Supplement 
with PLA or 
0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm.
Day 4: 
Supplement 
with PLA or 
0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm.
Day 5: 
Supplement 
with PLA or 
0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm.
Day 6:
No 
supplementation. 
Day 1: 
Supplement 
with PLA or 
0.3g/kg 
NaHCO3 split 
into three doses 
taken at 9am, 
12pm and 3pm.
Figure 4.1: Schematic of chronic supplementation protocol 
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During the habituation visit, subjects were provided with precise, written instructions on 
the appropriate procedure for supplementation over the 5 day period. Subjects were 
provided with five measures of their respective daily quantities of SB or PLA. Each daily 
dose of either 0.3g/kg SB or 0.02g/kg PLA (maltodextrin) was contained in identical 
gelatine capsules (matched for capsule number), which ensured the subjects remained 
blinded and, therefore, unbiased. The gelatine capsules also served to attempt counteract 
any potential gastro-intestinal disturbances due to their purported slow-release 
mechanism (Carr, et al., 2011). The daily doses were divided into three parts to be 
ingested at 9am, 12pm and 3pm each day for five consecutive days prior to the 
performance test. Subjects were advised to refrain from eating 60 minutes either side of 
ingesting the capsules to avoid gastrointestinal disturbances. Subjects were also advised 
to remain fully hydrated and to adhere to their normal diet throughout the week. Alcohol, 
caffeine and strenuous exercise were not permitted in the 24 hours prior to the 
performance test. 
 
4.2.5. Performance Test 
 
Following the five-day supplementation protocol, subjects returned to the exercise hall on 
Day 6 to complete the performance test. The performance test utilised in this study was a 
repeatable, controllable, specific protocol designed to simulate the typical movement 
patterns observed during GPS movement pattern analysis of rugby union sevens (Higham 
et al., 2012; Suarez-Arrones et al., 2011). The test, therefore, simulated the physiological 
demands of rugby union, in which repeated bouts of high intensity activity are 
interspersed with low-intensity active recovery periods (Suarez-Arrones et al., 2011; 
Deutsch et al., 1998, Roberts et al., 2008).  
 
Subjects began with a 10 minute standardised warm-up (see Illustration 4.1) which 
consisted of jogging at 3m/s, dynamic stretching (walking lunges, hamstring and groin 
stretches and sumo squats) along with exercises involving explosive leg movements (high 
knees, heel flicks and squat jumps).  
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a)   b)   c)   d) 
Illustration 4.1: Dynamic warm-up stretching including a) walking lunge; b) 
walking hamstring stretch; c) walking groin stretch; d) walking sumo squat. 
 
The performance test was divided into two distinct stages with a 2 minute standardised 
period of combined static and active recovery separating each stage. A detailed schematic 
of the performance test is presented in Figure 4.2. 
 
Stage 1  
 
Stage 1 (see Figure 4.2 below which corresponds to the colour code following each step 
outlined) consisted of six repetitions of a continuous seven step circuit outlined below: 
- Step 1: 20m walk (1.4m/s), 20m cruise (4.2m/s), 20m jog (3m/s) … 
- Step 2: 9m 25kg tackle bag carry shuttle x 2 ... 
o From a standing start 0.5m behind timing gate A (Figure 2), subjects 
passed through the gate, picked up the tackle bag, carried it 9m and placed 
it over a line before sprinting 9m back to the start line. The subject then 
turned and sprinted 9m back to the tackle bag, picked up the bag and 
carried it back 9m placing it back where it began and sprinted back 
through timing gate A. 
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- Step 3: Reactive agility speed (RAS) test … 
o Subjects sprinted straight 15m from timing gate 1 through timing gate 2, 
which triggered either timing gate 3 or 4 to flash continuously. The subject 
continued to sprint, making a sudden change of direction to sprint through 
the timing gate that was flashing. Gate 3 or 4 only flashed once the subject 
had passed through gate 2.  
o Reactive agility speed (RAS) may be broken down into three distinct 
elements: 
• RAS_15m (the initial 15m sprint) 
• RAS_reaction (a visually triggered change of direction reaction 
element over the subsequent 7m immediately following the 15m 
sprint) 
• RAS_total (the sum of RAS_15m and RAS_reaction) 
- Step 4: 25s jog back to start line ... 
o The subject then had 25s from the end of the RAS above to jog back to the 
start line. 
- Step 5: 15m sprint – Linear speed (LS) … 
o Upon return to the start line, the subject performed a single, maximum 
effort 15m sprint between timing gates 1 and 2. 
- Step 6: Jog backwards to start line (3m/s) ... 
o After completion of the 15 sprint, subjects jogged back to the start line at a 
speed of 3m/s. 
 95 
- Step 7: Change of direction speed (CODS) test ... 
o Similar to the RAS test, subjects sprinted from a standing behind timing 
gate 1 through gate 2 and changed direction to sprint through gate 3 or 4. 
However, in contrast to the RAS, subjects were verbally instructed as to 
which direction to change prior to each sprint. Subjects were encouraged 
to perform the change of direction as if to evade a defender thus resulting 
in a sharp change of direction.  
o Similar to RAS, change of direction speed (CODS) may be broken down 
into three distinct elements: 
• CODS_15m (the initial 15m sprint) 
• CODS_reaction (pre-ordained change of direction element over the 
subsequent 7m immediately following the 15m sprint) 
• CODS_total (the sum of CODS_15m and CODS_reaction) 
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Figure 4.2: A schematic representation of the performance test area (not to scale). 
 
 
2 minute recovery phase: 
o Subjects recovered passively for 1 minute while readings for MS, RPE and 
blood samples were collected. Subjects then performed 1 minute of active 
recovery which involved slow walking at 1.4m/s. 
 
 
 
Timing gate 20kg Tackle bag Rugby ball 
9m
15m
7m
1
2
3 44m
20m
Sprint start line
A
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Stage 2: 
 
Stage 2 consisted of the Illinois agility test (See Figure 4.3 below). The Illinois test 
consists of an agility course within a grid 10m long and 5m wide as illustrated in Figure 
3. Four cones were used to mark the starting point, finishing point and the two turning 
points. Another four cones were placed down the centre of the grid, an equal distance of 
3.3m apart. Each shuttle requires the subject to run approximately 60 metres in total. 
Each subject began the test lying faced down facing forwards with arms flat on the 
ground. On the “Go” command the subject jumped to their feet, picked up the rugby ball 
which was positioned at their head from their start position on the ground and negotiated 
the course in the fastest possible time. Subjects were instructed prior to the test to keep 
the ball in two hands at all times and to work maximally and avoid pacing. Each subject 
completed six shuttles of this agility test with 20 seconds recovery between each shuttle. 
The test was timed using Photocell Intermediate Beam timing gates (BrowerXS, 
Vermount, USA). 
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Figure 4.3: Illinois Agility Test 
 
4.2.6. Blood Lactate Analysis 
 
Blood lactate sampling technique was identical to the description in Section 3.2.6. Blood 
sampling occurred at pre-warm up, pre-test (post-warm up), pre-agility (within the 2 
minute recovery period between stage 1 and 2 of the test) and post-test (following stage 
2). 
10m 
5m 
2 1 
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4.2.7. Blood Gas Analysis 
 
Blood gas analysis, as previously described in Section 3.2.7, was carried out at identical 
time points to those mentioned for blood lactate (pre-warm up, pre-test, pre-agility, post-
test). 
 
 
4.2.8. Heart Rate 
 
Heart rate (HR) was recorded throughout the test using recordable HR-enabled watches 
with heart rate monitors (Garmin, Kansas, USA). Heart rate was subsequently wirelessly 
downloaded to a computer using the Garmin Training Centre (Garmin, Kansas, USA). 
 
 
4.2.9. Subjective Ratings 
 
At pre-warm up, pre-test, pre-agility and post-test time points, ratings of GI discomfort, 
perceived exertion (RPE) and muscle soreness were obtained using visual analogue 
scales (0-5, 6-20 and 0-10 for GI discomfort, RPE and muscle soreness, respectively).  
 
 
4.2.10. Testing Variability 
 
Subjects completed their performance testing on the same day, at a similar time of day 
and under similar environmental conditions to avoid any diurnal variation. Subjects were 
instructed to maintain their normal diet and hydration pattern, refrain from consuming 
any alcohol, sports drinks or ergogenic aids and avoid strenuous exercise – defined as 
exercise requiring great exertion, such as a match or strenuous training session – for the 
48 hours prior to each test. Subjects were familiarised with the testing procedure and 
protocols prior to each test. The performance test was performed in an indoor sports hall 
with an air temperature of 16-20ºC. All performance tests were measured using electronic 
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timing gates (Fusion Sport Smartspeed Timing Gates, Australia and BrowerXS, 
Vermount, USA). 
 
 
4.2.11. Statistical Analysis 
 
All statistical analyses were conducted using SPSS for Windows v. 16.0 (SPSS, USA). 
Paired sample t-tests were used to identify differences between the two conditions for all 
parameters. Linear regression of performance variables with mean GI symptoms for each 
condition was also performed in order to detect any relationship between performance 
and GI symptoms. A p value less than 0.05 was considered statistically significant. 
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4.3. Results 
 
4.3.1. Subject Characteristics 
 
Descriptive and anthropometric data for the 10 subjects are presented in Table 4.1. 
 
Table 4.1: Descriptive and Anthropometric Data (n=10) 
Variable Mean (± SD) 
Body mass (kg) 85.6 ± 17.6 
Height (cm) 180.9 ± 7.5 
Body mass index (kg/m
2
) 25.9 ± 3.6 
Age (yrs) 25 ± 3 
 
 
4.3.2. Standard Bicarbonate (StdHCO3
-
)  
 
No significant differences were observed between SB and PLA trials at any time point 
throughout the testing process (see Figure 4.4). Mean pre-warm up StdHCO3
- levels were 
26.4±1.4 mmol/L for SB supplementation and 26.1±0.85 mmol/L for PLA 
supplementation, respectively (p=0.882). Post-test StdHCO3
-
 was recorded as 
16.0±6.9mmol/L vs. 13.0±3.2mmol/L for SB and PLA supplementation, respectively 
(p=0.455). 
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Figure 4.4: Standard bicarbonate concentrations across time points for each 
supplementation protocol (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
4.3.3. Blood pH 
 
Baseline blood pH was measured prior to the chronic 5 day supplementation protocols 
and was identified as 7.40 ±0.01 pH units and, therefore, was within normal resting 
levels. No significant differences were found between SB and PLA trials at any time 
point (p>0.05) throughout the testing process (see Figure 4.5). Mean pre-warm up pH 
was recorded as 7.38 ± 0.02 for SB supplementation and 7.39 ± 0.02 for PLA 
supplementation, respectively (p>0.05). Post-test blood pH was recorded as 7.24 ± 0.10 
vs. 7.26 ± 0.07 for SB and PLA supplementation, respectively (p>0.05). 
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Figure 4.5: Comparison of pH levels across time points for each supplementation 
protocol (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
4.3.4. Base Excess in Extracellular Fluid (BE-Ecf) 
 
BE-Ecf was measured using blood gas analysis prior to the chronic loading period and 
then at four time points on the day of the performance trial – pre-warm up, pre-test, pre-
agility test and post-test. No significant differences in BE-Ecf were detected between 
chronic SB and PLA supplementation trials at any of these time points (see Figure 4.6). 
BE-Ecf values of 1.5 ± 1.1 vs. 1.8 ± 0.7 mmol/L were identified at the pre-warm up stage 
for SB and PLA trials, respectively (p>0.05). Post-test BE-Ecf also exhibited no 
significant difference between SB and PLA supplementation protocols (-11.4 ± 4.0 vs. -
11.0 ± 4.9 mmol/L, respectively (p>0.05). 
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Figure 4.6: BE-Ecf across time points for each supplementation protocol (n=10, 
values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
4.3.5. Blood Lactate Analysis 
 
Baseline lactate levels were identified as lying within the normal ranges prior to 
supplementation for all subjects (0.8-1.8 mmol/L) with no significant differences between 
the groups (p = 1.000). No significant differences in blood lactate concentration (see 
Figure 4.7) were observed between the SB and PLA chronic supplementation protocols at 
any of the four time points measured throughout the performance test (p>0.05 for all time 
points) – pre-warm up (SB 0.97 ± 0.14 vs. PLA 0.98 ± 0.18 mmol/L), pre-test (SB 1.50 ± 
0.39 vs. PLA 1.18 ± 0.21 mmol/L), pre-agility test (SB 8.66 ± 2.78 vs. PLA 8.76 ± 3.25 
mmol/L), post-test (SB 10.01 ± 3.51 vs. PLA 9.22 ± 3.47 mmol/L). 
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Figure 4.7: Comparison of blood lactate concentrations across time points for each 
supplementation protocol (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
4.3.6. Partial Pressure of CO2 (PCO2) 
 
No significant differences between supplementation protocols were observed at any time 
point for PCO2 (see Figure 4.8). Pre-warm up PCO2 values were identified as 5.57 ± 0.40 
vs. 6.03 ± 0.61 kPa for chronic SB and chronic PLA supplementation, respectively 
(p=0.349). Post-test PCO2 values were recorded as 4.60 ± 0.26 vs. 4.35 ± 0.82 kPa for 
chronic SB and chronic PLA supplementation, respectively (p=0.564).  
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Figure 4.8: PCO2 (kPa) across time points for each supplementation protocol (n=10, 
values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
4.3.7. Partial Pressure of O2 (PO2) 
 
Similar to PCO2, no significant differences in PO2 were detected at any time point 
between SB and PLA trials (see Figure 4.9). Pre-warm up PO2 values were identified as 
10.00 ± 0.57 vs. 10.55 ± 1.34 kPa for SB and PLA supplementation, respectively 
(p=0.754). Post-test PO2 values were recorded as 10.87 ± 1.12 vs. 11.70 ± 0.72 kPa for 
SB and PLA supplementation, respectively (p=0.452).  
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Figure 4.9: PO2 (kPa) across time points for each supplementation protocol (n=10, 
values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
4.3.8. Rugby Specific Performance Test 
No differences were detected between supplementation protocols in any of the 
aforementioned blood parameters analysed (see Sections 4.3.2 – 4.3.7). Similarly, no 
significant mean differences were observed in the performance test between the SB and 
PLA trials following the implementation of the chronic supplementation protocols. Five 
performance measures comprising the rugby sevens-specific circuit protocol were 
analysed with the group and individual results outlined below. These performance 
measures included: 
1. 2 x 9m tackle bag carry shuttle 
2. Reactive agility speed (RAS) 
3. 15m sprint 
4. Change of direction speed (CODS) 
5. Illinois agility test 
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4.3.9. Tackle Bag Carry Shuttle 
 
No significant group differences were observed for the 2 x 9m tackle bag carry shuttle 
between the SB and PLA trials (17.09 ± 1.82s vs. 17.01 ± 1.01s for SB and placebo 
supplementation trials, respectively; p=0.847).  
 
 
4.3.10. Reactive Agility Speed (RAS) 
 
Group means for all three elements of the RAS (15m sprint time, reaction time and total 
time) were not found to differ significantly between the SB and PLA supplementation 
trials. Total time for the RAS was 5.31 ± 0.32s for the SB trial and 5.25 ± 0.26s for the 
PLA trial (p=0.348). 
 
 
4.3.11. 15m Sprint 
 
As with the other performance measures, no significant group differences were observed 
between SB and PLA supplementation trials for 15m sprint times. Chronic SB 
supplementation produced a mean 15m sprint time of 3.05 ± 0.19s over the six circuits of 
the performance test, whereas chronic PLA supplementation resulted in a mean time of 
3.10 ± 0.22s (p=0.568). 
 
 
4.3.12. Change of Direction Speed (CODS) 
 
No significant differences were found between SB and PLA trials for any element of 
CODS performance. The recorded means ± standard deviations were 4.69 ± 0.27s vs 4.72 
± 0.34s for SB and PLA supplementation trials respectively (p=0.847).  
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4.3.13. Illinois Agility Test 
 
The Illinois agility test was performed following a two minute rest period subsequent to 
the initial six circuits of the rugby sevens-specific test protocol. Mean sprint times of 
16.99 ± 0.92s and 17.19 ± 0.81s were recorded for SB and PLA supplementation trials 
respectively, which were not found to be statistically significant from each other 
(p=0.728). 
 
 
4.3.14. Individual Performance Data 
 
Individual subject performances comparing the two trials were also investigated. From 
this analysis, it was determined that, out of the ten subjects tested, two subjects (20%) 
demonstrated enhanced performance with SB supplementation across the six circuits of 
the performance test when compared with the PLA trial. Furthermore, two subjects (20%) 
displayed no significant differences between the two trials. One subject (10%) showed 
improved performance with both SB and PLA supplementation in two different tasks of 
the performance test. The remaining five subjects (50%) recorded enhanced performance 
with PLA supplementation when compared to the SB trial. These individual results are 
outlined in detail as case studies below. Means and standard deviations presented are 
based on analysis of all six circuits completed by one individual subject. 
 
Subject 1 demonstrated lower sprint times with SB supplementation when compared with 
the PLA trial in several performance parameters measured. In relation to the 2 x 9m 
tackle bag carry shuttle, Subject 1 recorded an enhanced performance with SB when 
compared to PLA supplementation (15.87 ± 0.17 vs. 17.18 ± 0.33s, respectively). 15m 
sprint time also demonstrated a difference between the two trials for the same subject 
(2.78 ± 0.13 vs. 3.42 ± 0.16s for SB and PLA supplementation, respectively). With 
regard to the Illinois agility test, the SB protocol elicited a faster mean time across the six 
shuttles for Subject 1 when compared to the PLA trial (SB 16.08 ± 0.13 vs. PLA 18.9 ± 
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0.46s). In addition, Subject 1 recorded a lower CODS_15m sprint time with SB when 
compared to PLA supplementation (3.03 ± 0.14 vs. 3.29 ± 0.66s, respectively). 
 
Subject 2 exhibited a similar response to Subject 1 with a greater performance in the SB 
trial for the tackle bag carry shuttle when compared to PLA (16.12 ± 0.43 vs. 17.67 ± 
0.65s, respectively). CODS_total was also found to be faster with SB rather than PLA 
supplementation (4.62 ± 0.31 vs. 4.96 ± 0.49s, respectively). 
 
Subject 8 appeared to have responded comparably with Subject 1 and 2 to the SB 
supplementation protocol, recording a lower CODS_reaction speed than in the PLA trial 
(1.24 ± 0.03 vs. 1.28 ± 0.06s, respectively). However, conversely, this subject also 
demonstrated enhanced performance across the six circuits of the Illinois agility shuttle 
test with the PLA as opposed to SB supplementation (SB 16.54 ± 0.34 vs. PLA 16.17 ± 
0.26s).  
 
Subjects 4, 6, 7, 9 and 10 all displayed evidence of enhanced performance with PLA 
supplementation as opposed to the SB protocol. In Subject 4, differences between PLA 
and SB ingestion were observed for tackle bag carry shuttle speed (SB 17.38 ± 1.04s vs. 
PLA 16.39 ± 0.39), 15m sprint time (SB 3.25 ± 0.21s vs. PLA 2.84 ± 0.16), the Illinois 
agility shuttle (SB 18.45 ± 0.07s vs. PLA 17.39 ± 0.33s) and CODS_reaction (SB 1.42 ± 
0.09s vs. PLA 1.26 ± 0.03s). Subject 6 also recorded reduced Illinois agility shuttle times 
with the PLA (17.72 ± 0.32s) trial when compared to the SB trial (18.44 ± 0.12s). Faster 
RAS_reaction times were expressed in Subject 7 with PLA supplementation when 
evaluated against the SB trial (SB 1.75 ± 0.08s vs. PLA 1.58 ± 0.04s). In Subject 9, tackle 
bag carry shuttle (SB 19.35 ± 0.26s vs. PLA 17.84 ± 1.00s), RAS_15m (SB 3.60±0.09s 
vs. PLA 3.38±0.15s) and RAS_total (SB 5.52±0.18s vs. PLA 5.16±0.17s) were all 
adjudged to be faster with PLA supplementation in relation to the SB trial. Similarly, 
Subject 10 demonstrated faster CODS_total times with PLA when compared to SB 
supplementation (SB 4.86±0.22s vs. PLA 4.62±0.10s). Meanwhile, Subjects 3 and 5 
exhibited no differences in performance between the SB and PLA supplementation 
protocols. 
 111 
4.3.15. Gastro-Intestinal (GI) Ratings 
 
The difference between the SB and PLA supplementation protocols was not found to be 
statistically significant for either the mean or the total sum of GI ratings during the entire 
test overall. Nor was any significant difference found between the two trials at any of the 
four time points measured during the test (see Figure 4.10) – pre-warm up, pre-test, pre-
agility and post-test (p>0.05). In addition, the relationship between subjects’ GI ratings 
and each element of the performance test was low and not considered to be statistically 
relevant (r<0.620; r
2
<0.385; p>0.05 for all performance variables). 
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Figure 4.10: Mean GI ratings across each time point for each supplementation 
protocol (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
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4.3.16. Ratings of Muscle soreness 
 
No significant differences in perceived muscle soreness ratings were detected between 
the two supplementation protocols at any time point throughout the test (see Figure 4.11). 
The greatest muscle soreness ratings were recorded post-test, at which point mean ratings 
of 6.1 ± 1.8 and 5.1 ± 2.9 on a scale of 0-10 were observed for SB and PLA 
supplementation trials, respectively (p=0.363). 
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Figure 4.11: Mean muscle soreness ratings across each time point for each 
supplementation protocol (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
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4.3.17. Rating of Perceived Exertion (RPE) 
 
Similarly, RPE exhibited no significant differences between the SB and PLA 
supplementation trials at any time point (pre-warm up, p=1.000; pre-test, p=0.280; pre-
agility, p=0.462; and post-test, p=1.000) at the respective time points pre-test, pre-agility 
and post-test).  
 
 
4.3.18. Heart Rate 
 
As illustrated in Figure 4.12, no significant differences in mean (SB 137 ± 12 bpm vs. 
PLA 143 ± 10 bpm; p=0.204) or maximum (SB 192 ± 12 bpm vs. PLA 187 ± 8 bpm; 
p=0.181) recorded heart rates were observed between SB and PLA ingestion protocols 
over the course of the performance test. 
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Figure 4.12: Mean and maximum heart rate observed during performance test for 
each supplementation protocol (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
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4.3.19. Summary 
 
To summarise these results, no significant differences in any of the measured blood 
parameters were observed between chronic SB and PLA supplementation trials. Blood 
StdHCO3
-, pH, BE-Ecf, lactate, PCO2 and PO2 following chronic SB ingestion were 
found to be no different to the PLA trial at any time point (p>0.05). Similarly, no 
significant differences in performance variables were detected between SB and PLA 
trials (p>0.05). Furthermore, in relation to heart rate data, RPE, ratings of muscle 
soreness and GI, SB and PLA trials were not found to be significantly distinct from each 
other. Also, the effect of GI ratings on performance was deemed to be low (r<0.620; 
r
2
<0.385; p>0.05). The large degree of individual variability associated with SB ingestion 
was evident through the various individual differences in performance. The majority of 
subjects exhibited enhanced performance with PLA supplementation as opposed to SB. 
The following section (Section 4.4) will discuss these findings and present the potential 
underlying principles. 
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4.4. Discussion 
 
4.4.1. Introduction 
 
The findings of Study 1 revealed that chronic SB ingestion was not found to exhibit a 
statistically significant difference in any of the performance parameters measured. 
However, chronic SB ingestion, within Study 1, did show a significantly elevated mean 
StdHCO3
-
 after the first sprint of the repeated bout performance test when compared to 
the acute PLA condition (p=0.016). In addition, at certain points during the Study 1 
testing protocol, the difference between chronic SB ingestion and acute PLA relating to 
BE-Ecf was tending towards significance (immediately prior to the performance test 
p=0.083; and following Sprint 1 p=0.169). Furthermore, it has been widely documented 
that there is a high degree of individual variability associated with SB ingestion. This is 
believed to be due to adverse GI symptoms which may be experienced acutely following 
ingestion (Requena et al., 2005). Chronic SB ingestion has been purported to attenuate 
these symptoms (McNaughton and Thompson, 2001). In addition to this, there is an 
absence of scientific research concerning the effects of chronic SB ingestion on repeated 
bout high intensity performance. As a result, Study 2 sought to examine the effects of 
chronic SB supplementation on repeated bout high intensity intermittent activity.  
 
There are several other novel aspects to this study. In addition to the unique focus on the 
effects of chronic SB supplementation on repeated bout high intensity performance, this 
study incorporated a field-based test protocol which was designed to specifically replicate 
the physiological demands associated with a typical rugby union sevens match (Suarez-
Arrones et al., 2011). To the author’s knowledge, no other study has used such a test 
protocol. In addition, current research relating to rugby sevens has, thus far, been limited 
to analysis of either the incidence of injuries or the physiological demands of the sport 
(Higham et al., 2012; Suarez-Arrones et al., 2011; Suarez-Arrones et al., 2011; Fuller et 
al., 2010; Rienzi et al., 1999). Apart from one study examining the effects of Ramadan 
fasting on rugby sevens performance (Trabelsi et al., 2011), no other research has 
examined the effect of an intervention, such as SB ingestion, on performance in rugby 
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sevens. Similar to the findings reported in Study 1, the current study observed no 
significant differences in performance or blood parameters between chronic SB and PLA 
ingestion. The results of the current study would suggest that chronic SB supplementation 
has no ergogenic benefit in the performance of high intensity intermittent exercise 
indicative of the movement patterns and physiological demands of team field sports, in 
particular rugby sevens. 
 
 
4.4.2. Effects of Chronic SB Supplementation on Simulated Sports Performance 
 
A limited number of studies have examined the effect of chronic SB supplementation on 
simulated sports performance (Driller et al., 2012; Carr et al., 2012; Joyce et al., 2012). 
However, each of these three studies involve sport-specific performance in individual 
single bout events including 4-minute cycling time trial performance (Driller et al., 
2012), 2000m rowing performance (Carr et al., 2012) and 200m swim performance 
(Joyce et al., 2012). Carr et al. (2012) and Driller et al. (2012) published similar findings 
to the current study in relation to acid-base variables with chronic SB ingestion, 
demonstrating no significant increases in pH or StdHCO3
-
. Despite this, however, Driller 
et al. (2012) reported a significantly higher mean power output in a 4-minute time trial 
cycle ergometer test with chronic SB supplementation when compared to the PLA trial 
(427.5 ± 43.6 W and 418.3 ± 41.5 W, respectively; p=0.01). Evidence supporting the 
ergogenic effect of SB supplementation is generally accompanied by elevated StdHCO3
-
]and an increase in extracellular pH (McNaughton et al., 2008). Given that a significant 
performance enhancement was observed in the absence of pre-exercise alkalosis, Driller 
et al. (2012) proposed a potential alternative mechanism but failed to elaborate. However, 
within the aforementioned investigation (Driller et al., 2012), there was a trend towards 
an increased buffering capacity, as measured by blood StdHCO3
-
, with chronic SB 
ingestion when compared to the PLA trial (p=0.09). Therefore, it is, perhaps, more likely 
that the sample size (n=7) was insufficient to exhibit statistical significance in acid-base 
variables (Driller et al., 2012).  
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In the context of the current study, although the sample size was slightly higher (n=10) 
than Driller et al. (2012), this may provide some explanation for the lack of significant 
findings in blood or performance parameters for chronic SB ingestion in relation to the 
PLA trial. Previous research has also cited training status as a potential inhibiting factor 
to the ergogenic potential of SB ingestion due to an already enhanced buffering capacity 
(Peart et al., 2012). In contrast to the findings of the present study and previous research 
(Carr et al., 2012; Driller et al., 2012), Joyce et al. (2012) demonstrated a significant 
increase in plasma StdHCO3
-
, pH and BE-Ecf (p<0.05) following four days of chronic SB 
ingestion. However, this pre-exercise alkalosis did not translate into enhanced 200m 
swim performance (chronic SB 1:58.53 ± 0:05.64 vs. PLA 1:59.02 ± 0:05.82 mm:ss.00; 
p>0.05). Joyce et al. (2012) proposed that the training status of the athletes may have 
accounted for the inconsistent findings. As mentioned in Study 1, a meta-analysis by 
Peart and colleagues (2012) highlighted the potential effect of training status on the 
efficacy of SB supplementation. Ordinarily, throughout the current literature, studies 
involving trained subjects are statistically less likely to detect an ergogenic benefit with 
SB ingestion than those studies that have recruited untrained individuals (Peart et al., 
2012; Carr et al., 2011). Within the review by Peart et al. (2012), trained subjects were 
classified as athletes following a training plan relevant to their respective exercise task. In 
contrast, untrained participants made reference to healthy, recreationally active 
participants. In light of the high training status subjects involved in the current study, this 
may provide a potential explanation to the failure of the present study to demonstrate 
improved performance with chronic SB ingestion. Another possible justification for these 
results may be that this protocol of chronic SB ingestion was perhaps not conducive to 
causing a sufficient pre-exercise perturbation in acid-base balance. However, this SB 
dosage of 0.3g/kg BM per day had demonstrated a significant level of pre-exercise 
alkalosis in previous research (Joyce et al., 2012). 
 
Ingestion of SB chronically, in three or four multiple SB doses of 0.1g/kg BM throughout 
the day over 3-5 consecutive days prior to performance, has previously been reported to 
offset the gastro-intestinal side effects associated with SB ingestion (Burke et al., 2007; 
McNaughton and Thompson, 2001). This is corroborated by the current study, which 
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displayed no significant differences in GI disturbance between SB and PLA ingestion 
trials. RPE and muscle soreness were also no different between chronic SB ingestion and 
the PLA trial. Although no ergogenic benefits were recorded, chronic SB ingestion was 
not found to be detrimental to performance, as performance was maintained. This may 
represent a point of interest for athletes considering SB supplementation prior to 
performance. As previously mentioned in Study 1, it is widely acknowledged that there is 
a high degree of inter-individual variability and GI distress associated with acute SB 
ingestion (Requena et al., 2005; Carr et al., 2011). Therefore, chronic SB ingestion may 
provide a low-risk approach for athletes to experiment with this supplement.  
 
 
4.4.3. Chronic Supplementation Protocol 
 
Carr et al. (2012) employed a SB supplementation protocol of 0.5g/kg BM per day for a 
period of 3 days, resulting in no significant effect on induced alkalosis (StdHCO3
- values: 
chronic SB 28.0 ± 2.8 mmol/L vs. PLA 27.2 ± 2.5 mmol/L; p>0.05) or 2000m rowing 
performance (chronic SB 282 ± 65 W vs. PLA 277 ± 60 W; p>0.05) in comparison to the 
PLA trial. In contrast to Carr et al. (2012), McNaughton and Thompson (2001) dispensed 
an identical dose (0.5g/kg BM per day) but for a longer loading duration of 6 days and 
found significant pre-exercise alkalosis and performance enhancement in a single bout of 
90 second maximal cycling. In addition, Driller et al. (2012) administered a slightly lower 
chronic dose of 0.4g/kg BM per day for a period of 3 days, leading to no significant 
difference in acid-base balance but a significant improvement in 4 minute cycling time 
trial performance. Furthermore, Joyce et al. (2012) administered a dose of 0.3g/kg BM 
per day for a period of 4 days inducing a significant level of alkalosis but no 
improvement in 200m swim performance. The aforementioned research highlights the 
ambiguity surrounding chronic SB ingestion timing and dosage protocols and their 
respective outcomes in terms of performance.  
 
A chronic SB ingestion dose of 0.3g/kg BM per day, as implemented in the current study, 
has been shown to induce significant metabolic alkalosis, while minimising the potential 
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GI side effects (Joyce et al., 2012). The materialisation of GI symptoms often associated 
with higher doses (Peart et al., 2012) were deemed to be impractical for players in the 5 
days preceding a team field sport event , such as a rugby sevens tournament. The 5 day 
loading period selected was adjudged to be a realistic time frame for the loading period 
for team field sport athletes between tournament/match performances. As a result, this SB 
loading protocol of 0.3g/kg BM per day for 5 days functioned to most closely represent 
the preparation period prior to competitive team field sport performance. In accordance 
with previous studies (Joyce et al., 2012; McNaughton et al., 1992; Siegler et al., 2010), 
the dosage adopted within the current study has been shown to induce pre-exercise 
alkalosis, thereby providing the potential for an ergogenic effect on performance. 
However, this proved not to be the case in this study as no significant differences in 
blood StdHCO3
-
, pH, BE-Ecf or lactate were observed throughout the testing process 
between chronic SB and PLA trials. 
 
 
4.4.4. Summary 
 
Similar to Study 1, this research further highlights the contradictory nature of the area of 
SB supplementation. To date, few studies have investigated optimal SB loading strategies 
in terms of timing and dosage and the varied ingestion protocols utilised across different 
studies appear to contribute to the inconsistent results. The current study reported no 
significant shift in acid-base balance following chronic SB ingestion consisting of 5 days 
loading with 0.3g/kg BM per day. According to previous research (Peart et al., 2012; Carr 
et al., 2011; Matson and Tran, 1993), an enhancement of the body’s buffering capacity is 
the major mechanism by which SB ingestion may contribute to improved performance. In 
light of this, a performance enhancement in the absence of an alkaline environment 
within the blood would seem improbable. Although manifestation of pre-exercise 
alkalosis does not guarantee performance enhancement, a chronic SB ingestion protocol 
involving a higher daily dose may elicit a significant alkalotic response within the blood 
(McNaughton et al., 2001), thus enabling scientific examination of the proposed 
physiological mechanism. Several other factors such as training status, severity of GI 
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discomfort and specificity and nature of the performance test may also impact on the 
efficacy of chronic SB ingestion (Joyce et al., 2012; Peart et al., 2012). In addition, 
individual variability may play a key role in the outcome of studies involving SB 
ingestion. Although these other factors may have played a role, this study provides no 
evidence of any scientific basis for the use of this chronic SB supplementation protocol, 
involving the specific dosage and duration utilised, to enhance rugby sevens 
performance. Hence, the hypothesis that chronic SB supplementation would induce 
metabolic alkalosis and improve performance has been disproved.  
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Chapter 5 
 
Study Three: The Effects of Acute Sodium 
Bicarbonate Supplementation on High-Intensity 
Intermittent Performance using a Simulated 80 
minute Rugby-Specific Test Protocol in Elite 
Female and Sub-Elite Male Rugby Players 
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5.1. Introduction 
 
The aim of this study was to examine the effects of acute SB supplementation versus a 
PLA on high-intensity intermittent performance using a specifically designed test 
protocol developed to simulate typical demands of 80-minute rugby union match. The 
hypothesis involved predicted that acute SB supplementation would cause a significant 
increase in StdHCO3
-
, pH and BE-Ecf and result in enhanced high intensity intermittent 
performance, recovery during the 10 minute half time interval and subsequent 
performance when compared to a PLA trial. Following Study 2, it was evident that 
chronic SB supplementation appeared to show no effect on either blood or performance 
parameters. As a result, Study 3 returned to focus on acute SB supplementation, this time 
in relation to a field-based, sport-specific 15-a-side rugby test protocol. The study design, 
rationale and results are discussed within this chapter. 
 
 
5.2. Methods 
 
5.2.1. Subjects 
 
10 healthy male subjects and 10 healthy female subjects, aged between 18-35 years 
volunteered to participate in the study. Male subjects consisted of sub-elite trained club 
rugby players of Junior 2 level or above and were recruited from University and Leinster 
rugby clubs. Playing experience of each player was no less than 5 years. Female subjects 
consisted of elite trained rugby players currently involved at either International or 
Provincial level. Subjects were excluded from the study if they were suffering from any 
cardiovascular, pulmonary or metabolic diseases; if they were smokers; or if they had any 
injury or illness that may have affected their performance, as determined by a general 
health questionnaire (see Appendix B) completed by each subject prior to testing. Prior to 
participation in the study, each subject also provided written informed consent (see 
Appendix A3) Subjects were also excluded if they had used supplements or substances in 
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the previous six months that may have interfered with the results. All experimental 
procedures were approved by the Dublin City University Research Ethics Committee. 
 
 
5.2.2. Anthropometric Measurements 
 
Baseline anthropometric measurements were recorded prior to commencement of any 
physiological testing. Body mass (kg) was assessed barefoot and in minimal clothing 
using a portable digital scales and stadiometer (Seca, Germany). Data was reported to the 
nearest 0.1 kg. Standing height (cm) was measured to the nearest 0.1 cm using the same 
device. Body mass index (kg/m
2
) was calculated by dividing each individual’s body mass 
(kg) by the square of their height (cm). 
 
 
5.2.3. Overview of Experimental Design 
 
The study took place in the Exercise Physiology Research Hall (EPRH) in DCU. The 
study used a randomised, double-blind, cross-over design in which subjects performed an 
80-minute simulated rugby performance test on two separate occasions. Following a 
habituation session, each subject completed two experimental trials ingesting an acute 
pre-exercise dose of either 0.3g/kg BM of either SB or a PLA (maltodextrin). As with 
Study 1 and 2, every effort was made to standardise the pre-test procedures to ensure that 
any changes in performance could be attributed to the experimental protocol alone. 
Subjects were tested at the same time of day for both trials. Subjects were also requested 
to maintain normal dietary and hydration patterns for the 48 hours prior to Trial 1 and to 
replicate that for Trial 2. Alcohol, caffeine and strenuous exercise were not permitted in 
the 48 hours prior to the performance test. Within the habituation session, subjects were 
given a verbal and physical demonstration before three sub-maximal practice sets of the 
full performance test (described in Table 5.1). Subjects then completed 40 minutes (one 
half of a simulated match) of the 80 minute protocol at maximum effort. Subjects were 
 124 
deemed to be habituated to the protocol as they exhibited no further improvements in 
performance towards the latter stages of the performance test. 
 
 
5.2.4. Supplementation Protocol 
 
Subjects were required to fast for 3 hours prior to each performance test. 
Supplementation consisted of acutely ingesting either PLA (maltodextrin) or SB (0.3g/kg 
BM) subdivided into three doses of 0.1g/kg BM taken at 90, 60 and 30 minutes prior to 
the performance test. Therefore, subjects ingested the 0.1g SB/kg BM with 200mls water 
taken with each of the three doses (0.3g/kg BM in total) every 30 minutes for 90 minutes 
before commencement of the performance trial.  
 
 
5.2.5. Performance Test 
 
Immediately prior to testing, the subjects performed a standardised 10 minute 
standardised warm-up (see Section 4.2.5 and Illustration 4.1), which consisted of jogging 
at a self-selected pace, dynamic stretching, along with exercises involving explosive leg 
movements. The rugby match simulation test was completed in two 40 minute halves 
with a 10 minute half time period in between. The test consisted of 14 circuits of 11 
stations (see Table 5.1) involving the agility, speed, power and accuracy performance-
related activities designed to replicate the demands and specific movements involved in a 
rugby match situation. Players had 30 seconds to complete each station within the circuit. 
Once the task was completed at each station the player had the remainder of the 30 
seconds to rest and move to the next station. The test also included the passive and active 
recovery periods of standing and walking that comprise a large portion of games 
according to GPS match analysis (Cunniffe et al., 2009; Roberts et al., 2008; Deutsch et 
al., 1998). The 14 circuits were divided into two 40 minute halves with 7 circuits in the 
first half and 7 circuits in the second half, separated by a 10 minute half time period. 
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There was a 2 minute rest period after the fourth circuit of each half - circuit 4 in the first 
half and circuit 11 in the second half.  
 
All performance tasks were timed or quantified in an appropriate manner for that task 
(i.e. sprints were timed, jump height was measured, accurate passes were counted). The 
walking pace at stations 3, 5, 7 and 11 was set at 1.4 m/s in accordance with the pace 
observed for the action defined as walking in literature analysing match demands (Duthie 
et al., 2005, Roberts et al., 2008). The remaining stations consisted of the following 
activites: 
• Station 1: 20m sprint 
o Subjects performed a single, maximum effort 20m sprint. 
• Station 2: Reactive agility sprint (see Step 3 in Section 4.2.5 and Figure 4.2)  
• Station 3, 5, 7 and 11: Walk 
o Subjects were instructed to walk for 30 seconds at 1.4m/s. 
• Station 4: Power Phase 1 and 2 
o Phase 1: Standard vertical jump test – Subjects performed a vertical jump 
keeping hands on hips and legs straight in the air. 
o Phase 2: Weighted vertical jump – Subjects performed a vertical jump 
with a 10kg weight in each hand keeping arms and legs straight in the air. 
• Station 6: Modified T-test 
o Cones were placed in a “T” shape 5m away from each other. Subjects 
began lying face down at the start line (bottom of the “T”). Subjects 
sprinted 5m to the cone straight in front of them, then side shuffled 5m to 
the left cone and then 10m past the middle cone to the right cone, back to 
the middle cone and backwards to return to the start line. Subjects also 
completed a “down-up” at every cone, touching their chest off the ground 
and jumping back up. 
• Station 8: Tackle bag carry 
o Subjects were required to complete a shuttle of 4 x 5m sprint carrying a 
25kg tackle bag as fast as possible. 
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• Station 9: Passing accuracy 
o Subjects were required to pass a ball as rapidly as possible at a 1 x 1m 
target, which was placed 4m from the player and 1.5m above the ground. 
After each pass the subjects were instructed to pick up the next ball from 
the ground and repeat. Subjects were permitted 15 seconds to complete 
five passes. 
• Station 10: Agility shuttle 
o Cones were placed at 5m, 10m and 20m away from the start line. Subjects 
ran continuously out to each cone and back to the start line, performing as 
many shuttles as possible within 30 seconds.  
 
 
Table 5.1: Rugby-Specific 80 minute Performance Test Protocol 
Circuit Station Task Task Description Performance 
Measure 
1 20m Sprint 20m straight sprint Time 
2 Offensive Sprint Reactive Agility Sprint (RAS) Time 
3 Walk   
4 Power: Phase 1 
            Phase 2 
Vertical jump 
Weighted vertical jump 
Height 
Height 
5 Walk   
6 Defensive Sprint Modified T-test Time 
7 Walk   
8 Tackle Sprint 4 x 5m shuttle 25kg tackle bag 
carry 
Time 
9 Passing Accuracy Pass 5 balls at a target Number of target hits 
10 Agility shuttle 70m agility shuttle (5m, 10m and 
20m distances) 
Time 
11 Walk   
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Blood samples, muscle soreness, GI disturbance levels and RPE were taken at eight 
stages throughout each performance trial: pre-warm up, pre-first 40 minute half, after 
fourth circuit (Circuit 4) in first half, post-first 40 minute half, 5 minutes into half time, 
pre-second 40 minute half, after fourth circuit (Circuit 11) in second half, and post-
second 40 minute half. 
 
 
5.2.6. Blood Lactate Analysis 
 
Blood lactate sampling technique was identical to the description in Section 3.2.6. Blood 
lactate concentrations were recorded at the aforementioned blood sampling time points 
(See Section 5.2.5)  
 
5.2.7. Blood Gas Analysis 
 
Blood gas analysis, as previously described in Section 3.2.7 and was also carried out at 
identical time intervals to the blood gas analysis and subjective ratings. 
 
 
5.2.8. Heart Rate 
 
Heart rate (HR) was measured throughout each test and was recorded using recordable 
HR-enabled watches with heart rate monitors (Garmin, Kansas, USA).   
 
 
5.2.9. Subjective Ratings 
 
A level on the muscle soreness, GI disturbance and RPE scales (see Appendix C) were 
selected by each subject at the same time points as the blood sampling. The muscle 
soreness scale was a simple 11 point scale ranging from 0-10, which was used to allow 
subjects to rate their muscle soreness levels at different points before and after each 
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aspect of the testing..The RPE scale is the standard Borg scale ranging from 6-20 which 
is used to gauge the exercise intensity perceived by the subject. The GI disturbance scale 
was a six point scale ranging from 0-5. 
 
 
5.2.10. Statistical Analysis 
 
All statistical analyses were conducted using SPSS for Windows v. 16.0 (SPSS, USA). 
Paired sample t-tests were used to identify differences between the two conditions for all 
parameters. Linear regression of performance variables with mean GI symptoms for each 
condition was also performed in order to detect any relationship between performance 
and GI symptoms. A p value less than 0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 129 
5.3. Results 
 
5.3.1. Subject Characteristics 
 
The descriptive and anthropometric data for the 10 sub-elite male subjects are presented 
in Table 5.2. 
 
Table 5.2: Descriptive and Anthropometric Data Males (n=10) 
Variable Mean (± SD) 
Body mass (kg) 92.6 ± 7.4 
Height (cm) 182.3 ± 4.6 
Body mass index (kg/m2) 27.9 ± 2.9 
Age (yrs) 23.4 ± 2.6 
 
 
The descriptive and anthropometric data for the 10 elite female subjects are presented in 
Table 5.3. 
 
Table 5.3: Descriptive and Anthropometric Data Females (n=10) 
Variable Mean (± SD) 
Body mass (kg) 70.4 ± 9.6 
Height (cm) 168.2 ± 6.4 
Body mass index (kg/m
2
) 24.9 ± 2.8 
Age (yrs) 29 ± 3 
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5.3.2. Standard Bicarbonate (StdHCO3
-
)  
 
5.3.2.1 Sub-Elite Male Data 
 
No significant differences were detected between the two supplementation protocols for 
baseline levels of StdHCO3
-
 (p=1.000). As illustrated in Figure 5.1, StdHCO3
-
 were 
significantly greater with SB supplementation pre-warm up and post-warm up when 
compared with the PLA protocol. Immediately prior to the warm up, SB supplementation 
produced a mean StdHCO3
-
 of 28.94 ± 3.42 mmol/L as opposed to a mean of 24.30 ± 
1.02mmol/L recorded for PLA supplementation (p=0.021). This significantly elevated 
StdHCO3
-
 as a result of SB supplementation was maintained to the post-warm up 
sampling point ten minutes later, where p=0.028 (27.86 ± 3.79 vs. 23.22 ± 0.87mmol/L 
for SB and PLA supplementation, respectively). Although the mean StdHCO3
-
 visually 
appeared to be greater for SB than PLA supplementation at every other time point, no 
other significant differences between the two conditions were found throughout the 
remainder of the performance test (p=0.063 at post-test time point). 
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Figure 5.1: Standard bicarbonate levels across time points for each supplementation 
protocol (males), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
5.3.2.2 Elite Female Data 
 
As illustrated in Figure 5.2, StdHCO3
-
 levels were significantly greater with acute SB 
supplementation for all time points post-ingestion with the exception of 5 minutes into 
the half-time period along with the post-test measurements. The most significant 
difference between the two supplementation protocols occurred at the pre-warm up stage, 
at which point recorded StdHCO3
- consisted of 29.0 ± 1.8mmol/L and 23.2 ± 1.5mmol/L 
for SB and PLA supplementation, respectively (p=0.001) 
 
This significantly increased StdHCO3
-
 observed with SB supplementation when 
compared to PLA was maintained at the majority of sampling points including circuit 4 
(SB 23.0 ± 1.9 vs. PLA 17.5 ± 1.0mmol/L; p=0.016), half-time (SB 22.5 ± 1.3 vs. PLA 
17.8 ± 0.9mmol/L; p=0.041), pre-2
nd
 half (SB 26.8 ± 1.7 vs. PLA 19.7 ± 0.5mmol/L; 
* 
 * 
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p=0.011) and circuit 11 (SB 24.9 ± 2.6 vs. PLA 18.4 ± 0.5mmol/L; p=0.043). Although 
StdHCO3
-
 also appeared to remain elevated with SB supplementation at the remaining 
two blood sampling points (5 minutes into the half-time period and immediately post-
test), the difference between the two supplementation protocols was not found to be 
significant (p=0.054 and p=0.053 for each time point, respectively). 
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Figure 5.2: Standard bicarbonate levels across time points for each supplementation 
protocol (females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.3. Blood pH 
 
5.3.3.1 Sub-Elite Male Data 
 
Baseline blood pH was measured prior to supplementation and was identified as 7.40 ± 
0.01 pH units and therefore was within normal resting levels (p=1.000). Statistically 
 ** 
*  * 
 * 
* 
 * 
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significant differences in pH were found between SB and PLA supplementation protocols 
at blood sampling time points throughout the 80 minute rugby-specific protocol with the 
exception of post-circuit 4 and half-time (see Figure 5.3). The most significant difference 
between the two conditions was observed immediately prior to the 2
nd
 half (pre-2
nd
 half 
time point), where p=0.007 (7.43 ± 0.03 vs. 7.35 ± 0.01 pH units for SB and PLA 
supplementations, respectively). Comparable significant differences between SB and 
PLA supplementation protocols were also identified at pre-warm up (7.42 ± 0.03 vs. 7.37 
± 0.01 pH units, respectively; p=0.014), post-warm up (7.42 ± 0.03 vs. 7.37 ± 0.01 pH 
units, respectively; p=0.017), 5 minutes into half-time (7.40 ± 0.05 vs. 7.33 ± 0.02 pH 
units, respectively; p=0.030), post-circuit 11 (7.41 ± 0.04 vs. 7.35 ± 0.01 pH units, 
respectively; p=0.047) and post-test (7.41 ± 0.04 vs. 7.35 ± 0.02 pH units, respectively; 
p=0.037). 
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Figure 5.3: Comparison of blood pH levels across time points for each 
supplementation protocol (males), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 * * * * 
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5.3.3.2 Elite Female Data 
 
Baseline blood pH was measured prior to supplementation and was identified as 7.40 ± 
0.01 pH units and therefore was within normal resting levels (p=1.000). Statistically 
significant differences in pH were found between SB and PLA supplementation protocols 
at several time points throughout the 80 minute rugby-specific protocol (see Figure 5.4). 
Immediately prior to the warm up, supplementation with SB elicited a significantly 
higher mean pH value (7.47 ± 0.03 vs. 7.38 ± 0.02 pH units for SB and PLA, 
respectively; p=0.046). 
 
Blood pH was also found to be significantly different between the supplementation trials 
at Circuit 4. At this point, a mean value of 7.41 ± 0.007 pH units was reported for SB 
supplementation, whereas mean pH at Circuit 4 for the PLA trial was 7.31 ± 0.014 pH 
units (p=0.033). Following the 10 minute half-time period and immediately prior to the 
2nd half of the rugby specific protocol, pH was observed to be significantly different 
between SB and PLA supplementation (7.46 ± 0.006 vs. 7.36 ± 0.001, respectively; 
p=0.001). Similarly, at Circuit 11 (7.43 ± 0.03 vs. 7.33 ± 0.01; p=0.026) and also 
immediately post-test (7.42 ± 0.02 vs. 7.33 ± 0.01; p=0.016) i.e. for the remainder of the 
sampling time points in the 2
nd
 half, pH was found to be significantly higher with SB 
when compared to PLA supplementation. 
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Figure 5.4: Comparison of blood pH levels across time points for each 
supplementation protocol (females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.4. Base Excess in Extracellular Fluid (BE-Ecf) 
 
5.3.4.1 Sub-Elite Male Data 
 
No significant differences were detected between the two supplementation protocols for 
baseline levels of BE-Ecf (p=1.000). Following supplementation and immediately prior 
to the warm-up for the performance test, SB supplementation demonstrated a 
significantly higher BE-Ecf when compared with PLA supplementation (5.82 ± 4.12 vs. 
0.48 ± 1.55mmol/L for the respective supplementation protocols; p=0.020). SB 
supplementation appeared to elicit higher levels of BE-Ecf for all remaining blood 
 * 
 * 
 * 
 ** 
* 
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sampling time points (see Figure 5.5). However, this was not found to be significant at 
any other time point (p>0.065). 
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Figure 5.5: BE-Ecf across time points for each supplementation protocol (males), 
(n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
5.3.4.2 Elite Female Data 
 
No significant differences were detected between the two supplementation protocols for 
baseline levels of BE-Ecf (p=1.000). Following supplementation and immediately prior 
to the warm-up for the rugby-specific, high intensity, intermittent test, acute SB 
supplementation demonstrated a significantly higher BE-Ecf when compared with acute 
PLA supplementation (5.23 ± 2.10 vs. -1.33 ± 2.34mmol/L for the respective 
supplementation protocols; p=0.002). SB supplementation also elicited a significantly 
higher BE-Ecf response relative to PLA ingestion at 5 minutes into half time (1.30 ± 1.56 
vs. -7.15 ± 1.06mmol/L, respectively; p=0.026), pre-2
nd
 half (3.65 ± 0.92 vs. -5.70 ± 
* 
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0.01mmol/L, respectively; p=0.044) and following circuit 11 (0.13 ± 3.30 vs. -7.73 ± 
1.04mmol/L, respectively; p=0.040). The relationship between the two supplementation 
protocols followed a similar pattern at the remaining four time points (see Figure 5.6). 
However, this relationship, while tending towards significance, did not reach a 
statistically significant difference between SB and PLA supplementation, with the p value 
ranging from 0.055 to 0.089 for those remaining blood sampling time points during the 
test. 
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Figure 5.6: BE-Ecf across time points for each supplementation protocol (females), 
(n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
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5.3.5. Blood Lactate Analysis 
 
Baseline lactate levels were measured prior to supplementation and were identified as 
lying within the normal ranges prior to supplementation for all subjects (0.8-1.8mmol/L) 
with no significant differences between the groups (p = 1.000). Blood sampling was 
carried out at eight time points throughout the performance test: 
1. Pre-warm up  
2. Post-warm up  
3. Post-circuit 4 
4. Half-time  
5. 5 minutes into half-time   
6. Pre-2nd half  
7. Post-circuit 11  
8. Post-test  
 
5.3.5.1 Sub-Elite Male Data 
Blood lactate concentrations were found to be statistically greater with SB 
supplementation at several time points when compared to PLA trial (see Figure 5.7). 
These significant differences between SB and PLA trials occurred at post-warm up (1.70 
± 0.67 vs. 1.13 ± 0.31 mmol/L, respectively; p=0.024), half-time (7.20 ± 2.39 vs. 5.51 ± 
1.65 mmol/L, respectively; p=0.007), 5 minutes into half-time (6.47 ± 2.24 vs. 4.61 ± 
1.57 mmol/L, respectively; p=0.003), post-circuit 11 (6.83 ± 3.01 vs. 4.50 ± 1.73 
mmol/L, respectively; p=0.028) and post-test (6.76 ± 2.57 vs. 4.67 ± 1.67 mmol/L, 
respectively; p=0.006). In addition, although not reaching significance, there was a 
tendency towards a similar difference between the two trials at pre-warm up (p=0.098) 
and pre-2
nd
 half (p=0.064). 
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Figure 5.7: Comparison of blood lactate concentrations across time points for each 
supplementation protocol (males), (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.5.2 Elite Female Data 
 
Although blood lactate appeared to tending towards significance with SB 
supplementation following circuit 4 (p=0.078), no significant differences in blood lactate 
concentration were observed between the SB and PLA acute supplementation protocols at 
any of the eight sampling time points (see Figure 5.8). 
 * 
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Figure 5.8: Comparison of blood lactate concentrations across time points for each 
supplementation protocol (females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.6. Partial Pressure of CO2 (PCO2) 
 
5.3.6.1 Sub-Elite Male Data 
 
No significant differences between supplementation protocols were observed at any time 
point for PCO2 (see Figure 5.9). Pre-warm up PCO2 values were identified as 6.24 ± 0.67 
vs. 5.94 ± 0.45 kPa for SB and PLA supplementation, respectively (p=0.284). Post-test 
PCO2 values were recorded as 5.64 ± 0.71 vs. 5.06 ± 0.63 kPa for SB and PLA 
supplementation respectively, displaying a tendency towards significance (p=0.089).  
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Figure 5.9: PCO2 (kPa) across time points for each supplementation protocol 
(males), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.6.2 Elite Female Data 
 
Similarly no significant differences in PCO2 were observed between trials at any time 
point (see Figure 5.10). However, immediately prior to the 2
nd
 half, the difference 
between SB and PLA trials was approaching a significant level (5.20 ± 0.16 vs. 4.5 ± 
0.39 kPa for SB and PLA respectively; p=0.090). 
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Figure 5.10: PCO2 (kPa) across time points for each supplementation protocol 
(females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.7. Partial Pressure of O2 (PO2) 
 
5.3.7.1 Sub-Elite Male Data 
 
No significant differences in PO2 were detected at any time point between SB and PLA 
trials (see Figure 5.11). Pre-warm up PO2 values were identified as 10.52 ± 1.06 vs. 
10.68 ± 1.31 kPa for SB and PLA supplementation, respectively (p=0.763). Post-test PO2 
values were recorded as 10.58 ± 0.61 vs. 11.10 ± 0.73 kPa for SB and PLA 
supplementation, respectively (p=0.261).  
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Figure 5.11: PO2 (kPa) across time points for each supplementation protocol 
(males), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.7.2 Elite Female Data 
 
As with the sub-elite male subjects, no significant differences in PO2 were detected at any 
time point between SB and PLA trials for the elite females (see Figure 5.12).  
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Figure 5.12: PO2 (kPa) across time points for each supplementation protocol 
(females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
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5.3.8. Performance Analysis Overview 
 
Eight performance measures from the rugby-specific circuit protocol were analysed with 
the mean group and individual results for the 1
st
 and 2
nd
 halves outlined below. These 
performance measures included: 
1. 20m sprint 
2. Reactive agility speed (RAS) including its 3 components: RAS_15m sprint, 
RAS_reaction and RAS_total 
3. Power 1: Vertical jump 
4. Power 2: Weighted vertical jump 
5. Defensive speed agility T drill 
6. Tackle bag carry shuttle 
7. Passing accuracy 
8. Shuttle test 
 
 
5.3.9. Mean Rugby-Specific Circuit Performance 
 
The two conditions (SB and PLA) were compared using mean performance scores at 
each station of the circuit for 1st and 2nd half combined (all 14 circuits), mean scores for 
1
st
 half only, mean scores for 2
nd
 half only, mean of scores recorded in the first two 
circuits, mean of scores recorded in the last two circuits, the difference between the mean 
of the first two circuits and the last two circuits.  
 
5.3.9.1 Sub-Elite Male Data 
 
From analysis of the mean performance results from all fourteen circuits throughout the 
entire 80 minute performance test (see Figure 5.13), it was determined that there were no 
significant differences in any element of performance between SB and PLA 
supplementation (p>0.263). 
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Figure 5.13: Mean performance scores at each station over all fourteen circuits of 
the 80-minute protocol for SB and PLA supplementation protocols (males), (n=10, 
values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
Having observed no significant differences in performance between the two 
supplementation protocols over the course of the test as a whole, performance within 
each 40 minute half was then analysed separately. As shown in Figure 5.14 below, no 
significant differences in performance were identified between the two supplementation 
protocols. PLA supplementation seemed to record a slightly higher mean jump height for 
Power 2 (weighted vertical jump). However, this was not found to be significantly 
different to the SB condition (p=0.060 for Power 2 and p>0.203 for all other performance 
tasks). 
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Figure 5.14: Mean 1
st
 half performance scores for each task of the circuit for each 
supplementation protocol (males), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
As with the mean 1st half performance scores, no significant differences were detected 
between the two supplementation protocols upon analysis of the 2
nd
 half performance, 
where p>0.286 for all performance tasks (see Figure 5.15). 
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Figure 5.15: Mean 2
nd
 half performance scores for each task of the circuit for each 
supplementation protocol (males), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
As a marker of fatigue index, the mean of the first two circuits and the mean of the last 
two circuits in both trials were investigated (see Figure 5.16). No significant differences 
in performance were found between the SB and PLA trials for the mean of the first two 
circuits across (p>0.163). Similarly, no significant differences were observed between 
supplementation protocols for the mean of the last two circuits (p>0.347).  
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Figure 5.16: A comparison of the mean performance scores for the first two circuits 
and the last two circuits for both supplementation trials (males), (n=10, values 
denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
The difference between the mean of the first two circuits and the mean of the last two 
circuits was also investigated. Although a seemingly notable discrepancy between the 
mean of the first two and last two circuits appears for Power 2 in Figure 5.17, this 
difference did not reach significance (p=0.076). Therefore, no significant differences 
between the first two and last two circuits were identified across trials (p>0.118) for all 
performance tasks.  
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Figure 5.17: The difference between the mean of the first two circuits and the mean 
of the last two circuits across both supplementation trials (males), (n=10, values 
denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.9.2 Elite Female Data 
 
Although the difference in weighted vertical jump height (Power 2) between the two 
trials appeared to be tending towards significance (p=0.062), jump height was not 
adjudged to be significantly higher with SB when compared to PLA supplementation 
(20.93 ± 2.91 vs. 20.35 ± 2.74cm). As a result, only one significant difference between 
the two supplementation protocols was identified across the mean of all fourteen circuits 
of the 80 minute performance test (see Figure 5.18). Passing accuracy was found to be 
significantly more accurate over the course of the test in the PLA trial as opposed to with 
SB supplementation (SB 2.68±0.62 vs. PLA 2.99 ± 0.55 accurate passes out of five; 
p=0.009). 
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Figure 5.18: Mean performance scores at each station over all fourteen circuits of 
the 80-minute protocol for both supplementation protocols (females), (n=10, values 
denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
Following investigation of the mean scores for each station of the circuit in the first half 
and second half separately, just one point of significance in the each of the halves was 
observed between the two supplementation protocols. Within the 1
st
 half (see Figure 
5.19) the mean vertical jump height (Power 1) was found to be significantly greater with 
PLA supplementation when compared to SB. (SB 26.0 ± 2.9 vs. PLA 27.1 ± 3.3cm; 
p=0.010).  
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Figure 5.19: Mean 1
st
 half performance scores for each task of the circuit for each 
supplementation protocol (females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
Within the 2nd half (see Figure 5.20), no significant differences between the mean results 
for the two supplementation protocols were observed with the exception of a significantly 
greater level of passing accuracy with the PLA protocol (3.1 ± 0.4 accurate passes out of 
five) in relation to SB supplementation (2.7 ± 0.6 accurate passes out of five), where 
p=0.022. 
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Figure 5.20: Mean 2
nd
 half performance scores for each task of the circuit for each 
supplementation protocol (females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
As a marker of fatigue index, the mean of the first two circuits and the mean of the last 
two circuits in both trials were investigated (see Figure 5.21). No significant differences 
in performance were found between the mean of the first two circuits across SB and PLA 
trials. Similarly, no significant differences were observed between supplementation 
protocols for the mean of the last two circuits (p>0.05).  
 * 
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Figure 5.21: A comparison of the mean performance scores for the first two circuits 
and the last two circuits for both supplementation trials (females), (n=10, values 
denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
Subsequently, as illustrated in Figure 5.22, the difference between the mean of the first 
two circuits and the mean of the last two circuits was then explored. A significantly 
greater difference between the first two and last two circuits was identified with the SB 
trial when compared to the PLA trial for the defensive sprint T drill only (SB 0.75 ± 0.77 
vs. PLA 0.43 ± 0.70; p=0.012). No other significant differences between the mean of the 
first two and the mean of the last two circuits were detected across trials.  
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Figure 5.22: The difference between the mean of the first two circuits and the mean 
of the last two circuits across both the SB and PLA trials (females), (n=10, values 
denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
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5.3.10. Individual Performance 
 
5.3.10.1. Sub-Elite Male Data 
 
Following individual analysis, out of the ten sub-elite male subjects, four subjects (40%) 
demonstrated an enhanced performance in some performance tasks with SB 
supplementation; two subjects (20%) experienced an increased level of some 
performance components with PLA supplementation; two subjects (20%) displayed 
elevated performance levels with both supplementation protocols for different 
performance tasks within the circuit; and the remaining two subjects (20%) showed no 
differences between the supplementation protocols. As in Section 4.3.14, means and 
standard deviations presented are based on all fourteen circuits completed by one 
individual subject. 
 
Subject 8 encountered greater performance outcomes in six performance measures with 
SB when compared with PLA supplementation. 20m sprint (3.89 ± 0.13 vs. 4.03 ± 0.06s, 
respectively), RAS_15m (3.13 ± 0.04 vs. 3.37 ± 0.018s respectively), RAS_total (4.76 ± 
0.06 vs. 5.09 ± 0.22s, respectively), Power 1 (29.13 ± 0.97 vs. 27.94 ± 1.18cm, 
respectively), the defensive T agility drill (12.09 ± 0.30 vs. 12.71 ± 0.58s, respectively) 
and the tackle bag carry shuttle (8.30 ± 0.23 vs. 8.71 ± 0.32s, respectively) all revealed 
more favourable mean performance scores with the experimental condition as opposed to 
the PLA. 
 
Similarly, differences in performance were also found between the two supplementation 
protocols with Subject 1. SB supplementation elicited enhanced mean performance 
outcomes in RAS_15m (3.03 ± 0.08 vs. 3.18 ± 0.16s, respectively), RAS_total (4.47 ± 
0.12 vs. 4.64 ± 0.19s, respectively), Power 2 (36.80 ± 2.43 vs. 32.09 ± 2.80cm 
respectively), the defensive T agility drill (9.92 ± 0.42 vs. 10.77 ± 0.40s, respectively) 
and the tackle bag carry shuttle (10.56 ± 0.50 vs. 11.18 ± 0.51s, respectively) when 
compared with PLA supplementation. Subject 3 also recorded faster RAS_15m times 
with SB supplementation in comparison to PLA (3.16 ± 0.15 vs. 3.23 ± 0.16s, 
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respectively). In addition, Subject 5 displayed a beneficial performance outcome with SB 
supplementation with respect to the PLA in the agility shuttle task (17.07 ± 0.23 vs. 17.53 
± 0.21s for each respective supplementation protocol). 
 
In contrast, subject 6 and 9 exhibited superior performance outcomes with PLA as 
opposed to SB supplementation during certain elements of the performance test. Subject 
6 demonstrated faster times in the 20m sprint (SB 3.64 ± 0.11 vs. PLA 3.51 ± 0.08s), 
RAS_total (SB 4.70 ± 0.20 vs. PLA 4.50 ± 0.10s), RAS_reaction (SB 1.61 ± 0.07 vs. 
PLA 1.50 ± 0.06s), the defensive T agility drill (SB 11.52 ± 0.45 vs. PLA 10.75 ± 0.28s) 
and the agility shuttle (SB 17.67 ± 0.56 vs. PLA 16.63 ± 0.55s), along with greater jump 
height in Power 1 (SB 31.90 ± 2.88 vs. PLA 34.33 ± 1.98cm) throughout the course of 
the PLA trial when compared to the SB trial. Comparably, the PLA supplementation 
protocol yielded greater results in Subject 9 in four of the same performance measures as 
Subject 6. 20m sprint times (SB 3.37 ± 0.13 vs. PLA 3.25 ± 0.06s), RAS_15m times (SB 
3.01 ± 0.07 vs. PLA 2.93 ± 0.08s), RAS_total times (SB 4.62 ± 0.13 vs. PLA 4.48 ± 
0.14s) and Power 1 jump height (SB 43.29 ± 1.89 vs. PLA 45.63 ± 2.35 s) were found to 
be improved with the PLA trial as opposed to the SB condition for this subject. 
 
Subjects 4 and 7 experienced differences between the two trials, with performance 
enhancements being elicited by both PLA and SB supplementation with respect to each 
other for different elements of performance. Subject 4 recorded a greater mean 
RAS_reaction time (1.52 ± 0.03 vs. 1.58 ± 0.07s for SB and PLA, respectively) over the 
course of the 14 circuits in the SB trial when compared to the PLA. However, the same 
subject produced reduced sprint times for the 20m sprint (3.47 ± 0.05 vs. 3.38 ± 0.08s for 
SB and PLA, respectively), defensive T agility drill (10.43 ± 0.33 vs. 10.14 ± 0.21 for SB 
and PLA respectively) and agility shuttle (16.42 ± 0.31 vs. 16.06 ± 0.17 s for SB and 
PLA, respectively), along with significantly greater jump height in Power 2 (24.55 ± 1.42 
vs. 25.86 ± 1.49 cm for SB and PLA, respectively) in the PLA trial as opposed to the SB 
trial. 
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Similarly, Subject 7 experienced enhanced jump height in Power 1 (SB 38.45 ± 2.84 vs. 
PLA 40.95 ± 2.61cm) with PLA when compared to the SB trial. However, SB 
supplementation, as opposed to PLA supplementation, resulted in enhanced performance 
in the defensive T agility drill (SB 9.17 ± 0.25 vs. PLA 9.59 ± 0.35s) and the agility 
shuttle task (SB 16.64 ± 0.62 vs. PLA 17.01 ± 0.42). Subjects 3 and 10 displayed no 
differences between the two supplementation protocols for any performance measure 
quantified. 
 
5.3.10.2. Elite Female Data 
 
Following individual analysis, out of the ten elite female subjects, three subjects (30%) 
demonstrated an enhanced performance in some performance elements with SB 
supplementation only; three subjects (30%) experienced an increased level of some 
performance components with PLA supplementation only; and the remaining four 
subjects (40%) displayed elevated performance levels with both supplementation 
protocols for different performance tasks within the circuit. 
 
For Subject 6, SB supplementation elicited enhanced performance in the 20m sprint, 
RAS_15m and RAS_total, along with a higher vertical jump in Power 1 when compared 
to PLA supplementation. Similarly, Subject 5 experienced reduced sprint and reaction 
times for the 20m sprint and the RAS_reaction, respectively. In addition, SB 
supplementation resulted in a higher mean weighted jump height in Power 2 along with a 
faster agility shuttle speed when compared to the PLA protocol. 
 
In contrast to these three subjects, Subject 3 demonstrated improved times with the PLA 
supplementation protocol for the 20m sprint, defensive T agility drill, tackle bag carry 
shuttle and agility shuttle. Subject 4 also recorded greater levels of performance in the 
PLA trial with respect to SB for the 20m sprint, RAS_reaction, defensive T agility drill, 
passing accuracy and the agility shuttle. Furthermore, mean performance enhancements 
were also observed in the PLA trial for Subject 8 during the 20m sprint, Power 1, 
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defensive T agility drill, tackle bag carry shuttle and the agility shuttle, when compared to 
SB supplementation. 
 
The remaining four subjects experienced differences between the two trials, with 
performance enhancements being elicited by both PLA and SB supplementation with 
respect to each other for different elements of performance. Subject 1 recorded greater 
jump height in both Power 1 and Power 2 in the SB trial when compared to the PLA. 
However, the same subject produced faster sprint times for the agility shuttle and 
RAS_15m in the PLA trial as opposed to the SB trial. Subject 2 exhibited a faster mean 
defensive T agility time with PLA when compared to SB supplementation. However, SB 
supplementation produced enhanced performance in the tackle bag carry and agility 
shuttle. Similarly, Subject 9 generated a faster RAS_reaction with PLA when compared 
to SB supplementation. However, a faster mean tackle bag carry shuttle was recorded by 
the same subject with SB supplementation as opposed to PLA. Finally, Subject 10 
obtained a greater mean passing accuracy in the PLA trial versus the SB trial. However, 
SB supplementation was associated with increased performance in Power 1, Power 2, 
defensive T agility drill and the agility shuttle, when compared to the PLA protocol. 
 
 
5.3.11. Gastro-Intestinal (GI) Ratings 
 
5.3.11.1. Sub-Elite Male Data 
 
Although SB supplementation appeared to generate higher ratings of gastro-intestinal 
discomfort (see Figure 5.23), no significant mean differences were found between the 
two supplementation protocols at any time point throughout the performance test 
(p>0.537). As with the elite female subjects, the potential effect of GI discomfort 
experienced by subjects on performance during the trials was assessed using a linear 
regression analysis. Within the SB supplementation trial, the relationship between 
subjects’ GI ratings and each element of the performance test was low and not considered 
to be statistically relevant (p>0.306). However, there was a significant association 
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between mean GI ratings and mean performance in the PLA supplementation trial. A 
significant relationship was found in the PLA supplementation condition between mean 
GI ratings and performance in the 20m sprint (p=0.020, r=0.749, r
2
=0.562) RAS_15m 
(p=0.038, r=0.695, r
2
=0.484), RAS_reaction (p=0.017, r=0.762, r
2
=0.580), RAS_total 
(p=0.007, r=0.816, r2=0.665), defensive T agility drill (p=0.004, r=0.843, r2=0.710) and 
the agility shuttle (p=0.005, r=0.838, r
2
=0.702). 
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Figure 5.23: Mean GI ratings across each time point for each supplementation 
protocol (males), (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
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5.3.11.2. Elite Female Data 
 
Ratings of GI discomfort between the two trials were found to be relatively similar at the 
majority of time points (see Figure 5.24) and, consequently, no significant differences 
were found between the two supplementation protocols at seven of the eight time points. 
However, immediately following the fourth circuit of the 1
st
 half (Circuit 4), SB 
supplementation demonstrated a significantly greater mean GI rating than the PLA trial 
(SB 0.5 ± 0.53 vs. PLA 0.1 ± 0.32 on a GI rating scale of 0-5), where p=0.037. 
  
To assess the potential effect of GI discomfort experienced by subjects on performance 
during the trials, a linear regression analysis was conducted. Within the PLA trial, the 
relationship between subjects’ GI ratings and each element of the performance test was 
not considered to be statistically relevant (p>0.093). However, there was a significant 
association between mean GI ratings and mean performance in the SB supplementation 
trial. A regression analysis was conducted between mean GI ratings and mean 
performance scores in each of the performance elements of the 80-minute rugby specific 
protocol performance test. A significant positive relationship was found between mean 
GI ratings and RAS_15m (r=0.678, r
2
=0.460, p=0.031,), RAS_reaction, r=0.715, 
r
2
=0.511, (p=0.020), RAS_total (, r=0.695, r
2
=0.483, p=0.026), defensive T agility drill 
(r=0.826, r2=0.681, p=0.003), tackle bag carry shuttle (r=0.776, r2=0.603, p=0.014) and 
the agility shuttle (r=0.798, r
2
=0.637, p=0.006) in the SB supplementation condition i.e. 
the greater the GI rating, the lower the performance level. 
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Figure 5.24: Mean GI ratings across each time point for each supplementation 
protocol (females), (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
 
5.3.12. Muscle Soreness 
 
5.3.12.1 Sub-Elite Male Data 
 
No significant differences in perceived muscle soreness ratings were detected between 
the two supplementation protocols at any time point throughout the test (see Figure 5.25). 
Pre-warm up muscle soreness ratings of 0.9 ± 1.0 and 0.5 ± 0.7 on a muscle soreness 
scale of 0-10 were recorded for PLA and SB supplementation trials, respectively 
(p=0.104) The greatest muscle soreness ratings were recorded post-test, at which point 
mean ratings of 4.2 ± 2.3 and 4.2 ± 2.2 on a muscle soreness scale of 0-10 (Appendix C) 
were observed for PLA and SB supplementation trials, respectively (p=1.000). 
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Figure 5.25: Mean muscle soreness ratings across each time point for each 
supplementation protocol (males), (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.12.2 Elite Female Data 
 
No significant differences in perceived muscle soreness ratings were detected between 
the two supplementation protocols at any time point throughout the test (see Figure 5.26). 
The greatest muscle soreness ratings were recorded post-test at which point mean ratings 
of 4.3 ± 2.2 and 4.0 ± 1.9 on a muscle soreness scale of 0-10 were observed for SB and 
placebo supplementation trials respectively (p=0.734). 
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Figure 5.26: Mean muscle soreness ratings across each time point for each 
supplementation protocol (females), (n=10, values denote mean ± SD)  
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.13 RPE 
 
5.3.13.1 Sub-Elite Male Data 
 
Similarly, RPE exhibited no significant differences (see Figure 5.27) between the PLA 
and SB supplementation trials at any time point (p>0.141). 
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Figure 5.27: Mean RPE across each time point for each supplementation protocol 
(males), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
5.3.13.2 Elite Female Data 
 
Similarly, RPE exhibited no significant differences (see Figure 5.28) between the PLA 
and SB supplementation trials at any time point (p>0.143). 
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Figure 5.28: Mean RPE across each time point for each supplementation protocol 
(females), (n=10, values denote mean ± SD) 
(*p<0.05, **p<0.01, significant difference between treatments, paired sample t-test) 
 
 
 
5.3.14. Heart Rate 
 
 
5.3.14.1 Sub-Elite Male Data 
 
 
No significant differences in mean (SB 139 ± 13 vs. PLA 134 ± 11 bpm; p=0.266) or 
maximum (SB 183 ± 12 bpm vs. PLA 178 ± 9 bpm; p=0.198) recorded heart rates were 
observed between SB and PLA ingestion protocols over the course of the performance 
test. 
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5.3.14.2 Elite Female Data 
 
Similarly, no significant differences in mean (SB 137 ± 9 vs. PLA 136 ± 9 bpm; p=0.884) 
or maximum (SB 177 ± 10 vs. PLA 177 ± 11 bpm; p=0.932) heart rates were observed 
between trials for the elite female group. 
 
 
5.3.15. Summary 
 
From statistical analysis, several points of significance were identified between SB and 
PLA trials (p<0.05). Within the blood variables measured, SB ingestion in sub-elite 
males when compared to PLA ingestion displayed a significantly higher level of 
StdHCO3
-
 at pre-warm up and post-warm up only; significantly elevated pH at all time 
points apart from following circuit 4 and at half time; significantly greater BE-Ecf at pre-
warm up only; and significantly higher blood lactate concentrations at post-warm up, half 
time, 5 minutes into half time, post-circuit 11 and post-test. Elite females demonstrated a 
similar response with SB supplementation eliciting significantly greater StdHCO3
-
 levels 
at all time points with the exception of 5 minutes into half time and post-test; significant 
elevations in pH at pre-warm up, circuit 4, pre-2
nd
 half, circuit 11 and post-test; 
significantly greater BE-Ecf levels at pre-warm up, 5 minutes into half time, pre-2
nd
 half 
and following circuit 11; and no significant difference in blood lactate concentration but a 
trend towards significance at circuit 4 (p=0.078), when compared to PLA ingestion. No 
significant differences in PCO2 or PO2 were observed. 
 
In terms of performance, sub-elite males recorded no significant differences in 
performance between trials. In the elite female group, across the mean of all fourteen 
circuits, PLA ingestion resulted in significantly greater passing accuracy when compared 
to SB ingestion (p=0.009). Following analysis of mean 1
st
 half performance, the elite 
females recorded a significantly greater jump height in Power 1 with PLA when 
compared to SB ingestion (p=0.010). Upon examination of 2
nd
 half mean performance, 
the elite female group displayed significantly greater passing accuracy with PLA as 
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opposed to SB ingestion (p=0.022). In addition, the difference between the mean of the 
first two and mean of the last two circuits was found to be significantly greater in the SB 
trial than the PLA trial (p=0.012). 
 
GI disturbances were significantly greater with SB ingestion at one time point (circuit 4) 
in the elite female group (p=0.037). No significant differences in mean GI disturbance 
were recorded for males. A significant relationship was found between mean GI ratings 
and performance in the SB trial for the elite females. In contrast, the sub-elite males 
produced a significant relationship between mean GI ratings and performance in the PLA 
trial and not the SB trial. No significant differences in heart rate, RPE or muscle soreness 
were recorded between trials. A high degree of individual variability was also revealed. 
These results will be discussed in the following section. 
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5.4. Discussion 
 
5.4.1. Introduction 
 
Rugby union, along with many other team field sports, is characterised by the 
performance of repeated bouts of high intensity exercise interspersed with periods of 
active recovery of varying duration. The purpose of this study was to examine the effect 
of acute SB ingestion on this type of sport-specific performance. Results of this study 
indicated that, while acute SB ingestion had the capacity to induce pre-exercise alkalosis 
in both elite females and sub-elite males, conflicting findings were recorded in relation to 
the ergogenic benefit to rugby union-specific performance resulting from this 
perturbation in acid-base balance. This may indicate that, despite these positive ergogenic 
effects, the performance in activities typically associated with the specific physiological 
demands of rugby union, and other similar team field sports, may not benefit from acute 
SB ingestion. 
 
 
5.4.2. Sport-Specific Simulated Match-Play 
 
Previous research has suggested that the nature of the exercise protocol employed by 
research studies investigating SB ingestion may be critical in determining an ergogenic 
effect (Matson and Tran 1993). The mechanism by which SB ingestion is purported to 
operate is centred on an enhancement of blood buffering capacity (Siegler et al., 2010). 
This enhanced buffering capacity facilitates the removal of the excess H
+
 accumulation 
associated with the provision of energy from glycolysis during high intensity exercise 
(Robergs et al., 2005). In order for SB ingestion to have the potential to enhance the 
buffering capacity and, consequently, performance, the type of exercise protocol utilised 
must involve a sufficient degree of anaerobiosis (Matson and Tran, 1993). Depending on 
the exercise intensity and duration required at any given time point within a rugby union 
match, all three energy systems contribute towards the provision of ATP for muscular 
contraction (Nicholas, 1997). However, the typical high intensity, short duration bouts 
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associated with rugby union ensure a heavy reliance on anaerobic glycolysis for energy 
production (Deutsch et al. 1998). Given the lack of significant findings in relation to the 
performance outcome in the current study, however, it is possible that the recovery 
periods within the sport of rugby union may render the potential effect of enhanced 
buffering unnoticeable (Cunniffe et al., 2009). 
 
In an attempt to replicate the physiological demands associated with an 80 minute 15-a-
side rugby union match, a specifically designed test protocol was developed as the 
performance test for this study. A thorough review of the scientific literature revealed 
only one other study (Cameron et al., 2010) examining the effects of SB ingestion on 
rugby-specific exercise. However, this exercise protocol involved just 9 minutes of 
rugby-specific activity, followed by 10 x 40m maximal intensity sprints every 30 
seconds. Cameron et al. (2010) stated that this rugby-specific repeat-sprint performance 
test was designed to be applicable, based on time motion analysis, to both the sevens and 
15-a-side codes of rugby union. However, given the stark differences between the 
physiological demands of rugby sevens and 15-a-side rugby union, the evidence within 
the literature does not support this supposition (Suarrez-Arrones et al., 2012; Cunniffe et 
al., 2009). The researchers (Cameron et al., 2010) conceded that the protocol, designed 
by a strength and conditioning trainer, did not involve the typical rest intervals associated 
with rugby union. Therefore, Cameron et al. (2010) concluded that the 9-minute rugby-
specific training session represented 40-60 minutes of 15-a-side rugby union activity or, 
alternatively, the initial 9 minutes of a 14 minute rugby sevens match. While other studies 
have employed similar 80-minute rugby-specific protocols (Hamlin et al., 2008; Roberts 
et al., 2010), the current study is the first to the author’s knowledge, to examine the 
effects of SB ingestion on such a protocol.  
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5.4.3. Subject Characteristics 
 
Another distinctive aspect of the current research is the participation of elite female 
athletes. From examination of the literature up to 1993, a review by Matson and Tran 
(1993) calculated that the contribution of females athletes to research studies involving 
SB ingestion constituted just 3% of the total subject population (9 females out of a total 
of 295 subjects). In a more recent meta-analysis by Peart et al. (2012), data was presented 
for 47 females out of a total of 395 subjects across forty research articles (12% 
approximately). As a result, the recommendation to include female athletes in further SB 
investigations was suggested to examine the effect of SB ingestion on females and also to 
analyse any potential gender differences in response to SB ingestion (Matson and Tran, 
1993; Peart et al., 2012). In addition, the aforementioned review paper (Matson and Tran, 
1993), along with Peart et al. (2012) advocated the necessity for future research to 
explore the effect of SB ingestion on highly trained athletes in competitive performance. 
The current study aimed to address both of these issues through the recruitment of elite 
female subjects (currently playing at an international or interprovincial standard). 
 
As previously mentioned (see Section 5.2.1), a total subject group of twenty athletes, 
comprising of ten elite females and ten sub-elite males participated in the current study. 
As cited in Study 1 (see Section 3.4) and 2 (see Section 4.4) of this work, sample size 
may have contributed towards the failure to demonstrate significant performance 
enhancements following SB supplementation. In order to attempt to curtail this issue, a 
larger contingent of subjects were recruited for the present study. Matson and Tran 
(1993) reported the sample size range within investigations involving SB ingestion to lie 
between 4 and 23, with a mean sample size of 8 ± 2 subjects. As a result, the sample size 
of twenty subjects selected for the current study sits near the upper limit within the range 
of previous studies completed.  
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5.4.4. Effects of SB Ingestion on Blood Parameters 
 
The main findings of the current study demonstrated that, while both males and females 
responded relatively similarly to acute SB ingestion with regard to blood pH, StdHCO3
- 
and BE-Ecf (see Section 5.3.2, 5.3.3 and 5.3.4. respectively), significant differences in 
certain performance variables were identified (see Section 5.3.9). From these results it 
appears that 0.3g/kg BM of SB was sufficient to induce metabolic alkalosis in both males 
and females. In support of this data, previous research has exhibited a significantly higher 
alkalinity in trained males (Cameron et al., 2010) and elite female athletes (Tan et al., 
2010). Within the current study, there was, however, some dissimilarity between males 
and females in terms of post-exercise blood lactate response. In accordance with the 
majority of the literature (Requena et al., 2005; Peart et al., 2012), the male subjects in 
the current study recorded significantly higher blood lactate concentrations with SB 
ingestion at several time points including post-warm up, half-time, 5 minutes into half-
time, post-circuit 11 and post-test (p<0.05). This finding is widely supported in the 
research, particularly in investigations involving high intensity exercise with a heavy 
reliance on anaerobic metabolism (Bishop et al., 2004; Requena et al., 2005; Kupcis et 
al., 2012). Kupcis et al. (2012) reported peak blood lactate concentrations of 13.4 ± 1.7 
vs. 11.9 ± 1.9 mmol/L following SB versus PLA supplementation prior to 2000m rowing 
performance; p=0.001). An increase in the activity of the lactate/H+ co-transporter, 
promoting an increased efflux of lactate from the muscle cells, is purported to be the 
mechanism underpinning the increased post-exercise lactate concentrations observed with 
SB ingestion (Juel, 1998; Hollidge-Horvat et al., 2000).  
 
Within the current study, although there was a trend towards significance at one point 
post-circuit 4 (p=0.078), no significant elevations in post-exercise blood lactate 
concentration were observed in the elite females with SB ingestion when compared to the 
PLA trial. These findings are contrary to those of previous research involving the effect 
of acute SB ingestion on elite female athletes in simulated match performance (Bishop et 
al., 2005; Tan et al., 2010). In light of the fact that blood lactate concentrations were 
tending towards significance at one point in the present study, sample size may be a 
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possible explanation for the inconsistency. However, the sample size utilised in the 
current study was higher than the average of 8 ± 2 subjects observed in a review of 
research involving SB ingestion (Matson and Tran, 1993). In addition, neither of the two 
aforementioned studies (Bishop et al., 2005; Tan et al., 2010) involved running as the 
mode of exercise. Rather, field hockey match-play was simulated using a cycle ergometer 
protocol (Bishop et al., 2005) and water polo performance was replicated with swimming 
(Tan et al., 2010). As a result, due to the diverging modes of activity used, these two 
studies may not be entirely comparable to the current studies findings. Furthermore, the 
periods of active recovery involved in the match simulation protocol may also have 
encouraged an accelerated clearance of blood lactate in the elite female group. However, 
this was not observed in their trained male counterparts in performance of an identical 
rugby match simulation protocol. 
 
 
5.4.5. Effects of Metabolic Alkalosis on Performance 
 
In relation to performance, acute SB ingestion resulted in no significant difference 
between trials for male subjects. Mean first half weighted vertical jump height appeared 
to be approaching significance (p=0.060) in favour of SB ingestion. However, no 
significant differences in performance were observed. Cameron et al. (2010) also found 
no significant improvement in exercise performance in a similar subject group to the 
present study (trained male rugby players). As previously discussed, the rugby-specific 
protocol undertaken by Cameron et al. (2010) varied significantly from the present study 
and involved a much shorter duration, thus making absolute comparisons between the 
two studies difficult. However, both studies (Cameron et al., 2010 and the present study) 
entailed high intensity, intermittent running performance in rugby union players and as 
such, similarities may be drawn. On the contrary to the findings of Cameron et al. (2010), 
Bishop and Claudis (2005) observed a positive ergogenic effect with acute SB ingestion 
on team field sport simulation. The field hockey simulation protocol consisted of 2 x 36 
minute “halves” of intermittent repeat sprint activity. However, as previously mentioned, 
this protocol was carried out on a cycle ergometer.  
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Performance between the SB and PLA trials for the elite females presented conflicting 
results. From analysis of the mean of all fourteen circuits of the 80 minute performance 
test, passing accuracy was found to be significantly more accurate over the course of the 
test with PLA as opposed to SB supplementation (SB 2.68 ± 0.62 vs. PLA 2.99 ± 0.55)  
accurate passes out of five; p=0.009). Vertical jump height (Power 1) was also found to 
be significantly greater in the PLA trial than the SB trial (SB 26.0 ± 2.9 vs. PLA 27.1 ± 
3.3cm; p=0.010). In addition, acute SB ingestion was found to elicit a significantly 
greater difference between the mean of the first two circuits and the mean of the last two 
circuits for the defensive T sprint (SB 0.75 ± 0.77 vs. PLA 0.43 ± 0.70; p=0.012).  
 
Contradicting numerous studies reporting either significant performance enhancement or 
no difference between SB and PLA trials (Siegler et al., 2010; Carr et al., 2012; Bishop 
and Claudis, 2005), these results suggest that acute SB ingestion may have a detrimental 
effect on performance in relation to passing accuracy and lower body power. This may be 
partially accounted for by the significantly greater rating of GI disturbance recorded for 
the SB trial in comparison to PLA supplementation (SB 0.5±0.53 vs. PLA 0.1±0.32 on a 
GI rating scale of 0-5; p=0.037). However, this significant difference in GI disturbance 
was observed at just one time point (immediately following circuit 4) and as a result, may 
not be entirely responsible for the decrement in performance. Alternatively, as fatigue is 
multi-faceted, a separate factor may have contributed towards the significantly decreased 
performance in passing accuracy and lower body power. It may also be the case that SB 
ingestion did not cause a detriment, but rather that the PLA resulted in a performance 
enhancement. However, the substance utilised in this study (maltodextrin) has been used 
throughout the research as a valid placebo (Glaister et al., 2006; Abrams et al., 2005; 
Culbertson et al., 2010). As a result, the probability is that the GI symptoms were the 
dominant factor underlying the differences in performance. 
 
The aforementioned results, outlining diminished performance with acute SB ingestion, 
are in contrast to previous studies (Peart et al., 2012; Carr et al., 2011). Another potential 
explanation for the negative effect may lie in the nature of the performance test. To the 
author’s knowledge, no other published study has examined the effects of SB ingestion 
 175 
on an 80-minute rugby-specific match simulation protocol involving a diverse range of 
tasks indicative of those involved in rugby match-play. Previous sport-specific research 
utilising SB ingestion has involved cycling (Bishop and Claudis, 2005), swimming (Tan 
et al., 2010) or straightforward running for an insufficient duration to simulate team field 
sport match-play (Cameron et al., 2010). Within a sport-specific field test such as the 
current protocol, there may be a risk of increased variability when compared to a more 
reliable, controlled laboratory experiment such as a Wingate cycle ergometer test. 
However, in order to investigate team field sport fully, the exercise protocol selected or 
designed must be specific to the sport in question. Another possible factor contributing 
towards the conflicting findings is the high degree of individual variability associated 
with SB ingestion. Although only GI disturbance was only observed to be significantly 
higher at one time point within the females, it remains a potential factor. 
 
 
5.4.6. Effects of SB Ingestion on Recovery from High Intensity Intermittent Exercise 
 
The present research also examines the effect of acute SB ingestion on recovery during 
the 10 minute half-time period imposed to simulate the recovery period during 
competitive match-play. Following an observation of the changes in acid-base balance 
during simulated soccer match-play, Russell et al. (2012) reported that blood pH and 
buffering capacity reduced throughout soccer-specific exercise but returned to normal 
during half time. The current study corroborated this data and demonstrated that, 
although pH did decrease in both SB and PLA trials during the “first half” of the 
simulated rugby match, the half-time recovery period returned pH to the respective pre-
warm up levels in both males and females.  
 
The elevated pH exhibited following SB ingestion, in relation to the PLA, prior to the 
warm up for the performance test (7.47 ± 0.03 vs. 7.38 ± 0.02; p=0.046 for females and 
7.42 ± 0.03 vs. 7.37 ± 0.01; p=0.014 for males) was maintained following the half-time 
recovery period (7.46 ± 0.006 vs. 7.36 ± 0.001; p=0.001 for females and 7.43 ± 0.03 vs. 
7.35 ± 0.01; p=0.007 for males). This signifies that the widely reported metabolic 
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alkalosis observed with SB ingestion prior to exercise may become evident once again 
after a brief recovery period (Siegler et al., 2010; Carr et al., 2011; Peart et al., 2012). It 
has been reported (Peart et al., 2012) that metabolic alkalosis, resulting in an enhanced 
buffering capacity, is the major mechanism by which SB ingestion is purported to act. 
The current study suggests that SB ingestion may have the potential to impact on 
subsequent performance following a half-time recovery period. These results, therefore, 
establish the potential foundation for the use of SB ingestion as a recovery strategy. 
 
An analysis of the existing literature revealed that few studies have previously 
investigated the efficacy of SB ingestion in the context of recovery (Verbitsky et al., 
1997; Siegler et al., 2010). Verbitsky et al. (1997) reported reduced fatigue and enhanced 
recovery with acute SB ingestion following supramaximal cycling. Verbitsky and 
colleagues (1997) separated two bouts of cycling at 117% VO2max with 1 hour of SB 
ingestion of 0.4g/kg BM. Functional electrical stimulation was then applied to the 
quadriceps femoris. The resulting increased knee torque associated with SB ingestion 
suggested an enhancement of anaerobic metabolism in isometric contraction. In a more 
recent examination, Siegler et al. (2010) investigated the combination of SB ingestion 
with traditional recovery modalities. Following acute SB ingestion, performance of a 
series of 3 x 30 second Wingate tests was separated by 3 minutes of either active or 
passive recovery. The results of this study suggested that an amalgamation of pre-
exercise SB ingestion with active recovery between exercise bouts may enhance acid-
base recovery from high intensity exercise (Siegler et al., 2010). Siegler et al. (2010) 
proposed that the increased extracellular buffering capacity of the SB ingestion is 
complemented by the increased blood flow associated with active recovery, leading to 
improved high intensity intermittent performance. Both of the aforementioned studies 
(Verbitsky et al., 1997; Siegler et al., 2010), along with the current study support the 
potential benefit of SB ingestion in relation to recovery. However, further research is 
necessary to investigate the effects of SB ingestion on various recovery period durations, 
different modes of exercise and also the combination of SB ingestion with other recovery 
modalities such as ice bath immersion and compression therapy. 
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5.4.7. Summary 
 
The findings of the current study substantiate the previously reported observations within 
the existing literature regarding the capacity of acute SB ingestion to induce pre-exercise 
alkalosis (Siegler et al., 2010; Bishop et al., 2010). This study also lends support to a 
potential role of acute SB ingestion in recovery from high intensity exercise which may 
have implications for half time recovery strategies. However, in terms of performance, 
the results appear both conflicting and inconclusive with regard to the effect of acute SB 
ingestion on simulated rugby-specific performance. Although previous research in the 
area of SB ingestion has reported positive ergogenic effects in isolated single bout 
performance, this may not transfer to team field sport performance. There is currently a 
dearth of research involving the effects of SB supplementation on team sport 
performance, particularly studies involving sport-specific match simulation protocols. As 
a result, further research is required to investigate the effects of acute SB ingestion on 
sport-specific simulated or actual team-sport performance involving the intensity, 
duration, movement patterns and mode of exercise relevant to that sport. With regard to 
the current study, the hypothesis was partially proven regarding the metabolic alkalosis 
and enhanced recovery of the blood parameters following the half time period. However, 
once again, as with the previous two studies, the prediction of enhanced performance as a 
result of this acute SB supplementation protocol did not come to fruition. Therefore, there 
is no evidence to suggest that this supplementation protocol may be beneficial for either 
elite female or sub-elite male rugby union players. 
 
 
 
 
 
 
. 
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Chapter 6 
 
Summary, Conclusions and Recommendations for 
Future Research 
 
 
 
 
 
 
 
 
 
 
 
 
 
 179 
6.1. Summary 
 
The aim of this research was to examine the effects of acute and chronic SB 
supplementation on high intensity, intermittent performance, recovery and subsequent 
performance in trained rugby union players. In pursuit of this aim, three separate, yet 
closely linked experiments were designed and implemented. The major findings of this 
work suggest that pre-exercise metabolic alkalosis may be induced following acute but 
not chronic SB ingestion. However, results are inconclusive regarding the efficacy of 
acute or chronic SB ingestion to enhance performance in high intensity, intermittent 
exercise indicative of the movement patterns and physiological demands associated with 
rugby union. Results also appear to indicate a high degree of individual variability, which 
in part may be due to potential gastro-intestinal side effects of SB ingestion. 
 
Study 1 examined the effects of acute and chronic SB ingestion on high intensity 
intermittent performance. Following acute or chronic SB supplementation, subjects 
performed a 10 second Wingate test every 60 seconds for 6 minutes. Acute SB 
supplementation consisted of ingesting 0.1g SB/kg body mass at 90, 60 and 30 minutes 
prior to performance (0.3g/kg over 90 minutes). Chronic SB supplementation entailed SB 
ingestion of 0.3g/kg body per day for a period of 5 days prior to the performance test. 
Results from this study demonstrated the capacity of acute SB supplementation to 
maintain a significantly greater blood StdHCO3
-
 and blood pH at all time points when 
compared to all other supplementation protocols. Acute SB supplementation 
corresponded to a significant increase of 5.9mmol/L in mean StdHCO3
-
 (from 24.9 ± 
1.3mmol/L at baseline to 30.8 ± 1.1mmol/L pre-test) and a significant increase of 0.06 in 
pH (from 7.39 ± 0.02 at baseline to 7.45 ± 0.019 pre-test) following ingestion and 
immediately prior to the performance test (p<0.01). However, no significant differences 
in performance were observed. Chronic SB ingestion failed to demonstrate a significant 
level of pre-exercise alkalosis. Although mean StdHCO3
-
 was significantly greater than 
acute PLA at one time point (following Sprint 1) during the chronic trial (p=0.016), no 
ergogenic effect of chronic SB ingestion was established. It was purported that training 
status and gastro-intestinal side effects may have contributed to the inconsistent findings 
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with respect to acute SB ingestion. In relation to chronic SB ingestion, it was suggested 
that the body’s buffering capacity may have corrected for the acid-base balance 
disturbance caused by SB ingestion and returned pH to homeostasis levels prior to 
performance, hence no pre-exercise alkalosis was observed. In addition, the high degree 
of individual variability combined with the sample size (n=10) may have impeded a 
statistically significant finding. 
 
As outlined above, Study 1 examined the effects of both acute and chronic SB ingestion 
on a controlled laboratory experiment (repeated Wingate tests). In contrast, Study 2 
investigated the effects of chronic SB ingestion on a field-based running test protocol, 
designed to replicate the high intensity intermittent activity associated with rugby union 
sevens match-play. The specifically designed test protocol was a unique aspect of this 
study as, prior to this research, SB ingestion had not been examined in relation to rugby 
sevens. This chronic SB supplementation protocol, which consisted of SB ingestion of 
0.3g/kg per day for 5 days, exhibited no significant differences in blood parameters or 
performance related variables between SB and PLA trials. In light of the fact that no 
significant shift in acid-base balance was detected prior to performance, it was unlikely 
that SB ingestion would elicit a significant effect on performance unless an alternative 
unknown physiological mechanism was responsible for the previously reported ergogenic 
effect of SB ingestion (Siegler et al., 2010). As a result, a higher chronic SB dose of 
0.5g/kg per day, as used in previous research (McNaughton et a., 1999) may be required 
to examine the potential to maintain blood alkalinity after cessation of ingestion. 
 
Similar to the previous investigation (Study 2), Study 3, also examined the effects of SB 
ingestion on a sport-specific match simulation performance protocol, this time 
concentrating on 15-a-side rugby union. However, Study 3 focuses on acute SB ingestion 
as opposed to the chronic SB ingestion protocol utilised in Study 2. In an attempt to 
minimise sample size as a potential explanation for non-significant findings, a larger 
sample size (n=20; 10 elite females and 10 sub-elite males) participated in this study. In 
addition, taking into account that approximately only 12% of subjects investigated in 
previous studies were female, ten elite female athletes were recruited, thus enabling the 
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evaluation of possible gender differences. Results of this study indicated that acute SB 
supplementation with 0.3g/kg body mass ingested over the 90 minutes prior to 
performance (0.1g/kg body mass taken at 90, 60 and 30 minutes pre-performance) had 
the capacity to induce pre-exercise alkalosis in both elite females and sub-elite males. 
However, conflicting findings were recorded in relation to the ergogenic benefit to rugby 
union-specific performance resulting from this perturbation in acid-base balance. 
Additionally, as evident from an elevated pH following the half-time period, this study 
also lends support to a potential role of acute SB ingestion in short-term recovery from 
high intensity intermittent exercise. 
 
 
6.2. Study Implications and Conclusion 
 
It was hypothesised that acute and chronic SB ingestion would instigate pre-exercise 
alkalosis, leading to an enhanced extracellular buffering capacity and, thus, improved 
performance of test protocols designed to simulate the playing requirements of a team 
field sport, such as rugby union. Overall, despite a high degree of intra-individual 
variability of results, neither acute nor chronic SB loading demonstrated an enhancement 
in mean performance. However, acute SB ingestion was deemed to be capable of eliciting 
a significant shift in acid-base balance. Adopting a chronic supplementation protocol may 
prove beneficial for athletes in terms of ameliorating the gastrointestinal side effects 
associated with SB ingestion. However, further scientific research is necessary to 
definitively confirm the ergogenic effect of chronic SB ingestion. Recommendations to 
athletes regarding SB supplementation must stress the large degree of individual 
variability in terms of gastrointestinal side affects that may accompany SB ingestion. 
Research involving repeated acute SB ingestion has also detected a high within-subject 
variability of gastrointestinal symptoms (Carr et al., 2012). This may have implications 
for athletes considering SB supplementation as it indicates that regardless of prior 
familiarisation with SB, the manifestation of gastrointestinal side affects may vary on 
different occasions. As a result, despite experimentation with SB ingestion in training, 
athletes may not be guaranteed a similar response to SB ingestion during competition. 
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From a practical perspective, athletes and coaches may consider the use of SB 
supplementation on an individual, case-by-case basis, as responses appear to be highly 
individual which in part may be due to the variability of GI distress observed. However, 
on the basis of the three studies conducted throughout this research, there is no evidence 
to support the use of acute or chronic SB supplementation to enhance performance in 
elite female or sub-elite male rugby players. 
 
 
6.3. Recommendations for Future Research 
 
Results from this research suggest that, although pre-exercise alkalosis may be induced 
by acute SB ingestion, this may not translate into a performance enhancement in high 
intensity intermittent exercise. However, further research into this area is necessary in 
order to devise accurate and precise practical recommendations for athletes and coaches. 
Initially, the precise physiological mechanism underpinning the efficacy of SB ingestion 
to improve performance requires further investigation to be fully substantiated. Although 
improvements in performance with SB ingestion have largely been attributed to an 
enhanced buffering capacity, the potential mechanisms contributing to performance 
enhancement in the absence of significant blood pH changes following chronic SB 
ingestion require further examination. Recent research (Street et al., 2005; Sostaric et al., 
2006) has indicated that SB ingestion may reduce the exercise-induced increase in 
extracellular potassium (K+). As a result, further clarification in relation to primary and 
potential secondary mechanisms involved is required. Future research involving SB 
ingestion may benefit from analysis of the acid-base balance of the urine to identify any 
compensatory action by the body to eliminate the excess base ingested. In addition, 
muscle biopsy sampling may be advantageous to examine the intracellular muscle 
buffering capacity rather than the extracellular environment alone.  
 
Limited research has been undertaken regarding the optimal SB supplementation 
protocol, particularly with regard to chronic SB ingestion. As a result, further 
investigation into the dose, number of doses and timing of ingestion prior to exercise may 
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be required to identify the circumstances under which the maximum increase in 
StdHCO3
-
, pH and BE-Ecf may be observed. Future consideration should also be 
dedicated towards exploring the scope of SB ingestion as a potential recovery strategy. 
Finally, additional research is necessary to determine any potential differences in the 
response of trained and untrained subjects to SB ingestion. It has been purported that 
highly trained individuals may have an already enhanced buffering capacity, thus, 
limiting the potential effect of SB ingestion. However, the scientific evidence to 
corroborate this is not yet definitive. In addition, the present research is one of few 
investigations to include female athletes. As a result, future research should further 
investigate the effect of SB ingestion on female athletes. 
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Appendix A1 
Informed Consent Form 
 
 
I. Research Study Title: The effects of acute versus chronic sodium bicarbonate (NaHCO3) 
supplementation on high intensity, intermittent sprint performance. 
 University Department: School of Health and Human Performance 
 Principal investigator: Dr. Giles Warrington 
 Other Investigator: Paula Fitzpatrick 
  
II. Clarification of the purpose of the research 
Ingestion of sodium bicarbonate (NaHCO3), among other buffering substances, has been 
suggested to delay the onset of fatigue and improve performance during high intensity exercise. 
However any potential performance enhancement due to NaHCO3 ingestion appears to be highly 
individual and may involve side affects such as nausea and gastrointestinal discomfort. Therefore it 
may be beneficial to examine the effects of short-term NaHCO3 loading in the days preceding 
exercise performance to offset any possible gastro-intestinal issues during performance. The 
purpose of this study is to investigate NaHCO3 loading and monitor the effects both on 
performance and on the incidence of gastro-intestinal problems. 
III. Confirmation of particular requirements as highlighted in the Plain Language Statement 
I will be asked to visit Dublin City University (DCU) for testing on five separate days. I will be asked 
to take part in one of four strategies following a habituation visit:: (1) supplement with NaHCO3 90 
minutes before the performance test, (2) supplement with a placebo 90 minutes before the 
performance test, (3) supplement with NaHCO3 every day for five days before the performance 
test, (4) supplement with a placebo every day for five days before the performance test. The 
performance test will be a high intensity repeat sprint cycle ergometer test. I will also be asked to 
complete brief questionnaires on muscle soreness and blood samples will also be taken at various 
intervals throughout the testing process. This entire process must be completed on four separate 
occasions using a different nutritional strategy each time. Total time requirements on each day will 
be no more than 120 minutes. There will be no less than one week between each session.  
        
Participant – please complete the following (Circle Yes or No for each question) 
Have you read or had read to you the Plain Language Statement   Yes/No 
Do you understand the information provided?     Yes/No 
Have you had an opportunity to ask questions and discuss this study?    Yes/No 
Have you received satisfactory answers to all your questions?     Yes/No 
IV. Confirmation that involvement in the Research Study is voluntary 
I understand that I may withdraw from the testing procedures at any time. No penalty will be 
incurred for failure to complete all stages of the research study. 
 
V.  Advice as to arrangements to be made to protect confidentiality of data, including that 
confidentiality of information provided is subject to legal limitations  
Confidentiality is an important issue during data collection. My identity, or other personal 
information, will not be revealed or published. I will be assigned an ID number under which all 
personal information will be stored in a secure file and saved in password protected file in a 
computer at DCU. The investigators alone will have access to the data. 
Confidentiality of information provided can only be protected within the limitations of the law.  It is 
possible for data to be subject to subpoena, freedom of information claim or mandated reporting by 
some professions. 
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VII. Signature: 
I have read and understood the information in this form.  My questions and concerns have been 
answered by the researchers, and I have a copy of this consent form.  Therefore, I consent to take 
part in this research project 
 
  
Participants Signature:         
 
Name in Block Capitals:         
 
  
Witness:       
Appendix A2 
Informed Consent Form 
 
 
I. Research Study Title: The effects of chronic sodium bicarbonate (NaHCO3) supplementation on 
simulated rugby sevens specific performance. 
 University Department: School of Health and Human Performance 
 Principal investigator: Dr. Giles Warrington 
 Other Investigator: Paula Fitzpatrick 
  
II. Clarification of the purpose of the research 
Ingestion of sodium bicarbonate (NaHCO3), among other buffering substances, has been 
suggested to delay the onset of fatigue and improve performance during high intensity exercise. 
However any potential performance enhancement due to NaHCO3 ingestion appears to be highly 
individual and may involve side affects such as nausea and gastrointestinal discomfort. Therefore it 
may be beneficial to examine the effects of short-term NaHCO3 loading in the days preceding 
exercise performance to offset any possible gastro-intestinal issues during performance. The 
purpose of this study is to investigate NaHCO3 loading and monitor the effects both on 
performance and on the incidence of gastro-intestinal problems. 
III. Confirmation of particular requirements as highlighted in the Plain Language Statement 
I will be asked to visit Dublin City University (DCU) for testing on three separate days. I will be 
asked to take part in one of two strategies following a habituation visit: (1) supplement with 
NaHCO3 every day for five days before the performance test, (2) supplement with a placebo every 
day for five days before the performance test. The performance test will be a rugby sevens specific 
repeated sprint agility test. I will also be asked to complete brief questionnaires on muscle soreness 
and blood samples will also be taken at various intervals throughout the testing process. This entire 
process must be completed on two separate occasions using a different nutritional strategy each 
time. Total time requirements on each day will be no more than 45 minutes. There will be no less 
than one week between each session.  
        
Participant – please complete the following (Circle Yes or No for each question) 
Have you read or had read to you the Plain Language Statement   Yes/No 
Do you understand the information provided?     Yes/No 
Have you had an opportunity to ask questions and discuss this study?    Yes/No 
Have you received satisfactory answers to all your questions?     Yes/No 
IV. Confirmation that involvement in the Research Study is voluntary 
I understand that I may withdraw from the testing procedures at any time. No penalty will be 
incurred for failure to complete all stages of the research study. 
 
V.  Advice as to arrangements to be made to protect confidentiality of data, including that 
confidentiality of information provided is subject to legal limitations  
Confidentiality is an important issue during data collection. My identity, or other personal 
information, will not be revealed or published. I will be assigned an ID number under which all 
personal information will be stored in a secure file and saved in password protected file in a 
computer at DCU. The investigators alone will have access to the data. 
Confidentiality of information provided can only be protected within the limitations of the law.  It is 
possible for data to be subject to subpoena, freedom of information claim or mandated reporting by 
some professions. 
VII. Signature: 
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I have read and understood the information in this form.  My questions and concerns have been 
answered by the researchers, and I have a copy of this consent form.  Therefore, I consent to take 
part in this research project 
 
  
Participants Signature:         
 
 
Name in Block Capitals:         
 
  
Witness:       
Appendix A3 
Informed Consent Form 
 
 
I. Research Study Title: The effects of acute sodium bicarbonate (NaHCO3) supplementation on 
high intensity intermittent performance using a simulated 80 minute rugby specific test protocol. 
 University Department: School of Health and Human Performance 
 Principal investigator: Dr. Giles Warrington 
 Other Investigator: Paula Fitzpatrick 
  
II. Clarification of the purpose of the research 
Ingestion of sodium bicarbonate (NaHCO3), among other buffering substances, has been 
suggested to delay the onset of fatigue and improve performance during high intensity exercise. 
However any potential performance enhancement due to NaHCO3 ingestion appears to be highly 
individual and may involve side affects such as nausea and gastrointestinal discomfort. Therefore it 
may be beneficial to examine the effects of short-term NaHCO3 loading in the days preceding 
exercise performance to offset any possible gastro-intestinal issues during performance. The 
purpose of this study is to investigate NaHCO3 loading and monitor the effects both on 
performance and on the incidence of gastro-intestinal problems. 
III. Confirmation of particular requirements as highlighted in the Plain Language Statement 
I will be asked to visit Dublin City University (DCU) for testing on three separate days. I will be 
asked to take part in one of two strategies following a habituation visit: (1) supplement with 
NaHCO3 90 minutes before the performance test, (2) supplement with a placebo 90 minutes before 
the performance test. The performance test will be a rugby specific repeated sprint agility test. I will 
also be asked to complete brief questionnaires on muscle soreness and blood samples will also be 
taken at various intervals throughout the testing process. This entire process must be completed on 
two separate occasions using a different nutritional strategy each time. Total time requirements on 
each day will be no more than 180 minutes. There will be no less than one week between each 
session.  
        
Participant – please complete the following (Circle Yes or No for each question) 
Have you read or had read to you the Plain Language Statement   Yes/No 
Do you understand the information provided?     Yes/No 
Have you had an opportunity to ask questions and discuss this study?    Yes/No 
Have you received satisfactory answers to all your questions?     Yes/No 
IV. Confirmation that involvement in the Research Study is voluntary 
I understand that I may withdraw from the testing procedures at any time. No penalty will be 
incurred for failure to complete all stages of the research study. 
 
V.  Advice as to arrangements to be made to protect confidentiality of data, including that 
confidentiality of information provided is subject to legal limitations  
Confidentiality is an important issue during data collection. My identity, or other personal 
information, will not be revealed or published. I will be assigned an ID number under which all 
personal information will be stored in a secure file and saved in password protected file in a 
computer at DCU. The investigators alone will have access to the data. 
Confidentiality of information provided can only be protected within the limitations of the law.  It is 
possible for data to be subject to subpoena, freedom of information claim or mandated reporting by 
some professions. 
VII. Signature: 
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I have read and understood the information in this form.  My questions and concerns have been 
answered by the researchers, and I have a copy of this consent form.  Therefore, I consent to take 
part in this research project 
 
  
Participants Signature:         
 
 
Name in Block Capitals:         
 
  
Witness:       
Appendix B 
SCHOOL OF HEALTH ACD HUMAC PERFORMACCE 
DUBLIC CITY UCIVERSITY 
General Health Questionnaire 
 
Name:……………………………….. Occupation:…………………………… 
 
Address:………………………………………………………………………………. 
 
Telephone: (Home)………………….. (Work):……………………………….. 
_____________________________________________________________________ 
Do you have, or have you ever suffered from: -Diabetes?  Yes / No 
      -Asthma?  Yes / No 
      -Epilepsy?  Yes / No 
 
Have you ever had pains in your chest or heart?    Yes / No 
 
Do you ever feel faint or have spells of dizziness?    Yes / No 
 
Do you have or have you ever had high blood pressure?   Yes / No 
 
Do you have a muscle, back or joint problem that could be aggravated by physical                                                                                                            
activity or made worse with exercise?     Yes / No 
 
Do you have any current injuries?      Yes / No 
 
In the past week, have you suffered from any illness which required you to be in bed 
or off work for one day or more?      Yes / No 
 
Do you smoke?   If yes, how many per day?    Yes / No 
 
Do you drink?  If yes, how many units per week?   Yes / No 
 
Is there a good physical reason not mentioned here why you should not carry out 
laboratory testing?       Yes / No 
 
For females only - date of last menstrual period: ____________ 
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Please provide any further information concerning any condition/complaints which you 
suffer from and any medication which you may be taking by prescription or otherwise: 
 
……………………………………………………………………………………………… 
 
Date:_______________________Signature:___________________________________ 
 
Authorising Signature:  ____________________________________________________ 
Appendix C 
 
Muscle Soreness Scale 
 
0   A complete absence of pain 
1   Extremely weak pain 
2   Weak/Distracting pain 
3   Mild/Annoying pain 
4   Slightly moderate pain/Uncomfortable 
5   Moderate pain/Irritating 
6   Barely Strong pain/Distressing 
7   Strong pain/Agonizing 
8   Intense pain/Intolerable 
9   Very Intense pain/Unbearable 
10 Extremely Intense pain/Excruciating 
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